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Abstract 
Background: the dose and the length of rehabilitative interventions for optimal 
motor recovery after stroke are unknown. Dose optimization studies are 
required as precursors to efficacy trials, but are rarely conducted in stroke 
rehabilitation research. 
 
Objective: to overcome the knowledge gap on appropriate dose and length of 
rehabilitative interventions guiding the implementation of novel effective 
approaches to dose optimization in stroke rehabilitation research. 
 
Method: two systematic reviews on dose optimization in exercise-based 
training and pharmaceutical clinical research guided the development of a new 
approach to dose-finding suitable for physical interventions. The feasibility of a 
novel phase I 3+3 rule-based, outcome-adaptive dose-finding design was 
assessed with stroke survivors with moderate upper limb paresis. Moreover, 
the feasibility of a repetitive assessment procedure to identify the appropriate 
length of motor interventions was explored in stroke rehabilitation research. 
 
Results: the first literature review showed a lack of reliable approaches to dose 
optimization in exercise-based training. The review of pharmaceutical research 
highlighted dose optimization “gold” standard approaches, and helped in 
devising the dose-finding study for physical intervention. The dose-finding 
study was feasible using the applied model-task intervention. Preliminary 
explorations on the dose-response relationship were possible indicating a 
maximum tolerable dose and a potential recommended dose of 209 and 162 
repetitions respectively of the applied intervention-task. The repetitive 
assessment procedure was found feasible in a clinical efficacy stroke 
rehabilitative trial. The repetitive assessment procedure provided relevant data 
on the therapy effect over-time showing that more than six weeks of the 
applied upper limb intervention may be necessary to reach maximal therapy 
iv 
effects. Whereas, five weeks of intervention appeared enough to exploit 
therapy effects for the lower limb. 
 
Conclusions: results are promising on identifying relevant dose and protocol 
endpoints implementing dose-finding and repetitive assessments approaches 
in stroke rehabilitation. Further confirmative data are needed to validate these 
findings.  
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Chapter 1:   
 Introduction 
 
1.1 Stroke syndrome: definition and statistics  
According to the World Health Organisation (WHO), stroke is a clinical 
syndrome that occurs when the blood flow to the brain is interrupted with no 
apparent cause other than a vascular origin. It results in a damage to the brain 
tissue that is often serious and disabling. In the UK, stroke is the fourth largest 
cause of death after cancer, heart and respiratory diseases [1]. However, thanks 
to advances in medicine and rehabilitation, the majority of people survive after 
their first stroke, with an increasing number of hospital admissions1.  
Approximately half of people surviving a stroke make an incomplete recovery. 
In the UK, it has been estimated that around 33% of stroke survivors remain 
moderately or severely disabled [2], requiring assistance in their daily activities 
and long-term rehabilitation, on many occasions, for the rest of their life [3,4]. 
The impact of stroke for the healthcare system, patients and families is 
significant and likely to increase with the growth of the ageing population. 
 
 
                                                     
1 http://www.england.nhs.uk/statistics/statistical-work-areas/integrated-performance-
measures-monitoring/stroke-data/ (Accessed July 2014). 
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1.2 Effects of stroke: motor impairment 
Stroke is typified by a rapid development of signs of focal or global disturbance 
of cerebral functions, which last more than 24 hours or lead to death [5]. Stroke 
can result in a variety of signs and symptoms depending on the extent and site 
of the brain lesion. The greatest long-term effect of stroke is the development 
of physical and psychological impairments. These impairments often lead to 
limitations of activities and disabilities, which, in turn, reduce life participation 
of stroke survivors [6]. The most common and wide recognised impairment 
caused by stroke is motor impairment affecting about 80% of stroke survivors 
[7]. Other common areas of impairment are speech and language (about 42%), 
vision (about 18%), swallowing (about 45%), sensation (about 19%) and 
cognition (about 32%) [8,9,10].  
Motor impairments after stroke result from the interruption or disruption of 
descending signals from the motor cortex, premotor cortex, or cerebellum to 
the spinal moto-neurons [11]. Motor impairment is typified by a loss or 
limitation of muscle function and motor control commonly affecting the face, 
arm and leg of the opposite side of the brain damage. This limitation is called 
contralesional hemiparesis [12]. Complete loss of motor functions in one side 
of the body is called hemi-paralysis.  
The coexistence of ipsilesional motor deficits (same side of the lesion) after 
stroke have been reported from animal [13] and human studies [14,15]. But, 
these are milder than on the contralesional side.  
 
 
1.3 Functional motor recovery 
Recovery after stroke is heterogeneous in its nature and is influenced by many 
factors. Functional motor recovery refers to improvements in mobility and 
activities of daily living. It is a complex process linked to the ability of the 
injured brain to change [16]. These neural changes, called functional 
neuroplasticity, are possible because of the brain ability to reorganise itself by 
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the redundant connectivity within the central nervous system (CNS) and the 
ability of new circuits to form [17,18,19,20]. 
Functional motor recovery often follows stereotyped patterns and is said to 
be predictable in the first days after the brain injury [21,22]. A combination of 
spontaneous and training-induced recovery processes have been found in the 
motor recovery processes [23,24]. These include: 
i. restitution of functionality of injured neural tissue; 
ii. substitution and reorganization of spared or partly injured neural 
pathways to relearn lost functions; 
iii. compensation processes, often resulting as patients’ adaptation 
between motor impairments and the environment demands [25,26].  
The spontaneous recovery typically plateaus three months after the brain 
injury whereas, training-induced recovery has been observed long after the 
injury [27,28,29]. 
Faster motor improvements are seen on the initial stage followed by slower 
changes after the first few weeks. In the period from 12 hours to seven days 
after ischemic stroke onset, many patients who are without complications 
experience moderate but steady improvement in neurologic impairments 
[21]. The greatest proportion of recovery after stroke occurs in the first 3 to 6 
months and evidence supports the “six months window” as the gold standard 
timeframe for post-stroke care worldwide [30,31]. However, evidence has 
shown that patients can improve in later stage [32,33]. 
 
 
1.4 Rehabilitation after stroke 
Stroke rehabilitation is a multidisciplinary intervention which comprised of 
several interactive procedures. Its main aim is to reduce the disabilities and 
participation restriction following a stroke [24]. Its favourable effects in 
enhancing functional motor recovery is widely recognised by researchers 
[34,35,36,37,38,39] and stroke survivors [40].  
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In the last decades, many novel rehabilitation interventions have been 
developed, based on advances in neuroscience, to assist the natural pattern of 
functional motor recovery after stroke [24,39,41,42,43]. However, what is 
commonly referred to as the “black box” of therapy has not yet fully 
understood [44].  
The debate on which components of the rehabilitative intervention are more 
effective to enhance individual’s treatment responsiveness and functional 
motor recovery is far from being closed [42,45,46,47]. It is still unclear whether 
it is the content of a specific therapy or the therapy dose which matter more to 
enhance stroke motor recovery. Besides, there are still uncertainties whether 
it is the same therapy dose beneficial for all patients at any stage of stroke, or 
some patients and stages of recovery benefit more from a specific dose.  
Literature converged on the importance of characterizing what components of 
these interventions were key to support motor recovery [7,45,48]. Identifying 
the appropriate dose of rehabilitative interventions is thought to be pivotal to 
exploit training effects and enhance stroke survivors’ functional recovery 
[24,46,49,50,51,52,53]. However, the multifactorial and complex nature of 
stroke rehabilitation brings several challenges in fulfilling these gaps of 
knowledge and on conducting rigorous evaluation [54]. 
 
 
1.5 Neuroimaging and experience-dependent principles 
Effective therapeutic interventions following stroke depend on an 
understanding of brain changes, their time frame from the injury and their 
relationship with behavioural stimulus (training-induced changes in neural 
function) [20,26,55,56,57].  
In the last two decades, non-invasive neuroimaging studies have successfully 
contributed to investigate the dynamics of adaptive reorganization of the 
injured brain associated with functional recovery [33,55,58,59,60,61]. Among 
them, Transcranial Magnetic Stimulation (TMS), which uses magnetic fields to 
depolarize nerves cells in the brain, has been widely applied and has proven 
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to be a valuable and safe tool to better understand motor dysfunctions and 
recovery after brain injury. However, even with the use of non-invasive 
neuroimaging tools, the precise mechanisms of the brain reorganization 
underpinning functional recovery and the key active ingredients to maximise 
rehabilitative interventions outcomes after stroke remain topical and still 
unclear [24,26,33,62]. 
 
 
1.6  The dose of training 
In an injured brain, the amount of skilled practice is thought to be crucial to 
support the training-induced neuroplasticity and, consequently, the 
improvement of motor function [63,64]. The amount of skilled task-specific 
training provided after stroke is crucial to enhance improvements of functional 
outcomes [24,31,39,65,66,67,68,69]. Evidence converged on the assumption 
that the extent to which an intervention can be effective inherently depends 
on the delivered dose [67]. It seems that the brain reorganization is more 
influenced by the amount of training, rather than the type of intervention 
delivered [70,71,72]. Dobkin, for example, stressed the relevance of 
identifying at which dose of intervention it is possible to reach the “peak 
behavioural effects of training [to enhance patients’ outcomes and] for how 
long a physical intervention needs to be prescribed till a diminished therapy 
effect is seen” [73,74]. Hornby and colleagues reviewed the relevant literature 
on the key dose parameters of stroke rehabilitative interventions to improve 
lower limb functions. They highlighted that the amount and intensity of the 
locomotors practice2 have a prominent role to enhance motor recovery [50].  
The dose of training is also linked with important factors influencing the 
functional motor recovery such as, the motor learning processes (or re-
learning ability) of the brain and the time since the brain injury [43,63,75,76].  
                                                     
2 These parameters of the training were defined as the time or number of steps undertaken and 
the effort needed to pursue the training. 
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Regardless the presence of an injured brain, all motor learning processes in 
the brain are based on: functional skills acquisition, motor adaptations -or 
motor control-, and decision making processes. It is known that these 
processes are strictly linked with the dose of skilled practice [76] and can be 
conditioned by training [63,77].  
The functional neural plasticity following stroke is a process which sees a 
cascade of several events influenced by a variety of possible factors, rather 
than a standardised single event. The type of plasticity observed and its 
suitability to further change is likely to depend on the time point of the 
observation after the brain injury. How much therapy should be delivered to 
maximise functional recovery preserving patients’ safety is therefore linked 
with the time since the brain injury. Despite a general consensus that early 
initiation of rehabilitative intervention could enhance recovery [24,78,79], 
how early [80] and how much therapy should be provided given the risks of a 
vulnerable brain early after the injury [81] is still debated. Recently, the AVERT 
trial challenged the assumption that higher dose of therapy are always better, 
in particular in the early stage of the recovery [82]. 
Identifying the appropriate dose at which the intervention produces optimal 
outcomes is therefore of paramount importance in enhancing stroke 
survivors’ motor recovery at any stage of recovery and it is seen as a research 
priority.  
 
 
1.7 Recommendations for training dose after stroke 
Although there is growing interest on the appropriate dose and protocols of 
rehabilitative interventions after stroke, current evidence is sparse and 
inconclusive [83].  
In 2005, the American Health Association AHA/ASA-Endorsed Practice 
Guidelines reported the difficulty in generating guidelines on the appropriate 
dose of rehabilitative interventions after stroke due to the lack of information 
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on important dose thresholds for efficacy. The dose level below which the 
intervention is not effective and the dose level above which a marginal 
improvement is seen are still under investigation [84].  
In 2012, the Intercollegiate Stroke Working Party (ICSWP)[31] recommended 
a minimum threshold of 45 minutes of stroke rehabilitation therapy, for any 
patient able to sustain it, for a minimum of five days per week. This 
recommendation was the result of an experts’ consensus summit, rather than 
a guideline grounded on scientific evidence. They recognised, however, that in 
this context of uncertainty about appropriate dose and protocols of 
rehabilitative interventions after stroke, the recommendation was as specific 
as it could possibly be. 
The threshold of 45 minutes of therapy a day for 5 days a week was 
subsequently advocated by the National Institute for Health and Care 
Excellence (NICE) in their 2013 Stroke Rehabilitation guidelines [68]. 
 
One of the first challenges faced by stroke rehabilitation research when 
addressing dose optimization is the multifactorial aspects of the training 
protocol and training dose. In rehabilitation the training protocol is commonly 
shaped by three parameters: the dose, the frequency, and the total length 
(often in weeks) of the training period. In turn, the dose of training is often 
shaped by two: the intensity and the amount of training.  
The impact of these training parameters able to maximize stroke survivors’ 
motor recovery is still under investigation. Whether it is the time that patients 
spend engaging in therapy, the number of task-repetitions accomplished, the 
intensity of the rehabilitative sessions or the total length of the intervention 
that matter most to induce positive lasting brain changes is unknown.  
 
 
1.8 The optimal therapeutic dose 
In medicine and in pharmaceutical research in particular, the optimal dose 
(OD) or optimal therapeutic dose (OTD) is defined as the dose at which the 
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drug is able to provide the best possible outcomes with a tolerable onset of 
adverse events for the majority of patients. Translating this definition to 
rehabilitative interventions, the OTD of a physical intervention is the dose at 
which the applied intervention is likely to be feasible, tolerable and safe with 
the best observed outcomes for the majority of patients.  
Identify the OTD is not a straightforward task for complex motor interventions 
such as stroke rehabilitation. This can partially explain why these doses of 
motor intervention which are proven to be feasible, safe and able to maximise 
motor recovery after stroke are still not identified [50,74,83].  
The clinical process of studying the dose-response relationship of the applied 
intervention to identify the OTDs is commonly defined as the dose optimization 
process. The dose-response relationship describes how marginal changes 
(increases or decreases) in the dose affect the outcome of interest. Dose-
response data are typically graphed with a bi-dimensional graph, with the dose 
on the x-axis and the measured effect (response) on the y-axis.  
Figure 1 provides an example of two toxicant compounds (A and B) with 
different dose-response relationships. In this example it is possible to see that 
the dose-response of pharmaceutical compounds (drug element) normally 
takes the form of a sigmoid curve. The compound dose at which response (or 
toxicity) first appear is known as threshold. From this point the curve shows 
the increased observed benefits associated with higher doses. The slope of the 
curve represents the rapidity of the compound to reach effect (or toxicity). The 
compounds reached a dose beyond which no further benefit is observed, often 
defined ad plateau stage. In this example, toxicant compound A shows a higher 
threshold and a steeper slope than toxicant compound B. 
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Figure 1-1: Example of the dose-response relationships of two pharmaceutical 
toxicant compounds 
 
Notes: Toxicant A and Toxicant B represents the dose-response relationships pf the two studied 
compounds (drug elements); the x-axis reports the individual’ response to the applied 
compound; y-axis reports the dose applied. Source: National Library of Medicine, The 
Encyclopedia of Earth Toxicology webpage3. 
 
 
1.9 Evidence on training dose after stroke: is more 
therapy always better? 
Animal models with damaged motor cortex suggested that high dose of 
rehabilitative interventions after stroke enhanced motor recovery. In these 
studies, rats or primates, after induced brain damage, were trained on a 
repetitive motor task involving the retrieval of food pellets for an extensive 
amount of time per day, five days per week. Animals that were able to reach 
around 300/400 task repetitions per session had significant neural changes 
compared with those observed with lower dose [85,86,87,88,89,90,91]. Luke 
et al. found that animals exposed to low dose (60 reaching a day, five days a 
week) did not show any neural changes [53]. A recent study suggested the 
possible presence of a lower threshold in the number of repetitions performed 
                                                     
3 http://www.eoearth.org/view/article/151784/  
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(around 240 task repetitions), below which motor recovery was not seen [92]. 
Animal studies, however, often failed to identify a strong correlation between 
plasticity changes and acquisition of functional motor skills rather than 
adaptation and compensatory behavioural strategies [16,93]. 
Translating results from animal model studies to human clinical research, and 
eventually clinical practice, is not straightforward. This is particularly 
challenging in regard to the dose of motor interventions for several reasons. 
First, some morphological structures of the nervous system greatly differ. 
Among others, the rubrospinal tract4 differs in humans compared with rats 
and monkeys. The rubrospinal tract is an alternative pathway by which 
voluntary motor commands can be sent to the spinal cord. Although it is a 
major pathway in many animals, it is relatively minor in humans.  
Second, although the feasibility of high intensive protocols in sub-group of 
stroke survivors has been suggested [94,95], it is almost impossible to mimic 
among humans the same conditions in animal models. 
Finally, results from animal studies cannot be used to suggest what number of 
task-repetitions should be delivered in humans to see similar –or to some 
extent, proportional- neuroplasticity enhancement. 
The beneficial effect of high dose of rehabilitative interventions have also been 
questioned by other evidence that highlighted the vulnerability of the animals’ 
brain when engaged in intensive training early after the brain injury 
[96,97,98,99]. 
Despite the above-mentioned limitations and concerns emerging from pre-
clinical studies, the hypothesis that higher dose could maximise rehabilitative 
benefits after stroke is now well-accepted among clinicians and research. A 
wide-spread consensus is emerging from research and clinical practice on the 
                                                     
4 The rubrospinal tract is an axon tract originating in the red nucleus of the midbrain. After 
leaving the red nucleus, axons cross to the contralateral side and descend into the spinal cord, 
where they terminate in the ventral horns. The red nucleus is innervated by axons from the 
motor-cortices and the cerebellum. The rubrospinal pathway is an extrapyramidal route to the 
spinal cord. Source: Farlex Partner Medical Dictionary © Farlex 2012. 
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efficacy of high-intensive task-specific training protocols in enhancing stroke 
survivors’ motor recovery [29,95,100,101,102,103]. As a result, there is a 
proliferation of clinical studies assessing the effectiveness of these intensive 
protocols against routinely practice or lower dose [e.g., 
27,29,49,52,70,100,104,105,106,107,108,109,110,111,112,113]. 
In the majority of these studies high dose protocols were associated with 
better motor outcomes for patients regardless the stage of stroke.  
Few clinical studies reported no or limited evidence to support these intensive 
protocols. Di Lauro et al. investigated the efficacy of intensive rehabilitation, 
over standard rehabilitation. They showed that high intensity training may not 
always be required to produce positive motor changes in people early after 
stroke [114]. In 2009, the VECTORS’ study5 found that high intensity 
constraint-induced movement therapy was detrimental when delivered within 
28 days after stroke[115]. Detrimental effects on upper limb strength early 
after stroke have been reported from other studies [116,117]. Thus, it seems 
that more therapy may not always produce a better recovery [118,119]. 
The quality of some of the cited studies supporting the effectiveness of high 
dose protocols is another matter of concern. Appropriate trial design and dose 
optimization approaches were important to validate results on dose. For 
instance, results from observational studies could be confounded by the lack 
of random allocation procedure. Studies applying retrospective analyses could 
suffer from limitation brought by the specificity of the a posterior analysis 
[120]. In Randomised Controlled Trials (RCTs) the small number of doses 
tested could limit the relevance of the study on investigating the dose-
response relationship and thus, on the OTD [29,49]. Information on dose 
efficacy is only available for the tested dose and inference on the efficacy of 
other doses is not advisable.  
Variations in the training protocol between intervention groups (or across 
multiple research sites) was thought to be another important issue on dose 
                                                     
5 ”Very early constraint-induced movement study during stroke rehabilitation” study. 
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optimization in clinical trials. These variations could obfuscate the true effect 
of different doses confounding results on dose [100,108] and decreasing the 
reliability of the results on doses [42,50,83,121].  
When clinical trials were aggregate in quantitative analyses they seemed to 
suggest a positive dose-response relationship between intervention dose and 
motor recovery after stroke [22,39,72,122,123,124,125]. This positive therapy 
effect for intensive (repetitive) task-specific protocols was particularly evident 
in studies with higher treatment contrast [124] and it was suggested 
irrespectively to either, upper and lower limbs motor functions and stage of 
stroke [39]. However, caution is needed in interpreting results on appropriate 
doses and protocols coming from quantitative analyses which synthetize 
studies with heterogeneity across included studies and among study groups 
[46]. In the available literature syntheses [83,125,126], heterogeneity has 
been found with respect to:  
i) training protocols and dose characteristics;  
ii) patients’ characteristics and time since stroke;  
iii) trials designs; and  
iv) trial outcome measures. 
Two systematic reviews, which included studies assessing the effect of 
different doses of the same intervention, were able to collate seven and 
fourteen studies respectively [125,126]. With this restriction, both reviews 
concluded that evidence on the enhanced benefit of higher dose are limited. 
They argued that the differences in therapy effect size found among included 
studies is likely to reflect the difference in the protocols and in the dose-
matching across studies. They concluded that definitive evidence on how 
much therapy is needed to maximise recovery after stroke is still not available. 
Besides, the efficacy and safety of high intensive protocols were not yet 
supported by strong evidence.  
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1.10 The optimal length of training 
Alongside with the relevance on identify the OTD, another key aspect of the 
training protocol is to know for how long the selected intervention dose should 
be delivered. Information on the time course of rehabilitative interventions 
outcome are indispensable to identify the appropriate length of treatment 
able to maximise rehabilitative intervention outcomes and thus, plan cost-
effective interventions.  
In stroke rehabilitation research longitudinal studies were rare. Few studies 
investigated the time course effect of interventions [127,128] or added a mid-
point measure [129] between the more common pre- to post-intervention 
assessment points. As a result, the length of treatment is often left to arbitrary 
choice [130,131] decreasing the chance to maximise therapy benefit.  
 
 
1.11 Making advances in dose optimization approaches  
Gathering early information on appropriate dose to test in subsequent efficacy 
phase II trials could improve the stroke rehabilitation research pathway in a 
cost-effective manner. In other words, if more information on appropriate 
dose were available from early phase I studies then, the efficacy of phase II 
trial in targeting the OTD increases, reducing the likelihood to test sub-optimal 
or dangerous doses. This approach, which is supported by the scientific 
community [50,73,132,133,134], and advocated by the Stroke Progress 
Review Group (2012)6 and the UK Medical Research Council (MRC)7, stresses 
on the relevance to improve knowledge on the OTDs of stroke rehabilitation 
by implementing rigorous pilot phase I designs, prior to phase II clinical trial. 
                                                     
6 http://www.ninds.nih.gov/about_ninds/groups/stroke_prg/2012-stroke-prg-full-
report.htm#RR (last visited April 2015). 
7 http://www.mrc.ac.uk/documents/pdf/complex-interventions-guidance/ (last visited April 
2015). 
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This pathway, rarely conducted in stroke rehabilitation research 
[49,51,74,75,135,136,137], is common in other fields of medicine [138]. 
Similarly, information on the appropriate length of therapy able to maximise 
training effect in a cost effective manner are rare in stroke rehabilitative 
interventions. To investigate the appropriate length of rehabilitative 
interventions and thus, to investigate the therapy effect over time, within-
patient variations of the selected outcome at different time points were 
required. These longitudinal approaches are not yet common in stroke 
rehabilitation research [127,130], but promising to fill this knowledge gap on 
appropriate training protocols [95]. 
Despite this call for dose optimization studies, rigorous methodological works 
which focus on how to identify the optimal dose and length of motor 
interventions in general, and for stroke rehabilitation intervention in particular 
are still absent.  
 
 
1.12 Overall research focus and statement of aims 
The main aim of this thesis was to serve the complex and challenging field of 
dose optimization in motor interventions by developing effective and rigorous 
methods of dose optimization suitable for stroke rehabilitation research. These 
new dose optimization methods will be able to provide evidence on the 
appropriate 1) dose and 2) length of motor interventions. In doing so, in this 
research project it was planned to: 
1. devise an innovative approach to dose optimization for motor 
interventions; 
2. test the feasibility and informative nature of the novel dose 
optimization design in stroke rehabilitative research; 
3. test the feasibility and informative nature of a multiple assessment 
procedure to identify the optimal length of a rehabilitative intervention 
in a stroke clinical research setting. 
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To ground with evidence the devising of the new dose optimization study 
(point 1), the dose optimization designs and approaches currently applied in 
two health research fields, the exercise-based training8 and the 
pharmaceutical clinical research were investigated. 
The rational to explore dose optimization in exercise-based training literature 
was the direct relevance of this field to stroke rehabilitation research. Both 
fields, in fact, applied motor interventions to achieve their goals. Furthermore, 
in exercise-based training several guidelines and recommendations on 
appropriate training dose and protocols were available by leading health 
agency. Whereas, pharmaceutical research was investigated because assumed 
to apply the “gold” standard designs and approaches in dose optimization 
processes [139]. 
 
To fulfill this research breakthrough, the following specific aims and objectives 
were set and addressed in the remaining chapters of this PhD thesis.  
Aims 1: to identify dose optimization approaches that were suitable for use 
in stroke rehabilitation research. The specific objectives were to:  
a. identify the dose optimization approaches that have been applied in 
exercise-based training research (study 1, chapter 2); 
b. identify the pharmaceutical industry standard procedures of dose 
optimization used in clinical trials (study 2, chapter 3); 
c. use the information gathered from addressing objectives 1a. and 1b. 
to devise a dose optimization trial design suitable for use in stroke 
rehabilitation research (study 3, chapter 4). 
 
                                                     
8 The term exercise-based training was used, in all this thesis, to collate all the terminologies 
which refer to physical activity, exercise trainings and physical therapy programs. 
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Aims 2: to test the feasibility of a novel phase I dose optimization trial design 
for motor interventions after stroke (study 4, chapter 5). Specific objectives of 
this feasibility study were to: 
a. assess whether all the features of the new protocol to dose 
optimization were feasible for motor interventions after stroke; 
b. explore on the sample size in dose optimization trials of motor 
interventions; 
c. explore the informative nature to stroke rehabilitation of the dose 
optimization data provided; 
d. explore the feasibility of using the data generated from this design to 
dose optimization; 
e. investigate how results on dose could be used and shown; 
f. assess feasibility of the recruitment procedure and retention rate; 
g. identify any further refinements that could enhance the 
appropriateness of this design. 
 
Aims 3: to assess the feasibility and acceptability of undertaking repetitive 
assessments to identify the appropriate length of stroke rehabilitative 
interventions in a clinical efficacy trial (study 5, chapter 6). Specific objectives 
of this feasibility study were to: 
a. assess the feasibility of the repetitive assessment procedure  
b. explore the feasibility of using the data generated from this design 
to help determine the appropriate length of the trial intervention; 
c. explore the relevance of data collection on the intervention therapy 
effect over time and thus, on the intervention appropriate duration; 
d. explore the appropriateness of undertaking weekly measure points; 
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e. determine if there were additional requirements to implement the 
new trial design. 
The following chapter 2 was set to identify dose optimization methods and 
approaches applied in exercise-based training. This background of knowledge 
was then used to devise a newly dose optimization approach for stroke 
rehabilitation research.  
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Chapter 2:  
Dose optimization 
approaches in exercise-
based training research:  
a Systematic Review 
 
2.1 Introduction 
Stroke rehabilitation research does not apply dose optimization approaches to 
identify the optimal therapeutic doses. Stroke rehabilitation is a relatively 
young scientific discipline [37] and its complex nature could explain, in part, the 
challenge in addressing efficaciously the issue of appropriate doses of training. 
To ameliorate this research gap, it appeared useful to investigate dose 
optimization approaches in the broad field of exercise-based training (ExBT)9. 
ExBT literature includes all research applying exercises and motor interventions 
to achieve performance and health related goals. This field of research has a 
longstanding research history on the study of the optimal doses and protocols 
of training. The first speculation that the right dose of physical exercise was a 
critical component to preserve or improve individuals’ health was made by 
Hippocrates (460–377 B.C.). He believed that “if we could give every individual the 
                                                     
9 The term exercise-based training collated all the terminologies which refer to physical 
activities, exercise trainings, motor and rehabilitative interventions. 
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right amount of nourishment and exercise, not too little and not too much, we would 
have found the safest way to health” [140].  
Nowadays recommendations and guidelines on the appropriate training dose 
and protocols were issued by scientific and regulatory bodies including the 
WHO10, the American College of Sports Medicine (ACSM), the American Heart 
Association (AHA), and the US Department of Health and Human Service11. 
These agencies represent the main source of information for sport and health 
professionals to shape training programmes.  
The first recognised evidence-based recommendations on physical activity and 
exercise was published by the Centre for Disease Control and Prevention (CDC) 
and the ACSM in 1995 [141]. Since then, new recommendations and guidelines, 
based on updating evidence, have been regularly published on the appropriate 
dose to improve performance and health.  
Guidelines indications on appropriate training doses derive from the evidence 
upon which they were based. Therefore, the quality and validity of these 
primary studies are important to assess the strength of guidelines in providing 
reliable results on dose. The implementation of inadequate methodological 
approaches in primary studies to identify the dose and protocols could seriously 
distort results on dose and thus, it could invalidate the guidelines and 
recommendations outcomes. Despite the key role of studies upon which 
guidelines and recommendation were based, an assessment on their dose 
optimization approaches have not been done yet. Assessing the current dose 
optimization procedures of guidelines primary studies can guide in devising 
reliable method to dose optimization for motor interventions in general and 
stroke rehabilitation in particular.  
 
                                                     
10 WHO global health recommendations  
(http://apps.who.int/iris/bitstream/10665/44399/1/9789241599979_eng.pdf) Accessed 14 
Dec 2012 
11 Department of Health and Human Service online physical activity guidelines for Americans 
2008 http://www.health.gov/paguidelines/pdf/paguide.pdf. Accessed 25 Jun 2012 
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The main aim of this systematic review was to identify dose optimization 
approaches that were suitable for use in stroke rehabilitation research 
investigating dose optimization designs applied in exercise-based training 
literature (Overall Aim 1; objective 1.a) In addition, a taxonomic study on the 
definition of the training dose and its components towards dose optimization 
was conducted. The knowledge gathered from this review guided the devising 
a new dose optimization approach for use in physical interventions. 
 
 
2.2 Methods 
2.2.1 Design 
A systematic review of published data on dose optimization approaches applied 
to ExBT was conducted following the recommendations of the Cochrane 
Collaboration12. The PRISMA guidelines13 were used to report findings.  
2.2.2 Search strategy 
In ExBT guidelines and recommendations are considered the main sources of 
information on appropriate dose and protocols. Consequently, for this 
systematic review the search for relevant studies was based on the three latest 
guidelines published by the two leading public health agencies in ExBT, the 
ACSM and the AHA [142,143,144]. All the studies upon which these guidelines 
and recommendations were based were assessed for inclusion. 
These guidelines, however, were based on studies published between 1982 and 
2007. To update these searches a systematic search on relevant publications 
published between 2007 and 2011 was conducted in November 2011 and, 
subsequently, updated in September 2015. 
                                                     
12 http://www.cochrane-handbook.org/, last visit on July 2012. 
13 http://www.prisma-statement.org/ last visit on October 2012 
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The electronic searches were made in the following databases: Medline, 
Embase, CINHAL Plus, and CENTRAL. No language restriction was applied to the 
searches. The Medline search was implemented with the collaboration of the 
librarian at the University of East Anglia (UEA) and subsequently modified for 
each database search. The primary researcher (EC) performed all electronic 
searches. The complete electronic search strategies were provided in Appendix 
A.  
Lead authors14 were contacted to screen for unpublished (grey) relevant 
research and ongoing research. 
Main search terms included a combination of the following subject headings 
and keywords:  
(exercise or therapy or training or motor activity or physical activity) AND  
(dose or dose relationship or dose-response or dose-finding or intensity or 
frequency or duration or time or amount or power or how much or repetition or 
set or load or volume or work) AND  
(training or therapy or protocol or activity or program or schedule).   
2.2.3 Inclusion criteria 
Studies were included in this review if:  
1) they were dose optimization studies reporting empirical data. To be 
identified as a dose optimization a study should: 
- investigated the same intervention among groups apart from the dose or 
the training protocol. As the largest sport medicine and exercise science 
organisation in the word, the ACSM15 classification of different physical 
activities was used to assess the training programme characteristics 
[145]; 
                                                     
14 Lead author on the field was defined as any author who published at least three relevant 
studies. 
http://www.acsm.org/
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- involved more than one intervention group among which the different 
doses were applied.  
2) the training dose or training protocol was specified (i.e.: training intensity, 
amount, duration, volume of training, time spent exercising, frequency or 
length of training); 
3) assessed functional abilities (i.e.: activity of daily living (ADL), balance, 
walking, climbing steps) or muscular functions (i.e.: muscular strength, 
power, torque, endurance, force). Occurrences of adverse events (AEs) was 
considered when reported in the study.  
To be consistent with the inclusion criteria set by the guidelines used to identify 
relevant studies, papers were included if: 
4) involved healthy adults (18+ years) or, adults with chronic conditions16 aged 
50+ years;  
Translations were available for studies published in Italian, Spanish and French 
languages.  
2.2.4 Exclusion criteria 
Studies were excluded from this review if they included as a primary 
population: 
- athletes; 
- pregnant women or women who were in a post-partum period;  
- people in their pre or post-operative period. 
Only primary studies with empirical data were included so, literature reviews 
were excluded.  
                                                     
16 A chronic condition was defined as any condition requiring regular medical treatment or a 
condition which causes any physical functional limitation. Therefore, the acute stages of chronic 
conditions were included. This inclusion criterion was consistent with the inclusion criteria 
applied in the reviewed guidelines. 
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2.2.5 Identification of studies 
The primary researcher downloaded all citations on EndNote X6 programme17 
where the electronic de-duplication of papers was made.  
After de-duplication, the primary researcher and an additional reviewer (LC) 
independently screened all articles by title, abstract and full-text for inclusion. 
Reviewers met after each screening step checking selection results for 
agreement. If any inconsistent selection has arisen, reviewers went back to the 
original source and consensus was sought by discussion. If disagreement 
persisted between the two reviewers (EC and LC) a third person (VP) was 
available to make the final decisions. 
The study selection procedure was consistent for studies retrieved from 
guidelines and electronic searches.   
2.2.6 Data Extraction  
Data extraction was undertaken by the primary researcher. A predesigned data 
extraction sheet (see Table 2-1) was used to record information for each study 
on:  
- authors and date of publication;  
- trial design characteristics;  
- target population and sample size;  
- type of exercise-based training applied;  
- training schedule (frequency and length of the training);  
- training dose characteristics (number of dose applied, dose manipulation 
process and characteristic of the dose studied);  
- outcome measurements;  
- assessments and follow-up time points.  
Data from multiple reports of the same study were extracted from each report 
directly into a single data collection form.  
                                                     
17 See http://endnote.com/ for more details on the reference programme tool. 
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If any relevant data was missing from the study report an attempt was made to 
obtain it by contacting the lead authors by email. 
Table 2-1: Data extraction sheet 
 
 
 
2.2.7 Risk of potential bias assessment 
A methodological quality score was developed with items recommended by the 
Cochrane Collaboration18 tool for methodological quality assessment.  
Because not all the Cochrane Collaboration items were considered appropriate 
for dose optimization studies, a modification was made as used by Kwakkel and 
colleagues in a previous review investigating the effect of different intensities 
of training after stroke [53]. Focus of this review were the elements of the trial 
design and training protocol which could bias the dose optimization results. To 
validate the strength of the studies, trial designs and approaches used to dose 
optimization, five items were added. These scores assessed key variables of the 
study design and therapy protocol which could modify the intervention effect 
size biasing results on dose. In detail, a control on the presence of co-
interventions and on the adherence to the training protocol were added. These 
are important factors to increase reliability on the information on dose and on 
the methodological quality of the study. In a systematic review investigating 
the quality of reporting the training dose on stroke rehabilitation research using 
the FITT components (Frequency, Intensity, Time and Type of exercise), authors 
claimed that, without a detailed information on the prescribed and actually 
                                                     
18 See: Cochrane Handbook, Part:2, chapter 8.5 
(http://handbook.cochrane.org/chapter_8/figure_8_6_a_example_of_a_risk_of_bias_table_fo
r_a_single.htm). 
Population ExBT
Study R C 
gr
Length 
ExBT
Freq 
d/wk
nr of 
dose
s
Manipulation 
applied
Studied dose 
characteristic 
V 
const
.
type method
1
2
3
C gr= Control Group
V= training Volume
Design Characteristics
Trial design charact.
Controlled Trial (CT) 
Scheduling Dose Outcomes
Assessments 
& follows-up
RCT= Randomized controlled Trials 
R= Randomization procedure
R= Randomization procedure
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received dose and type of exercise training, results on dose were difficult to 
discern [45].  
The presence of baseline balanced group procedure and sample-size 
calculation was assessed to validate the strength of results on the intervention 
effect size and dose. 
The onset of AEs was an important indicators of the feasibility and safety of the 
applied dose.  
As a result, the following nine items were evaluated for each included study: 1) 
presence of randomization sequence procedure; 2) presence of allocation 
concealment procedure; 3) presence of blinding outcome assessor procedure; 
4) baseline balanced groups procedure; 5) sample-size calculation; 6) control 
for co-intervention; 7) adherence to the protocol; 8) consistency on outcome 
assessments; and, 9) recording of AEs. 
The risk of potential bias was assessed by the first reviewer based on a summary 
assessment of the risk of bias for each items.  
 
 
2.3 Analysis 
The aim of this review was not to test the effectiveness of any intervention 
dose, nor protocol but rather, to explore the designs and approaches applied 
to dose optimization. Thus, a meta-analysis was not planned for this review. 
Instead, narrative descriptions were undertaken on:  
 the dose optimization designs and approaches applied in ExBT;  
 the definition and manipulation of the training dose and training 
protocol towards optimization. 
Studies were grouped primarily according to the trial design. Sub-groups were 
made on the characteristics of the dose optimization approach implemented 
and on the applied definition and manipulation of the dose and training 
protocol. 
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2.4 Results 
2.4.1 Identification of relevant studies: flow of references 
Fifty-nine studies met the inclusion criteria of this review (reference list of 
included studies can be found in Appendix B). The flowchart of the review 
search and selection process following PRISMA recommendations19 is reported 
in Figure 2-1.  
In detail, 431 potential citations were identified from the three guidelines and 
recommendations of reference and, 1,223 citations were identified from the 
electronic searches. Articles were collated in one database and 1,623 potential 
studies were retrieved after electronic de-duplication. From the first screening 
on study titles, 962 citations were excluded because they were clearly not 
relevant for this review. 556 studies were then excluded based on their 
abstracts. Of the remaining 105 studies, the full texts were assessed for 
inclusion and 53 studies were further excluded. A list of excluded studies, with 
justification for exclusion is available in Appendix C). Major reasons for 
exclusions were: study not identified as a dose optimization study; different 
training modalities applied between groups or within the group; full text not 
available; populations and measures not compliant with the inclusion criteria. 
The update electronic search, performed in September 2015, identified 591 
further potential studies. Of them, 511 were excluded by title, 54 by abstract 
and 19 by their full text.  
A test to assess the two reviewers understanding of inclusion criteria was made 
for the first one hundred titles in the reference list. The agreement between 
the two authors was considered excellent, with a kappa statistic value [146] 
equal to 0.78. 
Persistent disagreement between the two reviewers (EC and LC) arose for two 
studies at the full-text stage. The disagreement was on the inclusion (or not) of 
two studies involving well-trained subjects. The two reviewers had different 
                                                     
19 See: http://www.prisma-statement.org/statement.htm, last visited on 07/2012 
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opinion on considering these subjects as athletes or well fit subjects. The third 
party (VP) made the final decisions including the two studies in the review. 
Figure 2-1: Flowchart of the review search and selection process on dose-
finding approaches in exercise-based training 
 
 
2.4.2 Characteristics of studies 
Table 2-2 summarises all the relevant characteristics of the fifty-nine studies 
included in this review, grouped by trial design and by the characteristics of the 
studied dose. Table 2-3 condenses the review’s key results reported on Table 
2-2. 
Primary studies included in this review  
n=59 
Identification after 
duplicate removal n=1,623 
Records excluded based 
on screening of title: 
962 
Records excluded based on 
screening of full-texts: 53 
No full-text available: 10 
Language restriction: 1 
Duplicate publication: 1 
Dissertation:  1 
No ExBT:   1 
Population:  4 
Outcome:  3 
Different training modalities:  13 
Not dose-finding study:  19 
Records retrieved from all 
databases: 1,223 
Search updates September 2015: 
591 new records retrieved. 
 Relevant records: 7 
Records excluded based 
on screening of 
abstract: 556 
Records retrieved from 
Guidelines and 
recommendations: 431 
Potentially relevant studies 
n=105 
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Table 2-2: Characteristic of included studies by trial design 
 STUDY 
TRIAL DESIGN CHARACT. 
POPULATION EXBT 
SCHEDULING DOSE OUTCOMES 
ASSESSM
ENTS & 
FOLLOW
S-UP 
DESIGN R C GR 
LENGT
H EXBT 
FREQ 
D/WK 
NR OF 
DOSE 
MANIPULATION 
APPLIED 
STUDIED 
DOSE 
CHARACTERIS
TIC 
V 
CON
ST 
TYPE METHOD 
Controlled Trial (CT) 
1 Ahtiainen, 2005 
cross-
over 
group 
N N 
13 healthy 
adults 
recreationally 
trained men (22-
35y), 
RT 
24 
weeks 
2 2 
HI/less sets vs. 
LI/more sets/ 
Intensity & 
amount 
N 
muscle 
strength 
1RM 
pre- 3 - 6 
months 
tests 
2 Berger, 1962a 
parallel 
group 
N N 
177 healthy 
sportive 
university 
students; 
RT 
12 
weeks 
3 9 
1Set 2RM vs.       1Set 
6RM vs.       1Set 
10RM vs.      2Set 
2RM vs.     2Set 6RM 
vs.     2Set 10RM vs.     
3Set 2RM vs.     3Set 
6RM vs.     3Set 
10RM 
Intensity & 
amount 
Y 
muscle 
strength 
1RM 
pre- 3 - 6 - 
9 and 12 
weeks 
3 Berger, 1962b 
parallel 
group 
N N 
199 healthy 
sportive 
university 
students; 
RT 
12 
weeks 
3 6 
2RM vs. 4RM vs. 
6RM vs. 8RM vs. 
10RM vs. 12RM 
Intensity & 
amount 
Y 
muscle 
strength 
1RM 
pre/post 
training 
test 
4 Signorile, 2004 
parallel 
group 
N N 
17 old (61-75y) 
untrained 
women 
RT 
12 
weeks 
3 2 
10reps, low 
resistance vs. 6reps, 
high resistance 
Intensity & 
amount 
N 
Average 
muscle 
power; peak 
torque 
dynamometer 
pre 
/weekly 
/post 
training 
test 
5 Borst SE, 2001 
parallel 
group 
N Y 
31 healthy 
subjects (25-
50y) 
RT 
25 
weeks 
3 2 1-set vs. multiple-set Amount N 
muscle 
strength 
1RM 
pre/ 13 - 
25 weeks 
6 Goto, 2004 
parallel 
group 
N N 
17 recreational 
active healthy 
young subjects 
(19-22y) 
RT 
(10 
wks) 4 
weeks 
2 2 
HI/low reps vs. 
HI/low reps+1 
additional 
set(LI/high) 
Amount N 
muscular 
strength and 
endurance 
1RM 
pre/post 
training 
test 
7 McBride, 2003 
parallel 
group 
N Y 
28 untrained 
young men and 
women 
RT 
12 
weeks 
2 2 1 Set vs. 6 and 3 Sets Amount N 
muscular 
strength 
1RM= dynamic 
test 
pre - 6 - 12 
weeks 
8 Hunter,1988 
parallel 
group 
N N 
44 young 
healthy subjects 
(20-28y) 
RT 
7 
weeks 
VAR 2 
3d/wk, 3 sets vs. 
4d/wk, 
Frequency Y 
Muscular 
strength and 
endurance; 
1RM free-
weight; 
endurance=max  
reps at 50%RM 
pre/post 
training 
test 
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9 Capen, 1956 
parallel 
group 
N N 
159 healthy 
university men 
RT 
12wee
ks 
VAR 4 
3d/wk, 8-15RM vs. 
5d/wk, 8-15RM vs. 
3d/wk, 5RMx3 vs. 
5d/wk,5RMx3 
Frequency N 
muscle 
strength 
1RM free 
weight and 
machines 
pre/post 
training 
test 
10 Jigami H, 2012 
parallel 
group 
N N 
36 women with 
hip 
osteoarthritis 
(42-79y) 
Land 
and 
aquatic 
exserc. 
10 
session
s 
VAR 2 
1/week vs. 1 
/fortnightly 
Frequency Y 
muscle 
strength; 
functional 
activity; 
questionnair
e. 
Peak force 
dynamometer; 
Timed up to go; 
Time of one-leg 
standing with 
open eyes; 
Harris Hip 
Score; SF-36 
pre/post 
training 
test 
11 Nakamura, 2006 
parallel 
group 
N Y 
45 healthy 
sedentary 
women (60-75y) 
Recrea
t. 
activity 
+ RT 
12 
weeks 
VAR 3 
90min 1d/wk vs. 
90min 2d/wk vs. 
90min 3d/wk 
Frequency N 
functional 
fitness test 
IADL 
pre/post 
training 
test 
Randomized Controlled Trial (RCT)        
12 Humburg H, 2007 
cross-
over 
Y Y 
21 untrained 
men and women 
(18-35y) 
RT 
9 
weeks 
X2 
3 2 1-Set vs. 3-Set Amount N 
muscle 
strength 
1RM 
pre -
middle 
and post 
training 
test 
13 Kemmler, 2004 
cross-
over 
Y N 
71 well-trained 
postmenopausal 
women (50-60y) 
RT 
29 
weeks 
(12wks 
x2) 
2 + 2 2 
single-set vs. 
multiple-set 
Amount Y 
muscle 
strength 
1RM free-
weight 
pre/post 
training 
test 
14 Anderson, 1982 
parallel 
group 
Y N 
43 healthy 
untrained young 
subject (18-24y) 
RT 
9 
weeks 
3 3 
HI-Lrep (6-8RM) vs. 
LI-Hrep (100-150RM) 
vs. MI-Mrep (30-
40RM) 
Intensity & 
amount 
Y 
muscle 
strength; 
absolute and 
relative 
endurance 
1RM 
pre/post 
training 
test 
15 Campos, 2002 
parallel 
group 
Y Y 
27 healthy fit 
untrained young 
male plus 5 
control (18-30y) 
RT 
8 
weeks 
2 (4 
wks); 3 
(4 wks) 
3 
LowR vs. IntR  vs. 
HighR 
Intensity & 
amount 
Y 
muscular 
strength and  
endurance 
1RM= free 
weight; 
endurance= 
max. nr of reps 
at 60%RM 
pre-post 
interventio
n 
16 Ewing J, 1990 
parallel 
group 
Y N 
21 young 
healthy men 
(20-26y) 
RT 
10 
weeks 
3 2 8RM vs. 20 RM 
Intensity & 
amount 
N 
isokinetic 
strength 
dynamometer 
pre/post 
training 
test 
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17 Holm, 2008 
parallel 
group 
Y N 
12 sedentary 
healthy young 
men (20-25y) 
RT 
12 
weeks 
3 2 
70%RM x 8reps vs. 
15.5%RM x 36reps 
Intensity & 
amount 
Y 
muscle 
strength, 
peack torque 
1RM= isokinetic 
dynamometer; 
pre, 10th, 
20th, 30th 
session 
and post-
tests 
18 Hsieh, 2011 
parallel 
group 
Y Y 
18 chronic 
stroke (45-70y) 
RT 
4 
weeks 
5 2 HI vs. Low I 
Intensity & 
amount 
N 
muscle 
strength; 
functional 
activity 
strength= MRC; 
function= FMA 
and motor 
activity log 
pre/post 
training 
test 
19 
Kalapotharakos, 
2004 
parallel 
group 
Y Y 
33 inactive 
participants (60-
74 y) 
RT 
12 
weeks 
3 2 
High-RT 8 reps 
80%RM vs. 
Moderate-RT 15reps 
60%RM, 
Intensity & 
amount 
N 
strength; 
peak torque; 
functional 
perform. 
1RM 
pre/post 
training 
tests 
20 Kraemer, 2004 
parallel 
group 
Y Y 
85 physical 
active college 
aged women 
RT 
24 
weeks 
3 4 
total-body 3-5RM vs. 
8-12RM; up-body  3-
5RM vs. 8-12RM 
Intensity & 
amount 
Y 
muscle 
strength and 
power 
1RM, power= 
Jump squat and 
ballistic press 
pre - 12 
weeks - 
post 
training 
21 Nemoto, 2007 
parallel 
group 
Y Y 
246 healthy 
middle-age/ old 
subjs 
Walkin
g train. 
20 
weeks 
4 2 
moderate-Int 
continuous vs.HI 
interval walking 
Intensity & 
amount 
N 
muscle 
strength 
1RM= isokinetic 
dynamometer; 
pre/post 
tests 
22 O'Shea, 1963 
parallel 
group 
Y N 
30 healthy 
young subjects 
RT 
6 
weeks 
3 3 
9-10RM vs. 5-6RM 
vs. 2-3RM 
Intensity & 
amount 
Y 
dynamic and 
static 
strength 
1RM free-
weight and 
dynamometer 
pre- 2 -4 -6 
weeks 
23 Paulsen, 2003 
parallel 
group 
Y N 
18 untrained 
young healthy 
male subjects 
RT 
6 
weeks 
3 2 
3set LL-1set UL gr vs. 
1set LL-3set UL 
Intensity & 
amount 
N 
muscle 
isometric and 
dynamic 
strength 
1RM free-
weight and 
isokinetic 
pre/post 
training 
test 
24 Rana, 2008 
parallel 
group 
Y Y 
34 healthy 
young females 
(18-23y) 
RT 
6 
weeks 
3 2 
TS: 6-10RM vs. TE: 
20-30RM 
Intensity & 
amount 
Y 
muscular 
endurance, 
strength, 
power 
1RM free-
weight; 
endurance= 
max reps at 
60%RM 
pre/post 
tests 
25 Stone, 1994 
parallel 
group 
Y N 
50 college-age 
women with no 
formal RT 
experience 
RT 
9 
weeks 
3 3 
HI/LowReps vs. 
MedI/MedReps vs.  
LI/LowReps 
Intensity & 
amount 
Y 
muscle 
strength; 
absolute and 
relative 
endurance 
1RM free 
weight; 
absolute 
endurance, 
relative 
endurance 
pre/post 
training 
test 
26 Vincent, 2002 
parallel 
group 
Y Y 
62 healthy old 
adults (60-85y) 
RT 
6 
month
s 
3 2 
50%RM, 13reps vs. 
80% RM, 8reps 
Intensity & 
amount 
Y 
muscular 
strength; 
1RM free 
weight; 
pre/post 
training 
test 
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27 Harris, 2004 
parallel 
group 
Y Y 
61 older 
untrained adults 
(70-90y) 
RT 
18 
weeks 
2 3 
2sets, 15RM vs. 
3sets, 9RM vs. 4sets 
6RM 
Intensity & 
amount 
Y 
muscle 
strength 
1RM free 
weight and 
machines 
pre- 6- 12 
weeks 
post 
treatment 
28 Fatouros, 2006 
parallel 
group 
Y Y 
58 healthy, 
inactive older 
men (65- 78 y) 
RT 
24 
weeks 
3 3 
LI 40-45%RM vs. MI 
60-65%RM vs. HI 80-
85%RM 
Intensity & 
amount 
Y 
muscle 
strength 
1RM= weight 
machines 
pre/post 
training 
test 
29 Weiss, 1999 
parallel 
group 
Y Y 
38 untrained 
young men (18-
30y) 
RT 
7 
weeks 
3 2 
3-5RM vs. 13-15RM 
vs. 23-25RM; 
Intensity & 
amount 
Y 
muscle 
strength, and 
peak torque 
1RM= dynamic 
RT machine; 
Peak torque 
pre/post 
training 
test 
30 Van Roie, 2013 
parallel 
group 
Y N 
56 community-
dwelling old 
subjects (60+y) 
RT 
12 
weeks 
3 2 
2 x 10-1* 20RM vs. 1 
x 80-100* 40RM 
Intensity & 
amount 
Y 
muscle 
strength, & 
volume, 
dynamic 
force 
dynamic peak 
torque, CT-
scan, 1RM 
pre/post 
training 
test 
31 Abrahin, 2014 
parallel 
group 
Y N 
30 elderly 
woman (65-71y) 
RT 
24 
trainin
g 
session
s 
2 2 1 set vs. 3 sets Amount N 
muscle 
strength, & 
performance 
1RM, sit-to-
stand test 
pre/post 
training 
test 
32 Baker, 2013 
parallel 
group 
Y Y 
20 recreationally 
trained young 
men (18-21y) 
RT 
8 
weeks 
3 2 1 set vs. 3 sets Amount N 
muscle 
strength 
1RM free 
weight 
pre/post 
training 
test 
33 Galvão, 2005 
parallel 
group 
Y N 
28 healthy old 
subjects (65-
78y) 
RT 
20 
weeks 
2 2 1-Set vs. 3-Set Amount N 
muscular 
strength, 
endurance 
and physical 
tests 
 
pre/post 
training 
test 
34 Han, 2013 
parallel 
group 
Y Y 
32 acute stroke 
(35-80y) 
MRP 
6 
weeks 
5 3 
1hour vs. 2hours vs. 
3hours 
Amount N 
functional 
activities and 
ADL 
FMA, ARAT, BI 
Pre- 2- 4 
weeks and 
post 
training 
35 Hass, 2000 
parallel 
group 
Y N 
49 adults weight 
recreational 
weightlifter (20-
50y) 
RT 
13 
weeks 
3 2 
single set vs. 
Multiple sets (3) 
Amount N 
isometric 
strength, 
endurance; 
isometric 
strength, 
endurance 
pre- 
7weeks- 
post 
training 
36 Kelly, 2007 
parallel 
group 
Y Y 
40 healthy 
recreational 
trained students 
RT 
8 
weeks 
2 2 single sets vs. 3  sets Amount N 
muscle 
strength 
1RM= isokinetic 
dynamometer; 
pre/ 4 -8 
weeks; 
37 Marzolini, 2008 
parallel 
group 
Y N 
72 old subjs with 
CD (55-65y) 
AT+RT 
24 
weeks 
3 + 2 
AT/RT 
2 single sets vs. 3  sets Amount N 
muscle 
strength; 
isokinetic, 
endurance 
1RM= isokinetic 
dynamometer; 
endurance 
pre/post 
tests 
53 
 STUDY 
TRIAL DESIGN CHARACT. 
POPULATION EXBT 
SCHEDULING DOSE OUTCOMES 
ASSESSM
ENTS & 
FOLLOW
S-UP 
DESIGN R C GR 
LENGT
H EXBT 
FREQ 
D/WK 
NR OF 
DOSE 
MANIPULATION 
APPLIED 
STUDIED 
DOSE 
CHARACTERIS
TIC 
V 
CON
ST 
TYPE METHOD 
38 Munn, 2005 
parallel 
group 
Y Y 
115 untrained 
young healthy 
subjects (18-
30y) 
RT 
6 
weeks 
3 4 
1setFast vs. 3setFast 
vs. 1setSlow vs. 
3setSlow 
Amount N 
muscular 
strength; 
1RM free 
weight; 
pre/post 
training 
test 
39 Rhea, 2002 
parallel 
group 
Y N 
16 recreationally 
trained men (19-
23y) 
RT 
12 
weeks 
3 2 
single-set vs. 
multiple-set 
Amount N 
muscle 
strength 
1RM free 
weight and 
machines 
pre/post 
training 
test 
40 Ronnestad, 2007 
parallel 
group 
Y N 
21 untrained 
young men (25-
30y) 
RT 
11 
weeks 
3 2 
3set LL-1set UL gr vs. 
1set LL-3set UL 
Amount N 
muscle 
strength; 
peak torque 
1RM free 
weight and 
machines; Peak 
torque 
pre/ 3, 6, 9 
weeks 
41 
Schlumberger, 
2001 
parallel 
group 
Y Y 
27 young active 
women (20-40y) 
RT 
6 
weeks 
2 2 single-set vs. 3-set Amount N 
muscle 
strength 
1RM machines; 
pre/post 
training 
test 
42 Starkey, 1995 
parallel 
group 
Y Y 
59 untrained 
healthy subjects 
(18-50y) 
RT 
14 
weeks 
3 2 
single set vs. multiple 
sets 
Amount N 
maximal 
isometric 
strength; 
Isometric 
torque= 
dynamic 
ergometer 
pre/post 
training 
test 
43 da Silva, 2014 
parallel 
group 
Y N 
20 stroke 
survivors (60-
80y) 
task 
oriente
d 
trainin
g (TOT) 
6 
weeks 
2 2 
TOT with vs. without 
load 
Intensity N 
functional 
tests 
upper 
extremity 
performance, 
FMA, strength 
pre/post 
training 
test 
44 Hunter, 2001 
parallel 
group 
Y Y 
15 sedentary old 
women and 
fifteen men (60-
70y) 
RT 
25 
weeks 
3 2 
High-RT 80%RM vs. 
Variable-RT 50-65-
60%RM, 
Intensity N 
muscle 
strength; 
isometric 
strength; 
daily tasks 
 
pre- every 
25days 
/post tests 
45 de Paleville, 2009 
parallel 
group 
Y N 
32 active 
healthy old subj 
(55-83y) 
Body 
RecT 
8 
weeks 
3 2 with vs. Without load Intensity N 
muscle 
isometric 
strength; 
dynamometer; 
functional 
ability tests 
pre/post 
training 
test 
46 Dromerick, 2009 
parallel 
group 
Y N 
52 Stroke 
survivors (50-
80y) 
CIMT 
2 
weeks 
5 2 
standard CIMT vs. HI 
CIMT 
Intensity N 
functional 
ability; 
Independenc
e; pain 
NIH stroke 
scale; ARAT 
test; FIM; 
Stroke Impact 
Scale 
pre/post 
training + 
90 days 
follow-up 
47 Miszko, 2003 
parallel 
group 
Y Y 
50 old subjects 
with low level of 
physical function 
(65-90y) 
RT 
8 
weeks 
3 2 80%RM vs. 40%RM Intensity N 
muscular 
strength; 
physical 
function test 
1RM free-
weight; physical 
function test= 
CS-PFP 
pre/post 
training 
test 
48 Neils, 2005 
parallel 
group 
Y N 
19 healthy 
young with RT 
experience (18-
30y) 
RT 
8 
weeks 
3 2 80%RM vs. 50%RM Intensity N 
muscular 
strength; 
peak power 
1RM free-
weight; peak 
power 
pre/post 
training 
test 
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V 
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ST 
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49 de Souza, 2010 
parallel 
group 
Y N 
20 recreationally 
trained men 
RT 
6 
weeks 
6 2 
constant vs. 
decreasing rest 
intervals and 
intensity 
Intensity N 
muscle 
strength; 
peak torque 
1RM free-
weight ; peak 
torque 
pre/post 
training 
test 
50 de Vos, 2005 
parallel 
group 
Y Y 
112 untrained 
healthy old 
subjects (≥ 60y) 
RT 
12 
weeks 
2 2 
20%RM vs. 50%RM 
vs. 80%RM 
Intensity N 
muscular 
strength, 
endurance 
and power 
1RM, and Watt 
week 0 -8 - 
12 
51 Pollock, 1993 
parallel 
group 
Y Y 
50 men + 28 
women; young 
with no RT 
experience (18-
35y) 
RT 
12 
weeks 
VAR 4 
1d/w 1set vs. 2d/w 
1set vs. 1d/w  vs. 
2d/w; 
Frequency N 
isometric and 
dynamic 
muscle 
strength 
CERVICAL 
Extensor 
machine 
pre/post 
training 
test 
52 Henwood, 2008 
parallel 
group 
Y Y 
67 old healthy 
subjects (65-
84y) 
RT 
24 
weeks 
2 2 
75%RM vs. varied 
load (45%, 60%, 
75%RM) 
Intensity N 
muscle 
strength, 
endurance, 
power, 
functional 
perform. and 
balance 
1RM, 
endurance, 
power, physical 
perform. tests 
pre/ 8- 24 
week 
53 Cauraugh, 2009 
parallel 
group 
Y Y 
30 chronic 
stroke (55-80y) 
CBT 
2 
weeks 
4 2 with vs. Without load Intensity N 
muscle 
strength, 
functional 
ability and 
dexterity 
level 
isometric and 
isotonic muscle 
contraction; 
Box and Blocks, 
functional and 
dexterity tests 
pre/post 
training 
test 
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Onambélé-
Pearson, 2010 
parallel 
group 
Y N 
34 healthy old 
active subjects 
(60-79y) 
RT 
12 
weeks 
3 2 80%RM vs.40%RM Intensity N 
muscle 
strength, 
max 
isometric 
force and 
functional 
ability; 
1RM, functional 
ability tests 
dynamometer; 
Cybex machine; 
pre/post 
tests 
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DiFrancisco-
Donoghue, 2007 
parallel 
group 
Y N 
18 healthy old 
subjects (65-
79y) 
RT 
9 
weeks 
VAR 2 1d/w vs. 2d/wk Frequency N 
muscle 
strength 
1RM free-
weight 
pre/post 
training 
test 
56 Candow, 2007 
parallel 
group 
Y N 
29 untrained 
people (27-58 y) 
RT 
6 
weeks 
VAR 2 
3d/wk, 2 sets vs. 
2d/wk, 3sets 
Frequency Y 
muscle 
strength 
1RM 
pre/post 
training 
test 
57 Farinatti, 2013 
parallel 
group 
Y Y 
48 active 
woman (60-78y) 
RT 
16 
weeks 
VAR 3 
1d/wk vs. 2 vs. 
3d/wk 
Frequency N 
functional 
performance 
and strength 
1RM, functional 
ability tests 
pre/post 
training 
test 
58 Sato, 2009 
parallel 
group 
Y N 
22 frail elderly 
subjects (75-
85y) 
water 
ex. 
2 years VAR 2 1d/w vs. 2d/wk Frequency N 
muscle 
strength; 
functional 
ability 
strength= 
dynamometer; 
ADL ability=FIM 
pre/ 
6months; 
1 and 2 
years 
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Other Trial Design        
59 McDermott, 2006 
categori
zed 
groups 
X X 
417 old subjects 
with PAD (≥ 55y) 
Walkin
g train. 
3 years VAR 3 
≥3d/wk (90min) vs. 1 
or 2d/wk(< 90 min) 
vs. <1d/wk 
Frequency N 
functional 
tests 
Functional tests 
pre/post 
training 
test 
 
 
 
Notes
RCT= Randomized controlled Trials  Wks= Weeks FMA=Fugl-Meyer Assessment 
R= Randomization procedure V= volume MRC= Medical Research Council scale 
CT= Controlled Trials HI= High Intensity ADL= Activity of Daily Living 
C gr= Control Group LI= Low Intensity IADL= Instrumental Activity of Daily Living 
RT= Resistance training MI= Median Intensity FIM= Functional independence measure 
AT= Aerobic training reps= repetitions CS-PFP= Continuous scale physical functional performance test 
CBT= Coupled Bilateral load training RM= Repetition maximum ARAT= Action Research Arm test 
Body RecT= Body recall training rpm= repetition per minute SF-36= Medical Outcomes Survey Short Form-36 
CIMT= Constraint-Induced Movement PDA= Peripheral Arterial Disease  
MRP= Motor-relearning program  CD= Coronary disease  
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Table 2-3: Summary table on characteristic of included studies by trial design 
DESIGN 
NR OF 
STUDIES 
STUDIED DOSE CHSRSCTERISTIC 
INTENSITY 
& 
AMOUNT 
AMOUNT INTENSITY FREQUENCY 
RCT 47 17 14 11 5 
CT 11 4 3  4 
other 1    1 
Notes 
 
 
 
Sample characteristics 
A sample of 3,294 people were involved in the included studies. The smallest 
study was an RCT including 12 sedentary healthy men [147]. The largest study 
was a longitudinal observation study including 417 older adults with peripheral 
arterial disease [148]. 
Forty-nine studies (83%) included healthy people from sedentary to physically 
active. Ten studies included people with chronic conditions 
[101,111,148,149,150,151,152,153,154,155].  
 
Study designs 
Forty-seven (79.7%) of the included studies were randomised controlled trials 
(RCTs). Eleven studies (18.6%) applied a quasi-experimental design being 
classified as non-randomized controlled trials (CTs). One study was a 
longitudinal observational study with more than one group [148]. 
 
Approaches to dose optimization  
All studies, apart from the observational study, implemented a set of 
predefined dose levels or protocols towards dose optimization. This approach, 
called dose-ranging, investigates only a pre-specified number and levels of dose 
RCT= Randomized controlled Trials  
CT= Controlled Trials 
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(or protocols). Among studies applying a dose-ranging design fifty-five studies 
(94.8%) implemented a parallel group design20; and three studies implemented 
a cross-over design to investigate the training optimal dose [156,157,158]. 
The observational study categorized participants into three groups depending 
on their (reported) weekly amount of exercise to investigate the optimal 
training dose. 
 
Characteristics of the training protocol and dose 
The mean number of doses considered per study was 2.5 with a maximum of 9 
doses investigated in one study [159]. Forty-five studies (76.3%) made a 
comparison between two doses. 
In fifty-seven studies (96.6%) the dose of training was defined as being 
composed by two characteristics: intensity and amount of training. Among 
them, forty-nine studies (86% of the fifty-seven studies) defined the intensity 
of the training as “the load applied to the exercise” and the amount of training 
as “the number of task repetitions undertaken during a training session” 
[147,149,151,152,153,155,156,157,158,159,160,161,162,163,164,165,166,16
7,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,18
5,186,187,188,189,190,191,192,193,194,195,196,197,198]. In the remaining 
eight studies (14% of the fifty-seven studies) the amount of the training was 
consistently defined as “the time spent exercising” whereas, the definition for 
intensity was heterogeneous, including:  
 the load applied to the exercise in two studies [199,200]; 
 the subject’s perceived exertion in two studies [154,201]; 
 the number of repetition tasks undertaken during a training session in 
two studies [101,202]; 
 the percentage of the peak oxygen uptake (% of VO2 peak) in one study 
[203]; 
                                                     
20 A dose-ranging parallel design involves two or more intervention groups of individuals 
allocated to different intervention dosages. 
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 the product of frequency of the training and the time spent exercising 
in one study [127]. 
Two studies (3.4%) defined the dose of training using only one parameter: the 
time spent exercising in one session. Dromerick referred to it as the intensity of 
training session [115] whereas, McDermott as the weekly amount of training 
undertaken [148]. 
The volume of training was defined in nineteen (32.2%) of the included studies 
with heterogeneity. In detail:  
 fifteen studies (78.9% of the nineteen studies that defined the volume 
of training) defined the volume as the product of the intensity and the 
amount of training undertaken in one training session 
[147,156,157,163,167,169,176,177,188,189,192,193,195,196,199];  
 three studies (15.8%) defined the volume as the product of total work 
and training sessions[181,194,202]; 
 one study defined the volume as the product of the intensity and 
amount undertaken in one training week [179]. 
The definition of the parameters of the training protocol was found more 
consistent than the definition of the dose components. Specifically, all studies 
defined the training protocol as composed by the dose, the frequency and the 
total length of the training. The frequency and total length of training were also 
referred as the training schedule. All the studies defined the frequency of the 
training as the number of training days per week. All studies, but two21, defined 
the length of the study as the total duration of the training protocol, often, in 
weeks.  
 
                                                     
21 Jigami et al. (2012) and Abrahin et al (2014) defined the total length of the study training as 
the number of sessions delivered. 
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Manipulation of the training dose and the training protocol  
The most studied parameter among included studies was the impact of the 
training dose investigated in forty-nine studies (83.3%). In detail:  
 Twenty-one studies (42.9% of studies investigating dose characteristics) 
manipulated both characteristics of the training dose, amount and 
intensity, to target the desire outcome. Among which, fourteen studies 
held the volume of the training constant between groups 
[147,159,163,164,165,167,176,182,186,196,197,198,199,204]. The 
remaining seven studies varied the volume of training between groups 
[101,156,172,188,194,202,203];  
 Ten studies (20.4% of studies investigating dose characteristics) 
investigated the effect of varying the intensity but keeping constant the 
amount of training [149,153,155,169,170,178,179,185,187,200]. In this 
studies the total volume of training varyed between groups; 
 Eighteen studies (36.7% of studies investigating dose characteristics) 
investigated the effect of varying the amount but keeping constant the 
intensity of training 
[111,115,152,157,158,160,161,166,174,175,177,181,183,184,191,192,
193,195]. In this studies the total volume of training varied between 
groups. 
The impact of different frequencies of the training sessions was assessed in ten 
studies (16.9%). Three studies investigated the effect of different frequencies 
of training holding the same total volume of training between groups 
[151,179,199]. Seven studies applied different total volumes of training among 
groups [148,154,162,168,171,189,201]. Consequently, in these seven studies, 
the optimization of the training frequency depended on two parameters 
(frequency and volume of training). 
The efficacy of different lengths of training was not investigated among any of 
the included studies. The mean total length of the studies protocols was 15.5 
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weeks with a minimum of two weeks [115,149] to a maximum of 3 years for 
the longitudinal study [148]. 
Forty-two studies (71.2%) applied a pre and post treatment assessments 
procedure to evaluate treatment effects. Seventeen studies (31.5%) 
investigated the treatment effect over time applying a multiple assessment 
procedure 
[111,147,154,156,157,159,166,170,176,177,178,180,181,182,183,186,192,19
4].  
 
2.5 Risk of potential bias assessment  
Table 2-4 summarises the results from the modification of the Cochrane 
Collaboration tool for risk of bias used in this review. In detail: eight studies 
(13.6%) were evaluated as having a low risk of bias 
[101,111,115,152,155,162,170,176], and nine studies (15%) as having a 
moderate risk of bias. Whereas, forty-two studies (71.2%) were classified as 
potentially having high risk of bias.  
The major observed issues for risk of bias were identified in the following 
procedures: (1) insufficient reporting or lack of randomization procedure and 
allocation concealment (87% and 88.9%); (2) lack on balancing baseline groups 
(57.4%); (3) omission of sample-size calculation (88.9%); (4) no control for co-
interventions or possible confounders (54.5%); (5)lack of adherence or control 
on the treatment protocol (14.5%); and (6) insufficient reporting or control on 
onset of adverse events (80%). 
  
61 
Table 2-4: Summary of the risk of potential bias assessment of included 
studies 
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1 Abrahin, 2014 U U U N U Y Y Y N 
2 Ahtiainen, 2005 N U N N U U N Y N 
3 Anderson, 1982 U U U Y U U Y Y N 
4 Baker, 2013 U U Y U U Y Y Y N 
5 Berger, 1962a N U U N U N Y Y N 
6 Berger, 1962b N U U N U U Y Y N 
7 Borst, 2001 N U U Y U Y U Y N 
8 Campos, 2002 U U Y N U U Y Y N 
9 Candow, 2007 U U Y Y Y U Y Y N 
10 Capen, 1956 N U U N U U Y Y N 
11 Cauraugh, 2009 U U U N U U Y Y N 
12 Han, 2013 Y Y Y Y N U Y N N 
13 de Paleville, 2009 U U U N U U Y Y Y 
14 de Silva, 2014 Y Y Y Y U U Y Y N 
15 de Souza, 2010 U U U Y U Y Y Y N 
16 de Vos, 2005 U U N Y U Y Y Y Y 
17 DiFrancisco-Donoghue, 2007 Y  U U N Y U U Y N 
18 Dromerick, 2009 Y U Y Y Y Y Y Y Y 
19 Ewing J, 1990 U U U N U Y Y Y N 
20 Farinatti, 2013 Y Y U Y U Y Y Y N 
21 Fatouros, 2006 U U U N U U Y Y Y 
22 Goto, 2004 N U U N U Y Y Y N 
23 Galvao, 2005 U U U Y U U Y Y N 
24 Harris, 2004 U U U Y Y Y Y Y Y 
25 Hass, 2000 U U U Y U N Y Y Y 
26 Henwood, 2008 U U U Y U U Y Y Y 
27 Holm, 2008 U U U N U U Y Y N 
28 Humburg, 2007 U U U X U U Y Y N 
29 Hunter, 1985 N U U N U U Y Y N 
30 Hunter, 2001 U U U N U Y Y Y N 
31 Hsieh, 2011 Y  Y Y Y U Y Y Y Y 
32 Kalapoth 2005 U U U Y U U Y Y N 
33 Kelly, 2007 U U U N U Y Y Y N 
34 Jigami H, 2012 N N Y Y N Y Y Y N 
35 Kemmler, 2004 U U U Y Y Y Y Y N 
36 Kraemer, 2004 U U U N U Y Y Y N 
37 McBride, 2003 N U U N U Y U Y N 
38 McDermot, 2006 X X Y Y X N N Y N 
39 Miszka, 2003 U U U N U Y U Y N 
40 Manzolini, 2008 Y Y Y Y U Y Y Y Y 
41 Munn, 2005 U U U N Y Y Y Y Y 
42 Nakamura, 2007 N U U N U U U Y N 
43 Neils, 2005 U U U N U U Y Y Y 
44 Nemoto, 2007 N N U N U U N Y N 
45 O'Shea, 1996 U U U Y U U Y Y N 
46 Onambélé-Pearson, 2010 U U U N U U Y Y N 
47 Paulsen, 2003 U U U N U U Y Y N 
48 Pollok, 1993 U U U N U U Y Y N 
49 Rana, 2008 U U U N U Y Y Y N 
50 Rhea, 2002 U U U Y U N Y Y N 
51 Ronnestad, 2007 U U U Y U Y Y Y N 
52 Sato, 2009 U Y N Y U U Y Y N 
53 Schlumber, 2001 U U U N U Y Y Y N 
54 Starkey, 1995 U U U N U Y Y Y N 
55 Signorile, 2004 N U U N U U Y Y N 
56 Stone, 1994 U U U N U U Y Y Y 
57 Van Roie, 2013 U U U N U U Y Y N 
58 Vincent, 2003 Y U U N U U Y Y Y 
59 Weiss, 1999 U U U N U U Y Y N 
Notes: N= criterion not verified; Y= criterion verified; Green= criterion satisfied; Yellow= Not 
known/partially satisfied; Red= criterion not satisfied; X= n/a; U= not known.  
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2.6 Interpretation 
This review highlighted standard dose optimisation designs and approaches 
used in exercise-based training clinical research since the middle of the 
twentieth century. 
The choice of the trial design itself plays a key role on the appropriateness of 
the study to answer specific questions on the optimal dose of training and on 
the dose-response relationships.  
All included studies identified the OTD or the optimal protocol of training by 
means of dose-ranging designs with a defined sample size, rather than more 
sophisticated optimization design such as, dose-finding designs.22  
Dose-ranging designs allowed the investigation of only pre-defined numbers 
and levels of dose. In these designs adjustments of the dose were not allowed. 
Ideally, when dealing with uncertainty on the efficacy and safety of the 
intervention dose-ranging study should cover a wide range of dose from low to 
high, reducing the efficiency of the study since it requires an ample number of 
cohorts (large sample-size). In these designs the likelihood of identifying the 
OTD can decline significantly as the appropriateness on investigating the dose-
response relationships crucially depends on the relevance of the tested doses 
and on the previous research upon which these doses were based. In 
pharmaceutical research, often, the main objective of an early dose-ranging 
study was to investigate the efficacy and safety responses at the given training 
dose, rather than targeting the OTDs [139,205,206,207].  
Although advocated as the more appropriate designs for dose optimization 
purposes [139], the implementation of dose-finding designs in exercise-based 
training literature was still limited. This could be mainly due to the complexity 
of their use in clinical settings. Dose-finding trial designs, also known as 
adaptive design for their adaptive (flexible) nature, are able to make changes 
on the dose levels, based on the results of interim analyses. This characteristic 
                                                     
See chapter 5 for details on dose-finding designs. 
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feature increases the study efficacy and accuracy on targeting the OTD but 
preserving patients’ safety [208,209,210,211]23. 
Among included studies the majority applied a parallel-group design (94.8%) 
with a mean number of 2.5 dose per study. Thus, the majority of studies (76.3%) 
made a single comparison between two dose levels. This approach limited the 
information retrieved on the dose-response relationship. When data were 
available only for two dose levels it was not possible to derive a dose-response 
curve. Furthermore, using this approach, the importance of the spacing (gap) 
between two doses increases. For instance, if two doses were chosen too close 
they may not suggest any difference in the intervention effect. On the other 
hand, if the two doses were chose too far apart the shape of the curve could be 
mistaken. 
The implementation of multiple assessment procedures was not common 
among included studies. Common practice was the implementation of two 
assessment points, at the beginning and at the end of the intervention. As a 
result, the data derived from pre and post intervention assessments cannot be 
used to speculate on the training effect over time and on the appropriate length 
of the training protocol. Consequently, the selection of the length of the 
training programme was often left to arbitrary or pragmatic decisions. This was 
in line with the literature which advocated longitudinal procedure as needed 
but uncommon in exercise based training research [73,111,136]. 
This review highlighted that the multifactorial aspects of the training dose 
could, often, complicate the dose optimization in exercise based training. This 
issue was even more relevant when data were synthetized across studies. 
High variability was found on the definition of the training dose and its 
characteristics across included studies. The ambiguity in the definition of dose 
could complicate the interpretation of data synthesis across studies and it could 
preclude the effective communication among practitioners and rehabilitative 
teams [37]. However the variability found on this review on the terminology 
                                                     
23 For a more detailed discussion, see chapters 5 and 6. 
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concerning dose could be, in part, explained by the inclusion of different fields 
applying exercise-based training. 
On the other hand, more consistency was found in the definition of the 
components of the training protocol, often shaped by the dose, frequency and 
length of the training. 
To identify the OTD, more than one characteristic of the dose was manipulated 
at a time in several studies (42.9% of studies investigating dose characteristics). 
This approach produced blurred results, given the impossibility to identify 
which characteristic of the dose was responsible for the outcome (therapy 
effect).  
Similar approach was often used across studies when investigating the optimal 
schedule (frequency) of training. Often, a different total volume of training was 
applied among groups (in seven studies out of ten), introducing further 
complexity on the understanding of the optimal frequency capable to maintain 
the level of stimulus delivered by the optimal dose of training over time.  
 
The studies’ quality assessment was classified as potentially high risk of bias for 
71.2% of the included studies. Risk of potential bias in dose optimization study 
protocols included: lack of reporting of randomization; lack of balancing 
baseline group characteristics; limited control over possible co-interventions 
and confounders and lack of adherence or control on the treatment protocol. 
As detailed before, the lack of control for co-interventions and protocol 
adherence could negatively influence the confidence on the results on dose. To 
improve the quality of dose optimization in exercise-based training it seemed 
crucial to plan and report in sufficient detail the training protocol, its adherence 
and any deviation from it. This approach will allow intervention replication and 
better result interpretation. Furthermore, detailed reporting of the training 
dose prescribed and received by participants will provide information on the 
tolerability and safety of the intervention. Ideally, a standard and consistent 
method, such as the so-called FITT components [212], should be used in 
reporting training protocols and dose characteristics.  
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2.7 Conclusion 
Despite a large number of studies pooled by guidelines and recommendations 
for training dose, this review has shown that only a small number of them 
investigated dose optimization and the associated dose-response relationships. 
Even the studies that claimed to investigate the optimal training dose or 
protocol very often applied sub-optimal designs. Inadequate trial design, with 
respect to dose optimization, the use of inefficient dose selection procedure, a 
poor definition of the training dose, and inefficient dose manipulation were 
often found among included studies. These issues could have a role in the lack 
of evidence-based knowledge on the appropriate dose and protocols 
experienced in many field of medicine applying exercise-based training 
[25,37,45,131,136,213] and in the constant need for updating once new 
evidence becomes available. 
To our knowledge, this review was the first that explored the methodological 
aspects of dose optimization in the primary trials upon which the 
recommendations on appropriate dose of exercise-based training were based. 
Understanding the designs and the approaches applied to dose optimization, 
the definitions and use of the training dose and protocol towards dose 
optimization gave indication on the strength of the results on dose, as well as 
providing indication for further research trajectories. The assessment on the 
risk of bias, tailored to the dose optimization protocols, gave further indications 
on the lack of strong evidence on the OTDs and optimal protocols in exercise-
based training research providing the basis for future good quality research.  
In ExBT in general, and stroke rehabilitation in particular, the development of a 
structured and standardised pathway towards the identification of the OTD and 
appropriate protocols could enhance research further. This procedure is in line 
with the view advocated by the American Congress of Rehabilitation Medicine 
Stroke Movement Interventions Subcommittee [37] and other scholars [45]. 
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2.8 Review limits 
This review had some limitations. Some dose optimization studies may have 
not been included due to the broad or vague terminology used to address 
physical activity, exercise and the dose of training. However, the systematic 
approach implemented in this review and the use of multiple electronic 
databases should have minimized this risk of bias. 
As any other review, this study may be subjected of publishing and reporting 
bias. However, the effort of contacting leader authors on the field looking for 
grey literature may have reduced this bias.  
Reviewers, in applying eligibility criteria, were not blinded to authors, 
institutions, journals, and study results. Blinding of the (two) reviewers was not 
considered to be feasible given their prior considerable knowledge of some of 
the studies included in this review.  
Only one researcher (myself) was involved in the data extraction and qualitative 
assessment procedure. However, the high level of standardization in both 
procedures should have reduced the likelihood of possible bias.  
To be consistent with the guidelines of reference, only included studies that 
dealt with healthy adults (18+ years) or, adults with chronic conditions aged 
50+ years have been involved. These criteria could have restricted the number 
of studies included in this review. Given the specific focus on the 
methodological design it is unlikely that the applied restriction criteria could 
have had an impact on the understanding of the designs and approaches 
applied to dose optimization in exercise-based training.  
Finally, the paucity of trial designs and approaches to dose optimization found 
among included studies made considerations and comparisons limited. 
However, this reflected the current dose optimization standards in exercise-
based training research. 
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2.9 Clinical and research implication 
This systematic review highlighted the importance of finding a meaningful and 
standardised definition of the “training dose”, which accounted for its 
multifactorial aspects when targeting optimal doses in exercise-based training. 
The need to use a systematic and consistent terminology on dose emerged as 
a way to avoid the existing heterogeneity on the way key concepts were 
defined.  
This review also helped in understanding how the different components of the 
training dose and protocol were manipulated in the existing practice of dose 
optimization in exercise-based training research.  
These considerations were relevant to guide the devising of a novel dose 
optimization approach for stroke rehabilitation. However, concerning 
approaches applied in exercise-based training to dose optimization, some 
methodological limitations were found that could hampered progresses 
towards an answer-search process. Main limitations were on the 
implementation of trial designs not purposely made to identify optimal dose; 
inappropriate dose selection; and improper use of dose manipulation 
[74,137,214,215]. 
For these reasons a review of dose optimization approaches applied in other 
fields of medicine was advisable. The following chapter reported a review on 
dose optimization in pharmaceutical research.  
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Chapter 3:  
What can we learn from 
dose optimization 
approaches in 
pharmaceutical studies?  
A Narrative Systematic 
Review. 
 
3.1 Introduction 
Commercialized drugs are delivered in a precise dose, frequency, and for a 
known period of time to maximise their therapeutic effect while limiting side 
effects. 
The dose and schedule of drugs were identified by dose optimization studies 
that characterise the drug dose-response relationships for efficacy and safety. 
The pharmaceutical dose optimization processes were among the more strictly 
regulated procedures to guarantee participants’ safety minimizing possible 
health risks since the early ninety.` 
Currently, the scientific community agrees on the implementation of this 
research approach to ameliorate complex interventions such as stroke 
rehabilitation research [73,132,134,216]. To follow these indications a 
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narrative review on dose optimization approaches applied in pharmaceutical 
clinical literature was undertaken to inform on appropriate dose optimization 
approaches for stroke rehabilitation research.  
A narrative systematic review was chosen to investigate the trial designs and 
approaches applied in pharmaceutical research from both, a quantitative and 
qualitative point of view [217]. Narrative reviews allow extensive investigations 
and discussions on a specific topic from a theoretical and contextual point of 
view [218]. 
The following part of this paragraph reports a brief overview of the 
pharmaceutical drug development stages with a specific focus on dose 
optimization processes.  
 
Pre-clinical trials are the first stages of the drug development. It is at this stage 
that a compound (drug element) is identified due to its potential for efficacy 
against the desired target. Pre-clinical studies involve first in vitro tests, outside 
a living organism, and, subsequent, in vivo tests on living organisms to identify 
the compound’s actions and reactions to and with biological systems. At this 
stage the compound starts to be investigated in term of efficacy, potency and 
safety. The compound action on the target, the kinetics of absorption, 
distribution, metabolism and extraction in the biological systems, the onset, 
persistency and gravity of adverse events are widely investigated at this stage 
[139,219,220,221]. All these information are used to characterise the first dose-
response relationships on efficacy and toxicity which will be used to set the first 
dose regimen to bring forward in the following phases of the research pathway. 
This is in contrast with the practice in exercise-based training in general, and 
motor intervention research in particular, where pre-clinical data are not 
commonly available to guide the selection of potentially efficacious and safe 
dose.  
About 64% of the tested compounds will pass the pre-clinical studies and be 
moved into phase I clinical trials [222], as “first in humans trials”. Phase I trials 
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often involve a small number of healthy volunteers24 used to establish key dose 
and schedule to use in subsequent phase II clinical evaluation trials [207,223].  
Specifically, phase I trials often allow the estimation of four important dose 
endpoints:  
 the maximum tolerable dose (MTD), defined as the highest dose at 
which the toxicity is still considered acceptable for patients;  
 the minimum effective dose (MinED), defined as the first dose at which 
a clinical relevant effect is found to be statistically significant superior 
from placebo;  
 the dose limiting toxicity (DLT), defined as the toxicity level that is 
considered unacceptable and limits further dose escalation; and  
 the recommended phase II dose (RPTD)25 is the dose found to be 
recommendable for further efficacy studies.  
 
About 48% of the compound which passed phase I moves into phase II clinical 
trial [222]. The main objective of a subsequent phase II trial is to assess the 
compound effectiveness, coupled with the confirmation of the optimal dose 
[224,225]. If the appropriate dose is not confirmed, the compound is brought 
back to a phase I and further efficacy trials are planned.  
It is known that only the minority of promising compound reach successfully 
the final phase III stage. In fact, according to the FDA’s research, nine out of ten 
drugs deemed successful in pre-clinical trials fails in clinical trials26. This third 
phase assesses, in a larger scale, the compound effectiveness and identifies 
intra-patients response variability. If the efficacy and safety of a specific dose is 
confirmed in this phase, the compound is ready to be submitted to appropriate 
regulatory authorities [219,226]. Otherwise, the compound is either brought 
back in the research pathways or failed.  
                                                     
24 Cancer therapy or therapies for other life-threatening illnesses are an exception to this 
involving patients with the target disease since the early stages [214]. 
25 The RPTD is often called as OD for phase II trials or, simply, the recommended dose (RD). 
26 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108576.htm 
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This brief summary of the drug development pathway has highlighted how 
structured and regulated a dose optimization process should be.  
The aim of the remaining parts of this chapter was to identify dose optimization 
approaches that were suitable for use in stroke rehabilitation research 
investigating pharmaceutical industry standard procedures of dose 
optimization used in clinical trials (Overall aims 1; Objectives 1.b). This, together 
with the results coming from the review on dose optimization in ExBT, helped 
in devising a novel dose optimization study suitable for stroke rehabilitation 
research. 
 
3.2 Methods 
3.2.1 Design 
A narrative systematic review was undertaken to identify dose optimization 
designs and approaches applied in pharmaceutical clinical research.  
With respect to a systematic review less prescriptive rules on study inclusion 
criteria were applied to this review to allow a broader inclusion of studies [217].  
3.2.2 Search strategy 
Studies for this review were retrieved from the two main medical electronic 
databases: Medline and Embase. Databases were searched from 1946 up to 
March 2012. An updating search is not planned because significant changes 
were not expect on the methodological aspects of the dose optimization within 
the time frame of this research project. 
The search terms included a combination of subject headings and keywords 
related to the clinical phases of the pharmaceutical research pathway and the 
dose optimization procedure. Language and date restrictions were not applied 
to the searches. 
The complete search strategy is reported in Table 3-1. 
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Table 3-1: Electronic search strategy on dose optimization procedures 
 Search terms 
1 (phase adj I).ab,ti. 
2 (phase adj II).ab,ti. 
3 (phase adj III).ab,ti. 
4 (seamless adj phase).ab,ti. 
5 1 or 2 or 3 or 4 
6 (clinical adj trial).mp. 
7 5 and 6  
8 dose-ranging*.ab,ti. 
9 dose-finding*.ab,ti. 
10  (optimal adj2 dos*).ab,ti. 
11 (dos* adj2 optimization).mp. 
12 12. 8 or 9 or 10 or 11 
13 7 and 12 
 
All electronic searches results were downloaded into the EndNote X6 program.  
3.2.3 Inclusion criteria 
Only original published articles on dose optimization procedure from 
pharmaceutical clinical research were included. Included studies were those 
that investigated dose optimization of a single or multiple compounds among 
adults aged 18+ years. To be identified as dose optimization, a study should 
[139]:  
 assess the same compound(s) among groups apart from dose;  
 apply the same administration protocol between groups; 
 involve more than one intervention group; 
 co-intervention(s), if present, should not differ among groups. 
In line with the objectives of this review, any kind of trial design and approach 
applied to dose optimization was accepted.  
Studies published in English, Italian, Spanish or French language were assessed 
for inclusion. 
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3.2.4 Identification of studies 
The primary researcher (EC) performed the searches and examined studies for 
inclusion. Electronic de-duplication of papers was detected by using EndNote 
X6 immediately after all titles were downloaded. 
Citations were initially screened accordingly their titles and abstracts to exclude 
studies that clearly did not meet the review inclusion criteria. Full-texts were 
obtained and reviewed for the studies that were included after the abstract 
screening stage. If the researcher was unsure whether or not a study should be 
included, a second researcher (LC) was available for discussion to reach 
consensus. 
3.2.5 Data extraction 
The primary researcher extracted the following data from included studies:  
1) study author(s) and year of publication, 
2) study design characteristics towards dose optimization;  
3) presence of random allocation procedure;  
4) use of blinding procedure toward intervention group(s);  
5) study sample size;  
6) study clinical research phase; 
7) procedure applied to select tested dose;  
8) study dose endpoints. 
 
When studies investigated more than one compound, data extracted referred 
only on the compound where dose optimization was applied. 
Studies were primarily grouped according to the applied trial design. Sub-
groups were subsequently generated according the features of the dose 
optimization approaches and the clinical phase of the study. 
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3.3 Analysis 
Descriptive analyses were planned to identify dose optimization designs and 
approaches applied in pharmacological clinical trials to inform stroke 
rehabilitation research. Trial designs, looking specifically at dose optimization, 
were explored in relation to dose optimization approaches, dose escalation 
procedures, and phase of pharmaceutical research in use.  
 
3.4 Results 
3.4.1 Identification of studies 
Reporting of search and selection processes followed PRISMA 
recommendations27. Figure 3-1 summarises the review search and selection 
processes applied. After electronic deduplication, 1,729 references were 
identified as potentially eligible for this review. Of them, 915 studies were 
excluded by title because they clearly did not meet the review inclusion criteria. 
From the remaining 814 studies, 546 were excluded by abstracts and 76 by full-
texts review. The remaining 192 studies were included in this review. The full 
list of excluded studies at the full-text stage, together with justifications for 
exclusion, are confined in Appendix D.  
  
                                                     
27 See: http://www.prisma-statement.org/statement.htm, last visited on 07/2012 
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Figure 3-1: Flowchart of pharmaceutical drug development review search and 
the selection process  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.2 Studies characteristics 
Table 3-2 lists included studies by their trial design characteristics, dose 
optimization approach and clinical research phase. Table 3-3 condenses the 
review’s key results reported on Table 3-2. 
Identification after duplicate 
removal n=1,729 
Records excluded based on 
screening of title: 915 
Remaining relevant 
studies n=814 
Primary studies included in 
this review n=192 
Records excluded based on screening 
of full-texts: 76  
No full-text available:   61 
No dose optimization study:  14 
No population of interest:  1 
Records retrieved from 
Medline database: 839 
Records retrieved from 
Embase database: 1,482 
Records excluded based on 
screening of abstract: 546 
Potentially relevant 
studies n=268 
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Table 3-2: Characteristics of included studies of dose optimization in pharmacological clinical literature by trial design 
 
Reference 
Trial design 
characteristics 
R B 
Sampl
e Size 
Clinical 
Phase 
Dose setting procedure Trial Endpoints 
Rule-based design          
1 Bajetta E, et al. (2009) 3+3 dose-finding NA  N 21 I Escalation procedure (predefined numerical 
sequence) 
MTD & DLT 
2 Gibbs DD, et al. (2002) 3+3 dose-finding NA  N 31 I Escalation procedure (predefined numerical 
sequence) 
DLT; dose-response 
3 Frasci G, et al. (1999) 3+3 dose-finding NA  N 44 I Escalation procedure (predefined numerical 
sequence) 
MTD;  
4 Fabi A, et al. (2008) 3+3 dose-finding NA  N 10 I Escalation procedure (predefined numerical 
sequence) 
MTD; DLT & survival rate 
5 Guarino MJ, et al. (2002) 3+3 dose-finding NA  N 30 I Escalation procedure (predefined numerical 
sequence) 
efficacy & safety study; OTD; DLT & MTD 
6 Boven E, et al. (2010) 6+6 dose-finding NA  N 21 I Escalation procedure (predefined numerical 
sequence) 
safety; DLT; PK & MTD 
7 Briasoulis E, et al. (2004) 3+3 dose-finding NA  N 44 I Escalation procedure (predefined numerical 
sequence) 
toxicity spectrum; DLT; MTD; OTD 
8 Fornier MN, et al. (2007) 3+3 dose-finding NA  N 30 I Escalation procedure (predefined numerical 
sequence) 
PK, safety and DLT 
9 Castellano D, et al. (2003) 3+3 dose-finding NA  N 19 I Escalation procedure (predefined numerical 
sequence) 
DLT; MTD 
10 Comella P, et al. (2002) 3+3 dose-finding NA  N 46 I Escalation procedure (predefined numerical 
sequence) 
MTD; DLT & OTD 
11 Di Costanzo F, et al. (2006) 3+3 dose-finding NA  N 32 I Escalation procedure (predefined numerical 
sequence) 
MTD; DLT 
12 Elkas JC et al. (2007) 3+3 dose-finding NA  N 13 I Escalation procedure (predefined numerical 
sequence) 
OTD; DLT  
13 JJonker D J, et al. (2011) 3+3 dose-finding (A) NA  N 18 I Escalation procedure (predefined numerical 
sequence) 
safety; PK; PD; MTD; DLT; lowest biologically 
active dose; OTD 
14 Lin J, et al. (2009) 3+3 dose-finding NA  N 28 I Escalation procedure (predefined numerical 
sequence) 
MinED; MTD & OTD 
15 Maenpaa J. and A. Leminen 
(2009) 
3+3 dose-finding NA  N 8 I Escalation procedure (predefined numerical 
sequence) 
MTD  
16 Masuda N, et al. (2008) 3+3 dose-finding NA  N 9 I Escalation procedure (predefined numerical 
sequence) 
OTD; MTD 
17 Nole F, et al. (2006) 3+3 dose-finding NA  N 44 I Escalation procedure (predefined numerical 
sequence) 
MTD; OTD 
18 Oostendorp RL, et al. (2010) 3+3 dose-finding NA  N 28 I Escalation procedure (predefined numerical 
sequence) 
MTD; DLT & PK 
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Reference 
Trial design 
characteristics 
R B 
Sampl
e Size 
Clinical 
Phase 
Dose setting procedure Trial Endpoints 
19 Pasini F, et al. (2005) 3+3 dose-finding NA  N 47 I Escalation procedure (predefined numerical 
sequence) 
MTD; toxicity & pathological response rate  
20 Ryan DP, et al. (2006) 3+3 dose-finding NA  N 51 I Escalation procedure (predefined numerical 
sequence) 
OTDs  
21 Pourgholami MH, et al. (2010) 3+3 dose-finding NA  N 33 I Escalation procedure (predefined numerical 
sequence) 
DLT; OTD 
22 Sykes A, et al. (2004) 3+3 dose-finding NA  N 24 I Escalation procedure (predefined numerical 
sequence) 
toxicity & efficacy study 
23 Tambaro R, et al. (2003) 3+3 dose-finding NA  N 30 I Escalation procedure (predefined numerical 
sequence) 
MTD; OTD 
24 Van Kesteren C, et al. (2000) 3+3 dose-finding NA  N 52 I Escalation procedure (predefined numerical 
sequence) 
MTD; DLT 
25 Venturini M, et al. (2002) 3+3 dose-finding NA  N 23 I Escalation procedure (predefined numerical 
sequence) 
OTDs 
26 Waters SH, et al. (2009) 6+6 dose-finding NA  N 12 I Escalation procedure (predefined numerical 
sequence) 
DLT & MTD 
27 Zeuli M, et al. (2001) 3+3 dose-finding NA  N 25 I Escalation procedure (predefined numerical 
sequence) 
MTD; DLT 
28 Dubinsky R. and C. Gray (2006) 3+3 dose-finding NA  N 9 I Escalation procedure (predefined numerical 
sequence) 
MTD;  toxicity study  
29 Bergmann MA, et al. (2005) 3+3 dose-finding NA  N 16 I/II Escalation procedure (predefined numerical 
sequence) 
MTD, DLT & OTD  
30 Case Jr DC, et al. (1988) 3+3 dose-finding NA  N 40 I/II Escalation procedure (predefined numerical 
sequence) 
response; MTD; toxicity; OTD 
31 Janinis J, et al. (2004) 3+3 dose-finding NA  N 11 I Escalation procedure (predefined numerical 
sequence) 
MTD; OTD 
32 Kocher M, et al. (2005) 3+3 dose-finding NA  N 14 I/II Escalation procedure (predefined numerical 
sequence) 
starting dose (I); MTD (II) 
33 Lissitchkov T, et al. (2006) 3+3 dose-finding NA  N 15 I/II Escalation procedure (predefined numerical 
sequence) 
MTD; DLT 
34 Laurent S, et al. (2009) 5+5 dose-finding NA  N 22 I/II Escalation procedure (predefined numerical 
sequence) 
efficacy; MTD & DLT 
35 Leonardi V, et al. (2009) 3+3 dose-finding NA  N 9 I/II Escalation procedure (predefined numerical 
sequence) 
MTD; OTD  
36 Matulonis UA, et al. (2006) 3+3 dose-finding NA  N 27 I/II Escalation procedure (predefined numerical 
sequence) 
MTD; OTD 
37 Okines AFC, et al. (2010) 3+3 dose-finding NA  N 29 II/III Escalation procedure (predefined numerical 
sequence) 
DLT; OTD 
38 Patnaik A, et al. (2000) 3+3 dose-finding NA  N 58 I/II Escalation procedure (predefined numerical 
sequence) 
MTD; DLT 
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Reference 
Trial design 
characteristics 
R B 
Sampl
e Size 
Clinical 
Phase 
Dose setting procedure Trial Endpoints 
39 Jansen EPM, et al. (2007) 3+3 dose-finding NA  N 32 I/II Escalation procedure (predefined numerical 
sequence) 
MTD; toxicity study 
40 Beldner MA,et al. (2007) 3+3 dose-finding NA  N 18 I Escalation procedure (mFS) OTD; MTD 
41 Mukherjee DC, et al., (2003 1+1 dose-finding NA  N 7 I Escalation procedure (mFS) MTD  
42 O'Bryant CL, et al. (2009) 3+3 dose-finding NA  N 33 I Escalation procedure (mFS) MTD; OTD 
43 Fizazi K, et al. (2000). 3+3 dose-finding NA  N 48 I Escalation procedure (mFS) MTD; DLT; safety; efficacy;  pharmacokinetics 
44 Verweij J, et al. (1992) 3+3 dose-finding NA  N 54 II Escalation procedure (%) DLT; OTD 
45 Chauncey TR, et al. (2000) 8+8 dose-finding NA  N 31 I Escalation procedure (%) DLT; MTD 
46 Chi KN, et al. (2001) 3+3 dose-finding NA  N 26 I Escalation procedure (%) efficacy & toxicity study; MTD; biological 
effects 
47 Blum W, et al. (2007) 3+3 dose-finding  NA  N 11 I Escalation procedure (%) MTD  
48 Kuenen BC, et al. (2005) 3+3 dose-finding NA  N 16 I Escalation procedure (%) MTD  
49 Lesimple T, et al. (2010) 3+3 dose-finding NA  N 56 I Escalation procedure (%) MTD; OTD 
50 Mudad R, et al. (2003) 3+3 dose-finding NA  N 14 I Escalation procedure (%) MTD  
51 Rubin EH, et al. (2005) 3+3 dose-finding NA  N 91 I Escalation procedure (%) MTD  
52 Starling N, et al. (2009) 3+3 dose-finding NA  N 20 I Escalation procedure (%) MTD  
53 Steele NL, et al. (2011) 3+3 dose-finding NA  N 46 I Escalation procedure (%) OTDs 
54 Glynne-Jones RD, et al. (2006) 6+6 dose-finding NA  N 18 I Escalation procedure (predefined numerical 
sequence) 
MTD  
55 Dumez H, et al. (2006) 3+3 dose-finding NA  N 31 I Escalation procedure (predefined numerical 
sequence) 
MTD; PK & DLT 
56 Eatock MM, et al. (2000) 6+6 dose-finding NA  N 24 I Escalation procedure (predefined numerical 
sequence) 
DLT ; OTD  
57 Hanauske A-R, et al. (2009) 3+3 dose-finding NA  N 95 I Escalation procedure (predefined numerical 
sequence) 
MTD; safety; PK; OTD  
58 Huisman C, et al. (2001) 3+3 dose-finding NA  N 19 I Escalation procedure (predefined numerical 
sequence) 
OTD & schedule  
59 Kobayashi T, et al. (2006) 3+3 dose-finding NA  N 16 I Escalation procedure (predefined numerical 
sequence) 
OTD;DLT & MTD 
60 Lortholary A, et al. (2000) 3+3 dose-finding NA  N 32 I Escalation procedure (predefined numerical 
sequence) 
MTD; DLT; OTD  
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Reference 
Trial design 
characteristics 
R B 
Sampl
e Size 
Clinical 
Phase 
Dose setting procedure Trial Endpoints 
61 Mitchell MF, et al. (1998 6+6 dose-finding NA  N 30 I Escalation procedure (predefined numerical 
sequence) 
OTD & MinED 
62 Girard NF, et al. (2010) 3+3 dose-finding NA  N 35 I Escalation procedure (predefined numerical 
sequence) 
MTD; feasibility & efficacy study 
63 Prince HM, et al. (1999) 4+4 dose-finding NA  N 33 I Escalation procedure (predefined numerical 
sequence) 
OTDs  
64 Ryan CW, et al. (2004) 3+3 dose-finding NA  N 35 I Escalation procedure (predefined numerical 
sequence) 
toxicity and PK 
65 Botdy JJ, et al. (1999) 3+3 dose-finding NA  N 30 I Escalation procedure (predefined numerical 
sequence) 
dose escalation procedure; MinED & active 
dose 
66 Yamamoto N, et al. (2008) 3+3 dose-finding NA  N 15 I Escalation procedure (predefined numerical 
sequence) 
MTD; DLT 
67 Souglakos J, et al. (2003) 3+3 dose-finding NA  N 31 I Escalation procedure (predefined numerical 
sequence) 
OTDs 
68 Delord JP, et al. (2000) 3+3 dose-finding NA  N 36 I Escalation procedure (predefined numerical 
sequence) 
DLT; OTD  
69 Stokes Z, et al. (2005) 6+6 dose-finding NA  N 13 I Escalation procedure (predefined numerical 
sequence) 
MTD  
70 Ford J, et al. (1998) 4+4 dose-finding NA  N 14 I Escalation procedure (predefined numerical 
sequence) 
safety; tolerability; MTD; side-effect study 
71 Chi KN, et al. (2005) 3+3 dose-finding NA  N 25 I Escalation procedure (predefined numerical 
sequence) 
biologically effective dose & toxicity response 
72 Tanaka C, et al. (2008) 4+4 dose-finding NA  N 16 I Escalation procedure (predefined numerical 
sequence) 
OTD & PK 
73 Tanaka Y, et al. (2010) 3+3 dose-finding NA  N 18 I Escalation procedure (predefined numerical 
sequence) 
OTD & MTD 
74 Caffo O, et al. (2003) 3+3 dose-finding NA  N 16 I Escalation procedure (predefined numerical 
sequence) 
MTD; response rate; DLT  
75 Blaney SM, et al. (2003) 3+3 dose-finding NA  N 23 I Escalation procedure (predefined numerical 
sequence) 
OTD; DLT; toxicity profile 
76 Oza AM, et al. (1994) 3+3 dose-finding  NA  N 19 I Escalation procedure (predefined numerical 
sequence) 
MTD; OTDs 
77 Rebattu P, et al. (2001) 3+3 dose-finding NA  N 16 I/II Escalation procedure (predefined numerical 
sequence) 
MTD; OTD  
78 Yang T-S, et al. (2003) 3+3 dose-finding NA  N 26 I/II Escalation procedure (predefined numerical 
sequence) 
MTD; DLT 
80 Gottlieb AB et al. (2004) 5+5 dose-finding NA  N 35 I/II Escalation procedure (predefined numerical 
sequence) 
safety; PK 
81 Gridelli CL, et al. (2000) 3+3 dose-finding (I) NA  N 15 I/II Escalation procedure (predefined numerical 
sequence) 
preliminary efficacy 
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Reference 
Trial design 
characteristics 
R B 
Sampl
e Size 
Clinical 
Phase 
Dose setting procedure Trial Endpoints 
82 Kuppens IELM, et al. (2006) 3+3 dose-finding NA  N 42 I/II Escalation procedure (predefined numerical 
sequence) 
MTD; DLT 
83 Maisano R, et al. (2005) 3+3 dose-finding NA  N 21 I/II Escalation procedure (predefined numerical 
sequence) 
MTD  
84 Boccardo F, et al. (1996) 3+3 dose-finding NA  N 12 II Escalation procedure (predefined numerical 
sequence) 
OTD; toxicity 
85 Zarate R et al. (2010) 3+3 dose-finding NA  N 27 II Escalation procedure (predefined numerical 
sequence) 
MTD; DLT; OTD  
86 Bernstein , et al. (2010) accelerated 
titration, dose-
ranging 
NA  N 17 I Escalation procedure (predefined numerical 
sequence) 
OD for inhibiting DNA which is be correlated 
with OTD 
87 Galsky MD, et al. (2008) accelerated titration 
dose-finding 
NA  N 23 I Escalation procedure safety profile; PK, immunogenicity;  
88 Giaccone GH, et al. (1995) accelerated 
titration, controlled 
dose-finding 
NA  N 62 I/II Escalation procedure toxicity and PK 
89 Hwang JJ, et al. (2010) accelerated titration 
dose-ranging; plus 
3+3 design 
NA  N 27 I Escalation procedure DLT; OTD 
90 Kearon C, et al. (2000) accelerated 
titration, controlled, 
dose-finding 
NA  N 14 I/II Escalation procedure efficacy; safety and dose-response 
91 Wolchok JD, et al. (2003) accelerated 
titration, controlled, 
dose-finding 
NA  N 15 I Escalation procedure optimal biological dose; MTD 
 Model-based design  
92 Kuzuya K, et al. (2001) dose-finding NA  N 12 I mCRM safety; OTD 
93 Levy V, et al. (2006) dose-finding NA  N 19 I CRM MTD; DLT; PK 
94 Monnerat C, et al. (2004) dose-finding NA  N 24 I CRM MTD; DLT & OTD 
95 Saji S, et al. (2007) dose-finding NA  N 17 I CRM MTD; OTD & PK 
96 Elkind MS, et al. (2008) dose-finding NA  N 33 I CRM MTD  
97 Gelmon KA, et al. (2000) dose-finding NA  N 29 I CRM dose-limit toxicity; MTD; OTD; PK 
98 Desfrere L, et al. (2005) dose-finding NA  N 20 II/III CRM MinED 
99 Jimeno A, et al. (2008) dose-finding NA  N 21 I/II mCRM MTD; PK 
100 Morita S, et al. (2007) dose-finding NA  N 13 I CRM MTD; OTD 
 Parallel-group design 
101 Gorse GJ, et al. (1996) dose-ranging Y DB 12 I fixed dose levels safety and immunogenicity study 
 82 
 
Reference 
Trial design 
characteristics 
R B 
Sampl
e Size 
Clinical 
Phase 
Dose setting procedure Trial Endpoints 
102 Illei GG, et al. (2010) dose-ranging N N 16 I fixed dose levels safety; preliminary data on efficacy 
103 Ishigooka J, et al. (2000) dose-ranging N N 156 I fixed dose levels efficacy & safety study and OTD 
104 Ito K, et al. (1999) dose-ranging N N 9 I fixed dose levels OTD 
105 Kumar NB, et al. (2010) dose-ranging N N 44 I fixed dose levels toxicity; OTD 
106 Levin RD, et al. (2010) dose-ranging N N 31 I fixed dose levels toxicity; OTD 
107 Li J, et al. (2008) dose-ranging N N 10 I fixed dose levels toxicity; OTD 
108 Overman MJ, et al. (2008) dose-ranging N N 63 I fixed dose levels MTD; DLT;  OTD 
109 Szeimies R, et al. (2008) dose-ranging Y N 132 I fixed dose levels toxicity & efficacy study 
110 Wirth L J, et al. (2010) dose-ranging N N 17 I fixed dose levels MTD  
111 Yan Z, et al. (2011) dose-ranging N N 23 I fixed dose levels toxicity; PK 
112 Young CW., et al. (1988) dose-ranging N N 33 I fixed dose levels toxicity and OTD 
113 Baumgart DC, et al. (2010) dose-ranging Y N 78 I/II fixed dose levels OTD; safety & tolerability 
114 Klemm E, et al. (2007) dose-ranging Y DB 210 I/II fixed dose levels toxicity & efficacy first dose-response data 
115 Ehrlich HJ, et al. (2003) dose-ranging Y N 405 II fixed dose levels OTD; DLT 
116 Groudine SB, et al. (2007) dose-ranging Y SB 50 II fixed dose levels efficacy and safety study 
117 Hirsh V, et al. (2001) dose-ranging Y N 34 II fixed dose levels dose-effect relationship 
118 Iwata H, et al. (2009) dose-ranging Y N 98 II fixed dose levels OTD 
119 Jacobson MA, et al. (1994) dose-ranging Y N 278 II fixed dose levels efficacy & toxicity study 
120 Quoix E, et al. (2004) dose-ranging Y N 182 II fixed dose levels OTD 
121 Wittekindt C, et al. (2006 dose-ranging N N 23 II fixed dose levels DLT 
122 Cotter,G, et al. (2008) controlled, dose-
ranging  
Y N 
301 I fixed dose levels DLT; OTD 
123 Dzavik V, et al. (2007) controlled, dose-
ranging  
Y N 
79 I fixed dose levels efficacy; safety study 
124 Hamilton JM, et al. (2009).  controlled, dose-
ranging  
Y DB 
16 I fixed dose levels safety; tolerability; pharmacokinetics; 
pharmacodynamics 
125 Hemmerling AW, et al. (2009) controlled, dose-
ranging  
Y DB 
12 I fixed dose levels safety, tolerability, and OTDs 
126 Hunt T L, et al. (1995) controlled, dose-
ranging  
Y DB 
80 I fixed dose levels  first safety and tolerability data 
127 McCormack S, et al. (2005) controlled, dose-
ranging  
Y DB 50 
I fixed dose levels toxicity of OTDs 
128 Stephenson I, et al. (2006) controlled, dose-
ranging  
Y SB 100 
I fixed dose levels efficacy & safety study 
 Parallel-group design 
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Reference 
Trial design 
characteristics 
R B 
Sampl
e Size 
Clinical 
Phase 
Dose setting procedure Trial Endpoints 
129 O'Loughlin J, et al. (2010) controlled, dose-
ranging  
Y N 36 
I fixed dose levels toxicity & safety study; PK 
130 Yamaguchi O, et al. (2011) controlled, dose-
ranging  
Y DB 951 
II fixed dose levels  efficacy, safety, and tolerability study 
131 Pang PS, et al. (2011) controlled, dose-
ranging  
Y DB 46 
II fixed dose levels efficacy & safety study 
132 Genovese MC, et al. (2008) controlled, dose-
ranging  
Y SB 
45 I/II fixed dose levels DLT; pharmacodynamics over time  
133 Gupta AK, et al. (2005) controlled, dose-
ranging  
Y DB 
151 I/II fixed dose levels  effectiveness & safety study; OTD 
134 Abrams P, et al. (1997) controlled, dose-
ranging  
Y SB 
126 II fixed dose levels OTD 
135 Alten R, et al. (2011) controlled, dose-
ranging  
Y DB 
277 II fixed dose levels Optimal dose regimen; PK; PD 
136 Amsterdam JD, et al. (2002) controlled, dose-
ranging  
Y DB 
35 II fixed dose levels OTD 
137 Barker JN, et al. (1999) controlled, dose-
ranging  
Y DB 
132 II fixed dose levels OTD; efficacy & tolerability 
138 Buller H, et al. (2008) controlled, dose-
ranging  
Y DB 
392 II fixed dose levels OTD; DLT 
139 Cunningham ET, et al. (2005) controlled, dose-
ranging  
Y DB 
162 II fixed dose levels efficacy; safety study 
140 Furst DE, et al. (2002) controlled, dose-
ranging  
Y N 
268 II fixed dose levels  efficacy & safety study; OTD  
141 Decensi A, et al. (2007) controlled, dose-
ranging  
Y SB 
210 II fixed dose levels optimal biologic dose and schedule 
142 Jilma-Stohlawetz P. et al. 
(2011) 
controlled, dose-
ranging  
Y N 
58 II fixed dose levels efficacy; safety; optimal regimen 
143 van Deventer SJH, et al. (2006) controlled, dose-
ranging  
Y DB 112 
II fixed dose levels minimally effective dose 
144 Vohra S, et al. (2008) controlled, dose-
ranging  
Y DB 65 
II fixed dose levels efficacy & safety study 
145 Von Krempelhuber A, et al. 
(2010) 
controlled, dose-
ranging  
Y DB 164 
II fixed dose levels efficacy & safety study 
146 Wallace DJ, et al. (2009) controlled, dose-
ranging  
Y DB 30 
II fixed dose levels safety & tolerability study 
147 Turpie AGG, et al. (2005).  controlled, dose-
ranging  
Y DB 621 
II fixed dose levels efficacy & safety study 
148 Puhringer FK, et al. (2008) controlled, dose-
ranging  
Y DB 176 
II fixed dose levels efficacy & safety study 
149 Ravn P, et al. (1996) controlled, dose-
ranging  
Y DB 180 
II fixed dose levels efficacy & safety study 
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Reference 
Trial design 
characteristics 
R B 
Sampl
e Size 
Clinical 
Phase 
Dose setting procedure Trial Endpoints 
150 Runge VM et al.  (2000) controlled, dose-
ranging  
Y DB 30 
II fixed dose levels efficacy & safety study 
151 Saini S, et al. (2011) controlled, dose-
ranging  
Y DB 90 
II fixed dose levels efficacy & safety study 
152 Teal P, et al. (2005) controlled, dose-
ranging  
Y DB 240 
II fixed dose levels safety & tolerability study 
153 De Souza JM, et al. (1987) controlled, dose-
ranging  
Y DB 
97 II/III fixed dose levels efficacy & safety study 
154 Matsumoto AK, et al. (2005) controlled, dose-
ranging 
Y DB 491 
III fixed dose levels efficacy & toxicity study; OTDs 
156 Kreisel W, et al. (2011) multicentre, dose-
ranging 
N N 20 I 
fixed dose levels toxicity; OTD  
157 Kim SW, et al. (2010) multicentre, dose-
ranging 
Y DB 145 
I fixed dose levels safety, immunological response; DLT; OTD 
158 Okubo K, et al. (2008) multicentre, 
controlled, dose-
ranging  
Y DB 240 
I fixed dose levels OTD  
 Parallel-group design 
159 Cannon CP, et al. (1998) multicentre,  dose-
ranging 
Y DB 
106 I/II fixed dose levels pharmacokinetics; pharmacodynamics; 
safety; tolerability, OTDs  
160 Sacks SL, et al. (1998) multicentre, 
controlled, dose-
ranging 
Y DB 96 
I/II fixed dose levels efficacy & safety study 
161 Cursiefen CF, et al. (2009) multicentre, 
controlled, dose-
ranging 
Y DB 
40 II fixed dose levels tolerability and efficacy; OTD 
162 Lewis RJ, et al. (2011) multicentre, 
controlled, dose-
ranging 
Y N 149 
II fixed dose levels toxicity; OTD 
163 de Francisco ALM, et al. (2006) multicentre, 
controlled, dose-
ranging 
Y DB 
61 II fixed dose levels efficacy study; starting dose 
164 Lim SG, et al. (2008) multicentre, dose-
ranging 
Y N 31 
II fixed dose levels OTD 
165 Malmstrom, P. U. (2002) multicentre, 
controlled, dose-
ranging 
Y N 115 
II fixed dose levels toxicity of OTDs 
166 Nota K, et al. (2006) multicentre, dose-
ranging 
Y N 109 
II fixed dose levels efficacy; OTD 
167 Osterborg A, et al. (2007) multicentre, dose-
ranging 
Y Y 93 
II fixed dose levels efficacy & safety study 
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Reference 
Trial design 
characteristics 
R B 
Sampl
e Size 
Clinical 
Phase 
Dose setting procedure Trial Endpoints 
168 Gallagher JC, et al. (2001) multicentre, 
controlled, dose-
ranging 
Y N 
48 II fixed dose levels pharmacokinetics; safety study 
169 Paick J-S, et al. (2008) multicentre, 
controlled, dose-
ranging 
Y DB 119 
II fixed dose levels efficacy & safety study 
170 Povsic TJ, et al. (2011) multicentre, 
controlled, dose-
ranging 
Y SB 800 
II fixed dose levels efficacy & safety study 
         
171 Cazzola M, et al. (1995) multicentre, dose-
ranging 
Y N 
146 II fixed dose levels optimal initial dose 
172 Lalezari JP, et al. (2003) multicentre, 
controlled, dose-
ranging 
Y N 71 
II fixed dose levels pharmacokinetics; OTD  
173 Landewe RBM, et al. (2010) multicentre, 
controlled, dose-
ranging 
Y DB 39 
II fixed dose levels efficacy; OTD 
174 Saini S, et al. (2000) multicentre, 
controlled, dose-
ranging 
Y DB 99 
II fixed dose levels efficacy & safety study 
175 Sakai F, et al. (2002) multicentre, 
controlled, dose-
ranging 
Y N 30 
II fixed dose levels efficacy & safety study 
176 Henry RR, et al. (2009) multicentre, 
controlled, dose-
ranging 
Y DB 
332 II fixed dose levels effects, and safety study 
177 Thijs VNSs, et al. (2009) multicentre, 
controlled, dose-
ranging 
Y DB 40 
II fixed dose levels safety & tolerability study 
178 Ste-Marie L-G, et al. (2009) multicentre, 
controlled, dose-
ranging 
Y N 370 
II fixed dose levels efficacy & safety study 
179 Valecha N, et al. (2010) multicentre, 
controlled, dose-
ranging 
Y DB 230 
II fixed dose levels efficacy & safety study 
180 Van Cutsem E, et al. (2005) multicentre, 
controlled, dose-
ranging 
Y DB 164 
II fixed dose levels toxicity & efficacy study 
181 Katz, B. (2005).  multicentre, 
controlled, dose-
ranging 
Y DB 162 
II fixed dose levels safety & efficacy study 
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Reference 
Trial design 
characteristics 
R B 
Sampl
e Size 
Clinical 
Phase 
Dose setting procedure Trial Endpoints 
182 Khuenl-Brady KS, et al. (2008) multicentre, dose-
ranging 
Y SB 176 
II fixed dose levels safety & efficacy study 
183 Hirsh VJ, et al. (2007) multicentre, dose-
ranging 
Y N 
218 II fixed dose levels dose-effect relationship 
184 Jha TK, et al. (2005) multicentre, dose-
ranging 
N N 120 
II fixed dose levels dose-response and safety study 
185 Wynn D, et al. (2008) multicentre, dose-
ranging 
Y DB 40 
II fixed dose levels toxicity and OTD 
186 Yamamoto A, et al. (2002) multicentre, dose-
ranging 
Y DB 68 
II fixed dose levels  efficacy, safety, and tolerability study 
187 Sumpter K, et al. (2005) multicentre, 
controlled, dose-
ranging 
Y DB 204 
III fixed dose levels DLT; OTD 
188 Haustein J, et al. (1992) multicentre, dose-
ranging 
N N 
30 III fixed dose levels efficacy and safety study; OTD; 
189 Kivitz A, et al. (2006) multicentre, 
controlled, dose-
ranging 
Y DB 360 
III fixed dose levels efficacy, dose-response, and tolerability 
study 
190 Johnson CD, et al. (2001) group-sequential, 
dose-ranging 
N N 278 
III fixed dose levels efficacy, toxicity study & survival trials 
 Cross-over design 
191 Dmoszynska A, et al. (2007) multicentre, cross-
over, dose-ranging  Y N 
64 I/II fixed dose levels dose-response; pharmacokinetics study 
192 Johnson BA, et al. (2003) controlled, four-
way, cross-over 
dose-ranging 
Y DB 23 
I fixed dose levels pharmacological; safety & tolerability study 
Notes:                R= Random allocation procedure DLT= dose limiting toxicity 
B= Blinding procedure mFS= modified Fibonacci sequence 
SB= Single Blind procedure NA= Not applicable 
DB= Double Blind procedure PD= Pharmacodynamics 
MinED= minimal effective dose 
OTD= optimal therapeutic dose 
MTD= maximal tolerate dose 
 
PK= Pharmacokinetic  
*groups with different protocols 
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Table 3-3: Summary of characteristics of included studies of dose optimization 
in pharmacological clinical literature 
Trial designs Trial design type Nr of studies 
Dose-finding designs     
Rule-based designs 3+3 dose-finding 73  
 4+4 dose-finding 3  
 5+5 dose-finding 2 
 6+6 dose-finding 5   
 1+1 dose-finding 1  
 8+8 dose-finding 1  
 Accelerated titration 6  
 Model-based designs CRM designs 9 
TOTAL   100 
    
Dose-ranging designs    
 Parallel designs  90  
 Cross-over designs  2 
TOTAL 
 
 92 
 
To make in context review results, a brief narrative description of the main 
features of the trial designs used in dose optimization is reported. 
 
3.4.3 Dose optimization trial designs 
As Table 3-4 summarises, in pharmaceutical research there are two main dose 
optimization approach: dose-ranging or dose-finding. 
Table 3-4 Dose optimization approaches and trial designs applied in 
pharmaceutical research 
Dose optimization approaches Trial designs 
Dose-ranging 
    Parallel group 
    Cross-over 
Dose-finding 
    Rule-based 
    Model-based 
 
As mentioned in chapter 2, in dose-ranging approaches each group of patients 
receives different intervention dose in parallel (parallel group design) or in 
sequence (cross-over design) [209]. The number of groups and the doses are 
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defined a-priori to inform on the efficacy and safety of the studied compound at 
specific dose levels and/or against placebo [205,206]. A random allocation 
procedure is often used, with or without a control group28. Randomization, 
control group and blinding procedures29 are applied to increase reliability and 
generalisability of the results. Estimates of the dose-response and the dose-
toxicity relationships can be gained from these studies but they are limited to the 
pre-selected tested doses. Inferences on other doses are not advisable. 
 
Dose-finding approaches have much to recommend them, given their flexibility 
[208]. They are commonly defined adaptive designs, with adaptive (flexible) 
conditions seen on randomization procedures [227], sample size [228], test 
statistics, sequential dose setting [229], outcomes, and target endpoints. Given 
the focus of this research, the adaptive condition of interest is around the dose 
setting, also called dose escalation procedure. However, this design flexibility on 
dose optimization comes with a cost. Generally, no a-priori information is 
available on the number of groups needed for the study and thus, a random 
allocation procedure or a balancing group procedure (minimization) are not 
feasible. 
Three assumptions are typically shared by these adaptive designs (or dose-finding 
designs). First, the individual’s responses (outcomes) to the treatment dose are 
going to be fairly similar. In pharmaceutical development this is often achieved 
by categorizing sub-groups of patients depending on precise biological targets 
(e.g.: blood cells count, hormone levels, etc.), which identify the disease stage 
and severity.  
                                                     
28 A control group is a group receiving a placebo intervention. A placebo is any drugs or treatment 
that actually contains no active ingredients, no actual medication or no therapeutic effect. In 
research a placebo is used as a control in testing the efficacy of another intervention 
(http://www.yourdictionary.com). 
29 Blinding procedures in clinical trials are often refer to single blind when the information about 
the intervention are kept from the participant until after the test, or double blind if both, assessors 
and participants are not aware on the allocated intervention. 
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Second, the drug effect can be measured in a predictable and often short period 
of time. Information on the drug effect over time are often derived from pre-
clinical studies. The expected changes typically occurs on a biological level (i.e. 
changes in the size of the tumor, changes in the blood pressure) and are thought 
to be intermediate endpoints which are promising for more positive outcomes 
(i.e.: increase of the surviving rate; reduction of incidence of stroke and heart 
attack) [230].  
Finally, and in particular in cancer research, a key assumption adopted is that the 
treatment effect will increase by dose. As a results, often, in pharmaceutical dose-
finding trials the main concern and guidance on the dose escalation procedure is 
the toxicity response. 
Although these assumptions are defensible in pharmaceutical research, the 
following chapters discussed and tested whether these assumptions held in dose 
optimization trial design suitable for use in stroke rehabilitation research. 
Depending on their operating characteristics, dose-finding designs can be rule-
based or model-based.  
Table 3-5 illustrates these two groups of dose-finding designs applied in 
pharmaceutical clinical research highlighting their characteristic dose escalation 
procedure.  
Table 3-5: Main adaptive trial designs and the dose escalation procedures 
Trial designs       Dose escalation procedures 
Rule-based 
3+3 design  
(and its variants) 
Mathematical approaches: 
 pre-defines numerical sequence 
 % dose increments 
 mathematical sequence  
(i.e.: modified Fibonacci sequence) 
Model-based 
Continual 
reassessment 
methods  
(and its variants) 
Statistical modelling approaches:  
 parametric/non-parametric 
 Bayesian designs  
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Rule-based dose-finding designs 
The rule-based dose-finding designs typically assign dose levels to subsequent 
groups of patients (cohorts), according to pre-specified rules based on actual 
observations of target events from the clinical data. Predefined mathematical 
sequences are applied to establish dose increments between subsequent 
cohorts, often without prior assumptions on the dose-toxicity curve [139,209].  
Typical example of rule-based designs is the 3+3 design. This design is considered 
a conservative design for its limited risk of participants to incur in a DLT compared 
to other designs (i.e. best to five designs) [231]. The probability of severe toxicity 
in these designs is of approximately 33%. 3+3 designs are largely applied in 
pharmaceutical cancer research under the common assumption that efficacy 
increases with dose and the drug toxicity is often the mean concern. 
In this design patients are assigned to increasing dose levels in subsequent 
cohorts of three patients without intra-cohort variation in the dose. The first 
cohort receives the intervention at the starting dose. The toxicity of the starting 
dose is evaluated at the end of the intervention for the three patients considered. 
At this first as well as any following stage (n) three scenarios can occur. 
1. No toxicities were observed in the entire cohort. In that case the dose is 
escalated for the following cohort, which is then assessed at the end of the 
new intervention period. 
2. Two or more patients in a cohort experienced an unacceptable level of 
toxicity (the dose-limiting toxicity: DLT). In this case the trial is stopped and 
the trial dose endpoints derived (i.e. the maximal tolerable dose: MTD, and 
the recommended dose for phase II trial: RPTD). 
3. One participant experienced a DLT. An additional three patients receive the 
same dose with results that could then fall in condition 1 or, the trial stops 
and the trial dose endpoints are derived.  
There are five main variations of a 3+3 design30. 
                                                     
30 For more details on rule-based designs see Storer (2001) and Le Tourneau et al. (2009). 
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The 2+4 design has stopping rules similar to a 3+3 design but an additional cohort 
of four patients is added if a DLT event occurs in a cohort composed by two 
patients.  
The 3+3+3 design has an additional cohort of three patients used when at least 
two of the six patients in the first two cohorts experienced a DLT. The trial 
terminates (and the MTD derived) if at least three of nine patients experience a 
DLT.  
The best-to-five design (3+1+1) is commonly considered an aggressive design 
implemented when preclinical data indicate a wide therapeutic window or when 
the tested drug is for life-treating illnesses with no other treatments available. 
The probability of severe toxicity in this design is higher than the 33% threshold 
often accepted in phase I trial. In this design one additional patients is added if 
one or two DLTs are observed among three patients. Then, another patients is 
added if two DLTs are observed among the four treated patients. Dose escalation 
is allowed if none of the three, one of four, or two of five patients experienced a 
DLT. The trial will stop and the MTD is derived if three or more DLTs are observed.  
The Storer’s two-stage designs [232] has a single patient that enters in the first 
stage with a starting dose level. If the first patient does not experience a DLT, the 
dose is escalated until a patient experiences a DLT. If that happen a second stage 
begins at a lower dose for a subsequent cohort with a fixed number of patients, 
generally from 3 to 5. The treated cohort is assessed and the next cohort is 
treated at higher, the same, or lower dose depending on whether none, one or 
more than one patient experienced a DLT.  
The Accelerated titration designs combine features from the traditional 3+3 
design and the model-based design although the patient assignment to dose is 
based on pre-specified rules. The size of the cohorts and the rules on toxicity to 
define the MTD vary among the Accelerated titration designs family (referred to 
as Accelerated titration design 1, design 2, design 3, and design 4). The first type 
of designs (design 1) shares the rules of a standard 3+3 design but with a 40% 
increments between cohorts. Design 2 sees single patient cohorts during the 
accelerated phase. When a first-course DLT or a second first-course moderate 
toxicity are observed, cohorts expand and evert to design 1. Design 3 has single 
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patient cohorts with double dose escalation steps (80%). It reverts to design 1 
with same trigger as design 2. Design 4 is equal to design 3 but triggers to revert 
to design 1 if any course DLT or second instance of any course moderate toxicity 
is experienced. 
Model-based dose-finding designs 
Model-based dose-finding designs apply statistical models to data on previous 
cohort to identify dose levels in subsequent cohorts. The shape of the dose-
toxicity curve is estimated (parametrically31 or non-parametrically) using 
collected data from a selected dose. Bayesian models are the most common 
statistical models applied in model-based designs32. In simplified terms, statistical 
models start with a prior distribution (estimation) of the toxicity curve which is, 
generally, derived from available preclinical data. This estimation provides the 
starting dose. Then, the occurrence, or not, of a DLT in the cohort treated, 
provides further information on the toxicity curve. New available data are used 
to estimate a posterior distribution that provides the new dose level for the 
following cohort. This process continues until pre-specified conditions on toxicity 
are met. A model-based design can provide good estimation of dose endpoints 
and data on the dose-response relationship but it might expose patients to high 
toxic dose, in particular if safety rules are not in place [208,233]. Besides, 
advanced statistical expertise is required to implement such a design, alongside 
with the availability of expensive software to fit the model in real time.  
 
The Continual reassessment method (CRM) was the first Bayesian model-based 
method applied in phase I trial design, introduced in 1990 [234]. In this design 
the estimate of the probability to incur in a DLT is updated for each new patient 
                                                     
31 Main characteristics of parametric methods is the assumption that the data has come from a 
type of probability distribution and makes inferences about the parameters of the distribution. 
32These trial designs can provide good estimation of dose endpoints and data on the dose-response 
relationship. However, reviews reported a possible risk to espouse patients to high toxic dose if 
specific safety rules are not in place [208; 232]. 
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who enters the study until a pre-specified condition on toxicity is met. Then the 
MTD and recommended dose for phase II are derived (RPTD) [235]. Variations of 
this design are seen since then to increase design efficacy and patients’ safety. 
Few examples are reported. 
The Escalation with overdose control (EWOC) is a modified CRM with additional 
safety measures to avoid excessive dosing and thus, excessive toxicity. Using 
statistical simulations, the probability to deliver a dose which is higher than the 
MTD is tested before a new cohort starts and the trial stops if this probability 
exceeds a predefined threshold.  
The Time to event endpoints (TTE) CRM design uses surrogate endpoints to 
reduce trial duration in phase I trials. Intermediate endpoints which are relevant 
to the final outcome (i.e. overall survival rate) are used to minimise trial duration 
[230].  
Review results: dose optimization trial designs and studies 
features 
Among included studies, ninety-two (47.9%) applied a dose-ranging approach. 
Characteristics of these studies were as follow: 
 ninety studies (97.8% of ninety-two studies) applied a parallel group 
trial design; two studies applied a cross-over design; 
 seventy-seven studies (83.7% of ninety-two studies) applied a 
randomised allocation procedure to balance baseline characteristics 
among groups or cohorts;  
 fifty-five studies (59.8% of ninety-two studies) implemented a control 
group; 
 fifty-three studies (57.6% of ninety-two studies) implemented a 
blinding procedure towards intervention groups. The majority (46 
studies) applied a double-blind procedure with which both, -the 
patients and research staff- were blind to the allocated intervention;  
 thirty-five studies (38% of ninety-two studies) were conducted in more 
than one site (multicentre studies); 
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 25% of ninety-two studies were implemented in phase I; 59% in phase 
II; 8% in a seamless phase I/II; and 8% in phase III (or seamless phase 
II/III); 
 safety and tolerability of the studies dose levels were investigated in 
67% of the studies. The OTD or optimal schedule was explored in 39% 
of the studies;    
 a total of 14,994 patients were included in these studies with a mean 
of 163 patients per study (minimum of nine participants; maximum of 
951 participants). 
The remaining one hundred included studies (52.1%) applied an adaptive dose-
finding approach to dose optimization. In detail: 
 ninety-one studies (91% of the hundred studies) applied a ruled-based 
design. Among them: 
- seventy-three (80.2% of the ninety-one studies) applied a 3+3 
design; six studies applied a 6+6 design; three studies applied a 
4+4 design; two studies applied a 5+5 design; one studies applied 
a 1+1 design; one study applied a 8+8 design; and six studies 
applied an Accelerated titration design;  
- to set the dose levels in subsequent cohorts -outcome adaptive 
dose escalation procedure- the majority of these studies 
(seventy-six studies, 83.5% of the ninety-one studies) used a 
predefined numerical sequence; ten studies applied a % 
increments; and four studies applied a predefined mathematical 
sequence called the modified Fibonacci sequence; 
 nine studies applied a model-based design using the CRM or a 
modification of it. A statistical approach was used in these studies to 
set the dose levels in subsequent cohorts; 
 78% of these one hundred studies were implemented in phase I of the 
clinical pathway; 18% in a seamless phase I/II; two studies in phase II; 
and two studies in a seamless phase II/III; 
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 the MTDs and DLTs were investigated in more than 68% of these studies; 
the OTDs were investigated in 52% of studies; 
 a total of 2,669 participants were included in dose-finding studies, with 
a mean of 26.6 participants per study (minimum of seven participants; 
maximum of 95 participants). 
 
 
3.5 Interpretation 
This review highlighted the standard procedures applied to dose optimization in 
pharmaceutical clinical research to inform a dose optimization approach suitable 
in stroke rehabilitation research. Included studies revealed that, both dose-
finding and dose-ranging approaches were used to dose optimization in 
pharmaceutical research, with a slightly preference for dose-finding designs 
(52.1%). However, dose-finding designs were mainly applied in the early phase of 
the research pathway. 78% of the dose-finding studies included were applied on 
phase I. This was due to the scope and ability of dose-finding designs to provide 
the first indication of the dose-response and dose-toxicity relationships and to 
gather the first evidence on appropriate dose to take forward in confirmatory 
studies. These designs were able to maximise efficacy in targeting dose 
endpoints. They avoided the selection of sub-therapeutic doses thanks to the 
implementation of interim analyses and were more flexible than dose-ranging 
design in setting dose levels while minimizing the required number of 
participants. 
The majority of dose-finding studies applied a rule-based design to target dose 
endpoints whereas, model-based designs were applied in only 9% of the 
reviewed studies. Model-based designs are advocated as being more efficient in 
targeting dose but their novelty and complexity could explain their limited 
implementation in clinical trials.  
Rule-based designs applied pre-defined rules on toxicity events which guide the 
escalation procedure until the target dose endpoint is reached. A pre-defined 
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numerical sequence was used in the majority of these studies to guide dose 
escalation procedures. Random allocation procedure or other procedure aiming 
at balancing patients’ baseline characteristics were not applied in these adaptive 
designs.  
Applied in 80.2% of the retrieved rule-based studies, 3+3 trial designs were the 
most commonly used designs. This is in line with pharmaceutical literature that 
argued that, despite the recent advances in the designs of innovative dose-
finding trial designs and the theoretical consensus on the superiority of model-
based designs, the 3+3 dose escalation design remains the most popular method 
employed in phase I of the research pathway [236,237].  
On the other hand, the majority of studies that have applied a dose-ranging 
approach (about 60%) were implemented in phase II of the research pathway. 
Dose-ranging studies efficiently seek the confirmation of the optimal therapeutic 
dose among a range of appropriate doses previously identified in phase I trials 
[206,208,225]. The implementation of randomization procedures and control 
groups were common in these designs to increase validity of the results. In line 
with the purpose of testing dose efficacy, overall, the studies implementing dose-
ranging designs have used a considerably bigger sample –on average, 163 
participants- than the one used in dose-finding studies -on average, 27 
participants-.  
 
 
3.6 Conclusion 
The results of this review could be put in the context of the current debate on 
dose optimization in pharmaceutical clinical research. In this field of research, 
dose-ranging and dose-finding approaches were known to be used in different 
phases of the research pathway to answer different questions on dose 
[139,211,213,231,238]. While dose-finding designs were known as the most 
appropriate designs to target accurately dose endpoints [139], dose-ranging 
designs were often used to subsequently test the efficacy of promising dose 
levels against placebo or other available treatments [206,239]. In pharmaceutical 
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research the availability of preclinical data, the relevance of drug adverse events, 
the severity of the illness, and the availability of other effective treatments were 
also important determinants of the appropriateness of the selected trial design 
[209]. 
Although the traditional 3+3 designs were the most common designs in 
pharmaceutical phase I dose-finding studies, some aspects of these designs have 
been challenged. By using sophisticated model-based dose-finding approaches it 
has been shown that a 3+3 design could possibly deliver sub-therapeutic doses 
involving more participants. As a result, 3+3 designs can and be less precise (and 
efficient) in targeting dose endpoints, such as the maximal tolerable dose and the 
recommended phase II dose [210,236]. However, the challenge in implementing 
the statistical aspects of model-based designs was perhaps the major limit to a 
wider use in clinical research [205,215,236,240]. These challenges and issues in 
implementing model-based approaches could be more relevant when 
transferring dose-finding approaches in stroke rehabilitation research. 
 
3.7 Review limits 
The major limit of this review was the limited number of papers retrieved, 
considering the number of drugs commercialised. This was an issue beyond my 
control. It is in fact a common practice in pharmaceutical research to publish in 
scientific journals only a limited and selected number of research, leaving the 
majority of research inaccessible to other scholars [241]. This selective trial 
dissemination is often in favour of studies which show statistically significant 
results [242,243]. However, it was unlikely that this paucity of studies could have 
impacted on the generalisability of the results on the “gold” standards used in 
pharmaceutical dose optimization research.  
Only one researcher (myself) was involved in the selection and extraction 
procedure creating possible bias. Furthermore, the limited knowledge of the 
researcher involved in the data extraction procedure on pharmacy and chemistry 
may have precluded the understanding of specific procedures. However, this 
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should not have impacted on the objectives of this review. The focus of this 
literature review was on the methodology applied to dose optimization per se, 
rather than on drugs efficacy and studies evaluation. Furthermore, the high level 
of standardization of the selection and data extraction procedures should have 
reduced the likelihood of possible bias.  
 
3.8 Clinical and research implication 
Results from this review were useful to inform the debate on dose optimization 
procedures suitable for motor interventions in general and stroke rehabilitation 
clinical research in particular. So far, no reviews of this kind has been published 
with the specific aim of providing key features from the pharmaceutical field to 
inform dose optimisation methods for stroke rehabilitation.  
Summarising, the keys points emerged from pharmaceutical dose optimization 
research, and possibly relevant to stroke rehabilitation research were: there was 
a clear and standardised research pathway which saw the implementation of 
early dose-finding studies as precursor of clinical efficacy dose-ranging studies. 
These subsequent trials, often, tested efficacy and safety of the selected dose, in 
larger samples. 
Furthermore, dose-finding designs were implemented under the following three 
key assumptions: 1) individual responses to the dose were relatively 
homogeneous; 2) the expected outcomes could be measured directly in a known 
and short time frame; and 3) the response to the treatment increased by dose. 
Assessing the relevance and validity of such hypotheses (or deviation from them) 
is of paramount importance, especially in the light of applying pharmaceutical 
dose optimization approaches to other domains. Finally, although promising in 
term of efficacy, the model-based designs were still rarely applied (9%) in clinical 
research. Rule-based designs were the standard procedure in phase I dose 
optimization trials and appeared the appropriate designs to stroke rehabilitation 
research.  
The devising of a new dose optimization study for stroke rehabilitation research 
is discussed in the following chapter.  
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Chapter 4:  
Development of an innovative 
dose-finding design for motor 
interventions after stroke 
 
 
4.1 Introduction 
Chapter 2 documented the limited availability of dose optimization trials in 
exercise-based training research (ExBT). Chapter 3 demonstrated that the designs 
commonly employed in pharmaceutical clinical research can provide useful 
recommendation to stroke-related research.  
The aim of this chapter was to use the information gathered from the two 
preceding reviews to devise a novel phase I dose optimization trial design for 
motor intervention (Overall aim 1; objective 1.c). A methodological framework 
and a description of the key elements for a dose optimization trial design in stroke 
rehabilitation research were reported in this chapter. The protocol and main 
results of a feasibility phase I dose optimization trial design with stroke survivors 
were reported in the subsequent chapter 5. 
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4.2. The dose optimization approach  
Chapter 3 documented the two dose optimization approaches used in 
pharmaceutical clinical research: dose-ranging and dose-finding. While Table 4-1 
summarises the advantages and disadvantages of the two approaches, the 
following section focuses on how such approaches could potentially inform 
stroke rehabilitation research. 
Table 4-1: Pros and Cons of dose-ranging and dose-finding approaches 
Approach Advantages Disadvantages 
Dose-
ranging 
Simple approach. 
Trial key features planned a priori. 
Use of balanced groups and of 
randomization procedure. 
Possible implementation of a 
control group. 
Only pre-specified dose are tested. 
Results depends on: the accuracy of 
prior information on selecting and 
defining tested doses. 
Low level of efficacy and accuracy in 
targeting dose levels. 
  Large sample-size are generally 
required. 
Dose-
finding 
High level of efficacy and ability to 
deal with limited prior data on the 
dose-response. 
Flexibility in setting various aspects 
of the design (adaptive designs). 
Control for type I error33. 
Potentials in informing accurately 
the dose-response relationship 
and in identifying target dose while 
preserving patients’ safety. 
Reduced requirements in terms of 
sample-size.  
Complex approach. 
In general, it is not possible to plan in 
advance all the key features of the 
trial. 
Random allocation procedure not 
possible. 
It assumes that individual responses 
to the dose are relatively 
homogeneous. 
It assumes that expected outcomes 
can be measured directly in a known 
and short time frame. 
  
 
  
 
Dose-ranging approaches, with parallel or cross-over designs, were the current 
standard for dose optimization in stroke rehabilitation research 
[65,127,244,245]. It has been acknowledged, however, that these approaches 
were unable to provide strong evidence on appropriate doses for motor 
interventions [66,83,131] and to improve current understanding of the dose-
response relationship for stroke rehabilitation [84]. Specifically, the rigidities 
imposed by a dose-ranging approach made it unsuitable in identifying dose 
thresholds for efficacy and safety such as, the minimal effective dose or the 
                                                     
33 Type I error refers to the incorrect rejection of a true null hypothesis (a "false positive"). 
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maximal dose above which detrimental effects are seen. In a dose-ranging 
approach only pre-planned dose levels were tested, imposing, by construction, 
restrictions in identifying the possible optimal dose and endpoints. In a dose-
ranging study tested doses should be properly spaced to avoid uncertainty in the 
definition of the dose-response curve that arises when tested dose levels were 
too far apart. To avoid non-identification of dose endpoints, a large range of 
doses should be implemented in these trials at the important costs of requiring 
large sample sizes for testing all pre-specified doses34. Besides such important 
inefficiencies, in particular when recruiting participants is costly, time-consuming 
and difficult, the likelihood to identify the “optimal”35 dose using dose-ranging 
approach is marginal.  
To overcome the inefficiencies of dose-ranging approach in identifying dose 
endpoints in stroke rehabilitation research, a novel and more complex dose 
optimization approach based on a dose-finding (adaptive) design was 
implemented. Furthermore, as it happened in pharmaceutical research, dose-
finding studies were applied in the early phase (phase I) of the research when the 
uncertainty on the dose-response relationship is greater. This appeared even 
more the case in stroke rehabilitation were the dose-response relationships were 
unknown.  
The novelty and complexity of this approach for stroke rehabilitation brought 
uncertainty on the success of this trial. However, the emerging need to identify 
appropriate doses to improve stroke rehabilitation outcome and the promising 
advantages brought by this approach put aside these uncertainties.  
This study was planned as a feasibility study. Feasibility studies are aiming at 
testing new designs and approaches to help subsequent confirmatory studies 
[246,247,248]. They can enhance the likelihood of success of future dose-finding 
studies informing on possible treats and challenges [249]. The implementation of 
                                                     
It should be noticed that the average number of pre-defined dose in stroke rehabilitation trials 
was limited to two. See Chapter 4 for details. 
35 Optimal is in bracket to underline the still early stage of the research and thus of the result on 
doses. 
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feasibility studies on dose optimization in stroke rehabilitation is also endorsed 
by the research community [73,132,133,216].  
 
4.3. The dose identification procedure 
Depending on the dose identification procedure applied, dose-finding trial 
designs can be grouped in: rule-based and model-based designs. While fully 
described in chapter 5, Table 4-2 summarises the main advantages and 
disadvantages of these designs. 
 
Table 4-2: Dose identification procedures: advantages and disadvantages 
Design Advantages Disadvantages 
Rule-based 
designs 
Simple. 
Good level of efficacy when certain 
conditions are verified. 
Decision to escalate the dose is 
based solely on data from current 
dose. 
Need adequate rules to preserve 
participants' safety. 
Good accuracy on targeting dose 
endpoints. 
   
Model-based 
designs 
Higher level of efficacy. 
Decision to escalate the dose is based 
on continuous estimation of the 
dose-response/toxicity curve. 
High accuracy on targeting dose 
endpoints. 
Complexity. 
Need prior knowledge to infer on 
the dose-response curve (prior-
distribution). 
Need of costly statistical software. 
Need of statistical expertise. 
      
 
 
A rule-based design was chosen for this trial for four reasons. First, it avoided the 
complexity of implementing statistical modelling (e.g., Bayesian analysis) while 
preserving the ability to deal with uncertainty on the dose-response relationship. 
Simplicity was key aspect in setting a successful first attempt to implement a 
dose-finding study for complex motor interventions such as stroke rehabilitation.  
Second, the lack of background knowledge on the dose-response curve in stroke 
rehabilitation precluded any reliable assumption on the shape of the dose-
response curve (prior-distribution) that was required for the correct 
implementation of Bayesian models. This, ultimately, reduced the efficacy of a 
model-based design in our context. 
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Third, pharmaceutical research suggested that dose endpoints can be identified 
with acceptable levels of precision and efficiency by using rule-based designs 
together with appropriate sequential interim analysis [208,250], rather than by 
embarking in the implementation of a more complex model-based design [251]. 
Finally, the possibility to adapt trial rules, the trial algorithm, and the dose 
escalation procedure embedded in a rule-based design seemed very appealing 
given our purpose to implement such designs in a new field.  
Among the rule-based designs36, a 3+3 design was chosen for four reasons. First, 
the 3+3 design is the commonest and more studied design in pharmaceutical 
phase I dose-finding design [231,237]. The reliability of this design is therefore 
undeniable. Second, the use of cohorts composed by three participants appeared 
potentially appropriate to increase trial efficacy but preserving validity of results.  
Third, when 3+3 designs are used in conjunction with an adequate dose 
escalation procedure, the sample size is minimised [252] and the efficiency of the 
whole design increases. This was important in our context given the difficulties 
and the costs in recruiting participants. Recruitment procedures are often 
challenging in stroke rehabilitation research and efficient trial designs that are 
able to provide reliable results using small sample size are welcomed. 
Finally, a 3+3 design is often suggested to be a conservative design that is 
appropriate when limited data are available on the toxicity response. This is 
because reduces the number of participants that risk to incur in a DLT compared 
for example to other rule-based designs, such as a best to five design [231].  
The complexity of implementing a 3+3 dose-finding design in stroke rehabilitation 
and the differences with pharmaceutical research were taken into account when 
selecting all the operating characteristics of this trial which were detailed in the 
following sections.  
 
                                                     
36 For more detail on the family of rule-based designs refers to Chapter 3 section 3.4.3. Dose 
optimization trial design.  
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4.4. The dose escalation/de-escalation procedure 
A dose escalation procedure is a plan applied to dose-finding studies which guides 
the selection of dose levels on subsequent cohorts.  
Pharmaceutical dose-finding studies mainly use escalation procedures because 
of the common assumption that the toxicity is a non-decreasing function of dose. 
This is particularly true in cancer research where the optimal therapeutic effect 
is achieved maximizing the dose [139,224]. This assumption might not hold in 
motor interventions and when dealing with the central nervous system. In our 
context, to account for a more flexible dose-response function a dose de-
escalation procedure was embedded in this trial.  
 
Dose escalation procedure 
Table 4-3 summarises the main dose escalation procedures applied in rule-based 
dose-finding designs in pharmaceutical clinical research.  
Table 4-3: Dose escalation procedures 
Dose escalation 
procedure 
Description 
Fixed numerical 
sequence (i.e.: d1; 2d1; 
3d1; etc.) 
Given a starting dose d1 then, the following dose are increase by 
an amount equal to the starting dose  
(e.g. with d1=50 then, d2=100; d3=150; etc.). 
% increment 
Given a starting dose d1 then, the following dose are increase by 
an equal percentage of the first dose  
(e.g. with a 10% increment then, d1=100; d2=110; d3=120; etc.). 
Pre-defined 
mathematical 
sequence 
Predefined mathematical sequences define the increments of 
subsequent dose levels. An example of a mathematical 
sequences commonly used is the modified Fibonacci sequence 
(see Table 4-4 and text below for more details). 
 
In the context of a dose-finding trial for motor intervention, the modified 
Fibonacci sequence (mFBS) was used as the dose escalation procedure. With 
respect to a fixed numerical or a % increment sequence, the mFBS had the 
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advantage of using an incremental ratio which tends to a smaller constant 
number, as Table 4-4 shows. In other words, the mFBS provided a sequence of 
dose increments which were initially large, when the adverse reactions (toxicity) 
were likely to be minimal, and then dose increments became smaller as the dose 
became higher, and the likelihood for adverse reactions (toxicity) increased. 
Increments were also relatively large, providing meaningful differences between 
subsequent doses and reducing the implementation of sub-therapeutic doses 
[253].  
 
Table 4-4: Classic modified Fibonacci dose escalation procedure in phase I trials 
Dose (n) mFBS Dose increments 
1 
 
Starting dose D1 
2 1 2D1 
3 0.67 1.67D2 
4 0.5 1.5D3 
5 0.4 1.4D4 
6 0.33 1.33D5 
Etc. 0.33 1.33Dn-1 
Notes: this table reports the dose spacing derived from the modified Fibonacci sequence (mFBS) 
at each dose level, column 2 shows the corresponding modified Fibonacci spacing (ratio) whereas 
column 3 reports the applied increase with respect to previous dose. 
 
In this trial the mFB sequence was used as commonly applied in pharmaceutical 
a dose-finding clinical trial. In detail: if the results from the first cohort of 
participants, at the initial dose D1, were positive (suitable to escalate the dose 
depending on the trial rules) then, the first increment for the second cohort was 
set at 100% of the starting dose (2D1). Thereafter, and as long as a new cohort 
was needed, the increments for subsequent cohorts were set respectively at 67% 
(1.67D2), 50% (1.5D3), 40% (1.4D4), and 33% (1.33D5,…n) of the preceding dose.  
 
Dose de-escalation procedure 
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When a dose decrement was needed, a dose was decreased, for the subsequent 
cohort, by 50% of the previous increment. If this occurs immediately after the 
starting dose, the following dose was decreased by 50% of the starting dose. 
4.5. The predefined rules  
This dose-finding trial followed predefined rules commonly applied in 3+3 dose-
finding pharmaceutical trials, but adjusted to fit motor interventions. Trial rules 
were based on actual observations of target events from each cohort at the end 
of their training period and were implemented to guide the dose escalation, the 
dose de-escalation procedures and the stop of the trial. 
In pharmaceutical trial the main target event is dose efficacy/toxicity. In this trial, 
due to the required participants’ effort needed to comply with the training dose 
(physical effort, mental effort and time-required in performing the task), the 
feasibility of the dose was also checked and used to guide the trial development. 
Alongside with efficacy and feasibility rules checking rules were introduced. 
These rules should limit the issue of implanting small cohort size avoiding that a 
dose was not deemed feasible or efficacious because of the individuals in that 
particular cohort, rather than the dose itself. They may reduce, in some respect, 
the issues of heterogeneity on patients’ presentation and therapy response 
common in stroke population and neglected in these kind of designs. The trial 
rules were reported as follow. 
Feasibility rules. The dose feasibility was defined as participants’ adherence to 
the target training dose. Adapting pharmaceutical standard rules, the target 
training dose was considered feasible for this trial if at least two of the three 
participants in a cohort were able to complete the exercise at the assigned target 
dose and no more than one participant experienced an adverse reaction 
(toxicity). 
Efficacy rules. The training dose was defined efficacious if at least two of the 
three participants in a cohort experienced a positive effect on the selected 
measure. 
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Checking rules. The first checking rule was that if the dose was found not 
feasible for two of the three participants, a new cohort was allowed at the same 
dose. If this dose was found again not feasible for at least two participants of this 
subsequent cohort then, the subsequent cohort was decreased following the 
dose de-escalation procedure. 
The second checking rule was the following. If a dose was feasible but not 
efficacious for at least two participants in a cohort, then the mFBS was adhered 
to and the dose for the subsequent cohort was increased. If that cohort also did 
not experience any improvement on the selected outcome measure, then the 
stopping rules were considered. 
Stopping rules. The trial was stopped if the dose of two subsequent cohorts 
(which have been increased following checking rule 2) were found feasible but 
no gains in the observed outcome occurred in at least two participants on each 
of the two cohorts. This first stopping rule was made to stop the trial if the trial 
intervention was found not efficacious or in the event of a plateau stage.  
The second stopping rule operated when the dose difference between two 
cohorts was equal or less than a certain pre-determined amount which was 
thought to be not meaningful in terms of amount of exercise undertaken. This 
amount was strictly related to the trial intervention. For the intervention applied 
in the following feasibility phase I dose-finding study this limit was set to 10% 
difference between doses. 
 
 
4.6. The trial algorithm 
The general deriving structural process (the trial algorithm) of this 3+3 dose-
finding design adjusted to fit motor interventions is reported in Figure 4-1. In 
detail: 
 participants were enrolled into cohorts of three people; 
 a cohort must have completed the training programme and the data had to 
be assessed before another cohort can be assigned to a subsequent dose; 
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 the first cohort (n=1) started at the starting dose (d1); 
 data coming from cohort n, where n=1,….N, were evaluated at dose level dn 
at the end of the intervention period for each cohort. At this point four 
scenarios were possible: 
1. dn was found feasible and efficacious for all three participants. The 
subsequent dose was escalated to dn+1 according to the mFBS;  
2. the target dose level dn was found not feasible for all three participants. 
The subsequent dose was decreased following the dose de-escalation 
procedure [(dn - dn-1)/2]. Thereafter, if the new dose level became 
feasible and efficacious, the dose for the subsequent cohort was 
increased by 67% of the previous increment and so on following again 
the mFBS; 
3. the target dose dn was found not feasible for two participants then, 
checking rule 1 was applied; 
4. the target dose level dn was found feasible for at least two of three 
participants but no gains in treatment efficacy were seen. Two 
possibilities were considered. 
a. No change in the selected measure between pre and post intervention 
points for at least two of three participants and maximum one 
participant experienced a detrimental effect. Checking rule 2 was 
implemented. 
b. Observed decrease in the selected measure between pre and post 
intervention points for at least two of three participants. The dose for 
the subsequent cohort was decreased following the dose de-
escalation procedure as in point 2.  
 
This process was repeated until the study stopping rules were met.  
Two counters (C1 and C2) were used in the algorithm to control the correct 
implementation of the two checking rules. These counters were increased by 1 
every time a checking rule was verified and were used to monitor that the 
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checking rules were not applied more than once consecutively. Counters were 
set equal to 0 at the beginning of the trial. 
Figure 4-1: Flowchart of the algorithm of the dose-finding trial for exercise-
based intervention 
 
Notes: ∆= variation of dose level according to modified Fibonacci sequence (mFBS). C1 and C2 are 
the counters to control checking rules. They are set equal to 0 at the beginning of the trial. 
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4.7. The trial dose endpoints 
The conventional main dose endpoint of pharmaceutical phase I dose escalation 
trials is the Maximum Tolerable Dose (MTD). In pharmaceutical research, the 
MTD is defined as the dose above which the drug toxicity is not tolerated by the 
group studied. In this trial, the MTD was defined as the highest dose above which 
the dose was not more feasible or efficacious for the selected sub-group of stroke 
survivors.  
In this trial a second dose endpoints for efficacy was set: the identification of the 
optimal dose to bring forward for following efficacy phase II studies. This dose is 
also known as recommended phase II dose (RPTD).  
In pharmaceutical trials, the optimal therapeutic dose (OTD) is generally derived 
by investigating the dose-response curve and defined as the dose at which the 
physical intervention is likely to be feasible, with the observed highest patients’ 
benefit defined by the selected outcome measure. Similarly, in this trial, the RPTD 
was defined as the appropriate dose to bring forward in the research pathway 
which had demonstrate to be feasible with the observed highest patients’ benefit 
defined by the selected measure. 
The approach to investigate the intervention efficacy seemed appropriate to 
motor intervention for the following two reasons. First, the aim of rehabilitative 
interventions is enhancing motor recovery. Therefore, our focus was to 
investigate the dose-response relationship to identify the OTD that maximises 
therapy effect, rather than, to identify the highest possible prescribed dose (the 
MTD). Second, in stroke rehabilitation the “toxicity” of the intervention may not 
be the main concern. Therefore, the MTD and the optimal dose may not be the 
same as it happen, for instance, in cancer drug research. In stroke rehabilitation 
the assumption that efficacy increases monotonically with dose has not been 
verified yet. 
This approach also addressed one of the major critique of phase I 3+3 designs, 
which focuses only on the MTD while neglecting the treatment efficacy [139,238]. 
To derive the RPTD, the statistical approach applied in pharmaceutical phase I 
dose optimization research to estimate –parametrically- the dose-response 
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relationship was used [139,209,231,254]. Specifically, the appropriateness of two 
parametric models – with a linear and a quadratic specification- were judged by 
means of goodness-of-fit statistics. The parametric model which potentially fitted 
better the data defined the dose-response curve. The RPTD was then the local 
maxima37 of this curve. In addition to the current pharmacological practice, a 
locally weighted regression of the outcome variable(s) on dose was run38. The 
graphical comparison of the estimated curves under this nonparametric model 
with the curves obtained from the parametric ones served to guide on which 
parametric model was more appropriate.39  
                                                     
37 Also called relative maximum of the function studied. 
A locally weighted regression is a non-parametric regression method. Despite being 
computentially intensive, non-parametric methods have the advantage of being free of 
assumptions about the distribution from which the data were drawn. On the other hand, 
parametric statistical procedures rely on assumptions about the shape of the distribution of the 
data. When such assumptions are correct, parametric methods will produce more accurate and 
precise estimates than non-parametric methods. Morevover, the simplicity of parametric formulas 
(line and parabola, in our case) enables us to use estimated parameters in deriving dose endpoints, 
such as the local maxima. 
39 All analyses were undertaken using Stata 13 statistical software. 
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Chapter 5:  
Feasibility of a phase I 
dose-finding design for 
stroke rehabilitation 
research 
5.1 Introduction 
In this chapter the term feasibility was used with two specific and different 
meanings. Firstly, it was used to identify the dose-finding trial as a feasibility 
study. The focus of the dose-finding trial was to investigate the methodological 
feasibility of the applied trial design towards dose optimization to help 
subsequent confirmatory studies. Feasibility trials have the characteristics to 
test new designs and approaches to help subsequent bigger confirmatory trials 
[246,247]. Secondly, the term feasibility was used in relation to the dose of 
training participants were able to sustain and tolerate which was defined as a 
feasible dose (or not).  
The main aim of this chapter was to test the feasibility of the operating 
characteristics of the dose-finding trial design devised in the previous chapter 
(Overall aim 2 and specific objectives). Furthermore, the relevance of the results 
in informing current and future stroke rehabilitation research was explored. 
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The first part of this chapter presents the protocol of the feasibility phase I dose-
finding study for motor interventions assessed among participants with 
moderate upper limb paresis following stroke. The motor intervention applied 
was a repetitive model-task intervention for the upper limb. The second part of 
this chapter details trial results. 
 
 
5.2 Method 
5.2.1 Design 
A single arm, 3+3 rule-based, outcome-adaptive dose escalation design was 
applied (more details were available on chapter 4). 
5.2.2 Recruitment procedure 
A multi–stage recruitment procedure was planned, given the sequential feature 
of a 3+3 design. This avoided over-recruiting and subsequent possible ethical 
issues of contacting people who were not going to be involved in the research. 
Figure 5-1 provides the flowchart of the multi-stage recruitment and participation 
procedures applied. The interim analysis which guided the multi-stage procedure 
is highlighted. 
Interim analysis was planned for each cohort, at the end of the two weeks 
intervention period. Retrieved data was used to guide the progression or the end 
of the trial. If the trial continued (the stopping rules were not verified and the 
dose endpoint not already reached40), then a new cohort was needed and the 
recruitment procedure (re-)started until three new participants entered the trial.  
A gap of about six to eight weeks was anticipated between two following cohorts. 
This gap allowed sufficient time to: deliver the trial intervention, undertake the 
outcome measures, perform the data analysis, initiate the recruitment process 
for a new cohort, and organize the start of a new cohort.  
                                                     
40 For more details see trial algorithm on Chapter 4 
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Potential participants were recruited from the local community through stroke 
survivors support groups that were active in the East Anglia at the time. When a 
new cohort was needed, the administrator of a new stroke group was contacted 
to agree a meeting and present the trial to possible participants. This process 
progressed until the cohort was formed.  
When possible, the researcher requested to present the trial during a support 
group meeting. However, a face-to-face meeting was possible if potential 
participants expressed the preference to do so. The participant information 
sheets (PIS) and the informed consent (IC) were left with interested stroke 
survivors during those meetings. Their interest in taking part in the trial was then 
recorded. No less than 24-hours later, the researcher contacted (by phone) 
interested people to seek confirmation of their willingness to participate in the 
trial. A second appointment was then made with those interested to further 
discuss trial details, to clarify any queries, to seek written IC and, ultimately, to 
test subjects for inclusion. Following written IC and satisfactory inclusion criteria, 
the subject was enrolled in the trial.  
If enrolled, a letter providing information about the trial was sent to the 
participant’s GP, requesting whether he/she had any medical concerns on 
patients’ participation in the study. If no concerns were expressed within seven 
working days, the participant was formally enrolled, seeking an agreement on 
dates to start the study intervention.  
The PIS, IC, GP letter and participant screening form are confined in Appendix E . 
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Figure 5-1: Flowchart of the multi-stage recruitment procedure and 
participation 
 
Notes: In orange the interim analysis which guide the multi-stage recruitment procedure.   
Stopping rules verified? Or 
Dose endpoint reached? 
1st meeting with stroke support groups or stroke 
survivors to introduce trial details 
PIS & IC left to interested people 
Data Analysis 
Contact with stroke groups 
support administrators 
2nd meeting: discussion to check understanding and satisfy 
any query. IC sought and then Participants’ screening for 
study inclusion 
Book appointment at Movement Laboratory (UEA) or 
at participants’ home 
GP’s letter 
Outcome measurements 
Two weeks Intervention 
procedure  
 
At least 24-hours later: interested people contacted, if they are 
happy to proceed then, a second meeting was agreed  
GP advises participants should 
not take part: excluded 
Baseline measurements 
and 1st training day 
NO 
YES 
Stop trial 
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5.2.3 Target population and inclusion criteria 
Adults (18+ years) discharged from stroke rehabilitation care by the Health 
Service at any time after stroke, and able to participate independently in the 
training, were potentially eligible for this trial if they were able to meet the 
following criteria: 
1. presence of moderate upper limb impairment following stroke. Moderate 
upper limb impairment was defined as the ability to open and close the most 
affected (paretic) hand for six times in one minute, but inability to do this for 
26 times in one minute41 when an extra, extra-light elastic rubber band42 was 
placed around their fingers and thumb.  
These upper and lower thresholds on participants’ motor ability were set 
considering a balance between limiting the variations in participants’ baseline 
presentation and preserving the feasibility to enrol participants. A restriction 
in inclusion criteria was needed due to the features of this design which did 
not imply randomisation procedure and used cohort of three participants. At 
the same time, implementing to restrict criteria on upper limb limitation 
could bring difficulties on the recruitment procedure due to the broad 
spectrum of stroke survivors’ presentations; 
2. ability to imitate actions with the less impaired (non-paretic) upper limb. This 
ability was assessed by the researcher that, by sitting alongside the potential 
participant performed the intervention task for five times while the potential 
participant observed. Participants were then required to perform the same 
task five times with the less impaired arm. The accuracy of the task imitation 
was assessed and scored using the following point scale: 2 points= task 
correctly reproduced; 1 point= task reproduced but incorrectly (i.e. 
participant was not able to place the elastic band correctly on the tripod; see 
                                                     
41 An effort was made to select these inclusion criteria as directly relevant to the trial task. Ninety 
repetitions of the tested task in one minute was considered an achievable target for the normal 
population as tested among twenty-five health adults. 
42 Rubber band manufactured by: DIGI-EXTEND® and identified as xx-light; colour beige. See Figure 
5.4 for detail. 
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Figure 5.2); 0 point= task not reproduced. Subjects scoring 8/10 or above 
were considered able to imitate; 
3. not being involved in any rehabilitative training to improve motor–function 
for their paretic upper limb. This criteria was introduced to avoid potential 
confounding effects that arise from participation in other rehabilitative 
interventions. However, participants were asked to continue with their usual 
activities and trainings. 
Trial participant’s screening form is available in Appendix E. 
5.2.4 Research setting 
Participants self-trained in their own homes for two weeks with no supervision 
for the majority of the training period. Participants gathered three times at the 
Movement and Exercise Laboratory (MoveExLab) at UEA with no financial costs. 
In these occasions participants were supervised by the primary research. 
Specifically: 
1. in the first trial day (training day 1, week 1). All participants of a cohort 
gathered to undertake pre intervention (baseline) measures, set the physical 
task intensity identifying their appropriate elastic band, receive instructions 
and conduct the first supervised training session; 
2. in the first training day of the second week (training day 1, week 2). All 
participants in a cohort gathered to reinforce training dose adherence, 
control the accuracy of the physical task, and discuss any possible concern or 
problem; 
3. between one to seven days from the end of the training period. Participants 
came to the MoveExLab to undertake post intervention (outcome) measures. 
To increase participants’ adherence to the intervention and follow-up it was 
aimed that all three participants of a cohort attended the MoveExLab on the 
same day and time. If needed the researcher could visit participants in their home 
instead. 
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5.2.5 Ethics 
The ethical approval for the feasibility phase I dose-finding trial was granted on 
the 7th of February 2014 by the Norfolk NRES Committee East of England 
(Reference ID: 14 EE 0005). See Appendix F which provides the NRES ethical 
approval documentations. 
The University Research and Enterprise service (REN) approval was received 
beforehand with a site specific approval and insurance cover for the duration of 
the entire trial. No amendments to the original protocol were needed.  
5.2.6 Sample size 
Sample size is not usually pre-defined for this type of open-ended dose-finding 
study [139,209]. Typically, the final sample size is based on each cohort’s data 
which informs the decisions on subsequent dose following the trial algorithm.  
In pharmaceutical research, the number of patients enrolled in phase I dose-
finding trials range between 12 and 40 [255]. In line with this evidence, our review 
on pharmaceutical literature (chapter 5) found that the average number of 
people engaged in dose-finding was around 26 participants per study. 
Although there was no pre-imposed limit on the number of cohorts, for this 
study, it was estimated that between 4 to 7 cohorts (twelve to twenty-one 
participants) were required to estimate the predefined dose endpoints and to 
gain early data on the dose-response relationship. This expectation arose from 
the following trial features: 
 the initial high increment rate of dose brought by the mFBS which should 
avoid sub-therapeutic doses reducing sample size; 
 the implementation of checking rules in the trial algorithm; 
 the results from mathematical simulations ran before the trial begins which 
considered trial feasibility and efficacy rules (see section 7.2.11).  
5.2.7 Trial motor intervention  
The delivery, control and adherence to the target dose can be challenging for any 
intervention. As discussed in chapter 1, this is surely true for motor interventions 
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given also the multifactorial aspects of the training dose. Indeed, the risk of bias 
can dramatically increase if all the key aspects of the training dose were not taken 
into account. This becomes particularly relevant in a dose optimisation study 
where the true effect of dose could be then mistaken.  
In a dose-finding study the applied intervention should be identical among 
participants and sessions, apart from the dose. Moreover, to avoid bias, all 
parameters of the dose (studied and not) should be controlled and any variation, 
away from the target dose, should be reported for evaluation. 
In considering the key features of a dose-finding study and the training-induced 
principles of neuroplasticity (see chapter 1), the trial intervention was set as 
following: 
1. a repetitive physical task; 
2. challenging but achievable; 
3. meaningful for stroke survivors;  
4. novel for the majority of participants;  
5. enabling control of the training dose and schedule; 
6. allowing minimal variation between tasks to guarantee that tasks are 
similar across sessions and among all participants in the trial; 
7. allowing equalization of all parameters of the dose among participants 
minimizing differences on participants’ initial level of upper limb 
impairment; 
8. all parameters of the training dose are recordable; 
9. the intervention can be undertaken in participants’ home without 
supervision. 
To some extent, for this phase I trial, the intervention was created similar to the 
one used in animal model studies investigating motor recovery after brain injury.  
5.2.8 Intervention task model and training device  
The training task devised for this trial was a model of a motor intervention. A 
simplified training task, rather than a “real word” rehabilitative intervention, was 
applied to allow high level of control in the dose and to limit further complications 
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in evaluating the feasibility of this study design. However, the features of a 
rehabilitative task remained by the implementation of a meaningful, repetitive 
and challenging task alongside with strengthening components. The trial 
intervention was designed to increase participants’ ability to produce and 
modulate voluntary force in the antagonistic muscle groups of the paretic hand 
and forearm. Very often stroke survivors experience difficulty in releasing their 
grip on objects with their paretic hand. This difficulty can limit their ability to 
perform fundamental everyday tasks such as drinking, washing, and cooking. 
The trial task involved a synergistic extension and abduction movements of the 
fingers and thumb of the paretic hand against a tailored resistance applied by a 
resistance-graded rubber band. This task was thought to contrast the decline of 
muscle strength, which may also contributing to the loss of movement and 
performance often experienced after stroke [256].  
The training task consisted of inserting fingers and thumb into a tripods frame 
(see Figure 5-2 a) and then, opening the hand (extend and abduction fingers and 
thumb) to take off the rubber band and place it on a second but identical frame 
(see Figure 5-2 sequences b-d). Each removal and placing of a band counted as 
one repetition.  
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Figure 5-2: Tripods frame exercise device  
a)  
b)   c)    
d)  
Notes: figure a) shows the tripods wooden frame exercise device with red rubber band; sequence 
b) to c) shows a repetition task.  
 
Participants were asked to move the elastic band from one tripod frame to the 
other, and back again, for the assigned (target) daily number of task repetitions. 
Participants were asked to train five days per week for two consecutive weeks at 
the assigned training dose.  
An electronic counter with display was supplied to help participants in tracking 
and recording the achieved number of daily task repetitions (Figure 5-3). The 
counter was controlled by a switch and two buttons. The switch turned on and 
off the counter. The red button on the right side initialised the SD card integrated 
in the counter whereas, the black left button was the actual count recorder. Every 
time the black button was pressed the number on the display increases by one.  
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The tripods frame and counter were originally designed with the contribution of 
the Mechanical Laboratory at UEA.  
Figure 5-3: Electronic counter provided with the tripods exercise device 
 
Notes: participants initialized the session pushing the red button; by pushing the black button 
participants recorded the number of repetitions achieved in a SD card. 
 
 
 
 
5.2.9 Training protocol and dose 
As discussed in chapter 2, the complexity and multi-factorial aspects of the 
training dose and protocol brought two main challenges when studying a dose-
response relationship. Firstly, if the parameters of the training protocol, or the 
characteristics of the dose, were not controlled the risk of bias could arise. 
Secondly, manipulating more than one characteristic of the dose at the same time 
complicated the understanding of trial results. Which characteristic of the 
training dose could have influenced outcomes remained unclear.  
The first issue of controlling and limiting any variations on the training protocol 
(apart from the studied dose characteristic) was taken into account by creating a 
simplified trial intervention task (model intervention) and device. 
To avoid the second issue only one characteristic of the training dose was 
manipulated in this trial, and all other parameters of the training protocol and 
dose remained fixed among sessions and participants during the entire study.  
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In line with the recommendation endorsing to use specific terminologies and 
definitions regarding the training protocol and its components in stroke 
rehabilitation [37], in this dose-finding trial the training protocol comprised of 
three parameters defined as follow. 
 The dose of training, which, in turn, was composed by: 
- amount of training (A) defined by the number of task repetitions participants 
achieved daily (the total number of rubber band removed and replaced 
each day by participants). Amount of training was the studied 
characteristic of the dose, which was manipulated (varied) across cohorts 
to study the dose-response relationship and to identify dose endpoints of 
the applied training task. The amount of repetitive practice was 
investigated due to its key role on driving positive functional neurological 
reorganization (see chapter 1). The number of task repetitions achieved 
daily by participants was recorded by the electronic counter and self-
reported by participants in the dose-monitoring form; 
- intensity of training (I) defined by the level of resistance applied to the 
repetitive task. The level of resistance was graded using resistance-graded 
rubber bands which identified participants’ effort to complete the task. 
Five different colour-code resistance-graded rubber bands were available 
by manufacturer (Figure 5-4).  
Intensity was equalized among all trial participants. For each participant, 
the training intensity was set during the first training session and it was kept 
constant throughout all the training period. At each participant was 
assigned the strongest resistance band which enable them to perform six 
task repetitions in one minutes. To identify participants’ trial band, and 
thus, training intensity, they were tested starting with a yellow band which 
corresponds to an extra-light intensity. Participants then progressed up or 
down in the resistance depending on their personal ability until the 
participants’ trial resistance band was found. 
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Figure 5-4: Colour-coded resistance-graded rubber bands 
 
Notes: colour–coded rubber bands manufactured by: DIGI-EXTEND®. From the first row left side: 
xx-light (beige); x-light (yellow); light (red). From the second row right side: medium (green); hard 
(blue).  
 
 
 The frequency of the training was defined as the number of days participants 
exercise per week. In this trial the frequency was set at five training days a 
week. Participants reported the dates of the training in the dose-monitoring 
form. 
 The training total length was defined as the total length in weeks of the 
training protocol. In pharmaceutical research the time needed to evaluate 
drug effect is often short as well as predictable from early preclinical studies. 
Whereas, in stroke rehabilitation evidence on the appropriate length of the 
training protocol to see optimal therapeutic effect are lacking. Investigation 
on the time-curse effect of rehabilitative interventions are still limited. 
Previous literature suggested improvement in motor function in response to 
a two weeks period of training [257,258,259]. Thus, to minimise the 
possibility of attrition and increase adherence to the target training dose 
while preserving the possibility to induce motor-changes, the trial length was 
set at two weeks.  
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Data on the duration of the training session were also collected. This was defined 
by the total time (in minutes) participants spent daily on the repetitive tasks. The 
duration of the training was self-reported by participants as well as recorded by 
an internal clock in the electronic counter. Participants reported the duration of 
the daily sessions on a dose-monitoring form reported in Appendix G. 
 
Participants were allowed to split the daily session as needed to achieve the 
target training dose.  
Participants were instructed to strictly follow the given training protocol to 
increase the rigour of this research.  
5.2.10 Starting dose 
One of the crucial aspects to minimize the number of patients required in the trial 
and increase trial efficacy was to identify an appropriate starting dose.  
In phase I dose-finding pharmaceutical studies the starting dose is typically based 
on pre-clinical data and it represents a safe dose which should avoid any toxicity 
but higher than the minimal effective dose (MinED).  
A conservative starting dose (𝑑1), which was thought to show motor 
improvements, was selected for this trial equals to: 
𝑑1 =  50 𝑑𝑎𝑖𝑙𝑦 𝑡𝑎𝑠𝑘 𝑟𝑒𝑝𝑒𝑡𝑖𝑡𝑖𝑜𝑛𝑠 𝑥 𝐼   (1) 
where 𝐼 was the intensity of the repetitive task assigned by the trial and equalised 
for each participant. 
The starting dose was justified by: 
 the choice of using a conservative starting dose to avoid onset of adverse 
reactions such as, fatigue and tiredness; 
 the background knowledge on animal models [92], clinical research 
[69,88,260,261] and quantitative analyses 
[7,26,35,42,66,72,118,122,123,262,263,264,265] which indicated that 
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relatively high dose of training were feasible and can be required to induce 
motor learning after stroke (chapter 1); 
 the use of a dose escalation procedure (mFBS) which allowed for initial rapid 
increments of the training dose, as described with the mathematical 
simulation in Figure 5-5; 
 the recommended 45 minutes of therapy a day issued by the Royal College of 
Physician43; 
 participants’ motor ability thresholds set as trial inclusion criteria. If 
participants were able to open and close their paretic hand six time in one 
minute against the lighted bans (lower threshold), it was estimated that they 
should been able to undertake 50 task-repetitions in about 30 minutes of 
training.  
5.2.11 Mathematical simulation of the trial dose escalation 
Before the trial began, a mathematical simulation with four possible dose 
escalation scenarios was run with the main aims to: anticipate a possible trial 
sample size, estimate the trial starting dose and early assess the feasibility and 
acceptability of some numerical scenarios on trial doses. 
These hypothetical simulations were based on background knowledge on animal 
models with induced brain injury and stroke survivoirs which suggested the need 
and the feasibility of a large amount of task-specific daily repetitions to facilitate 
motor learning. 
Figure 5-5 shows the four possible scenarios of trial dose escalations analysed. In 
detail: 
Case 1 (condition: YYYYYYY, blue line in Figure 5-5)  
In this case all dose were considered feasible, efficacious until cohort 7. Table 5-1 
reports the numerical results of the dose escalation applied using the mFBS.  
                                                     
43 http://www.rcplondon.ac.uk/sites/default/files/national-clinical-guidelines-for-stroke-fourth-
edition.pdf (last visit 11/04/13). 
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The simulation was stopped at cohort 7 because the following dose of 827 daily 
repetitions (highlighted in grey) was considered not feasible because too high.  
Figure 5-5: Mathematical simulation of trial dose escalation 
 
Notes: blue line= case 1; orange line=case 2 grey line= case 3; yellow line= case 4 
Table 5-1: Mathematical simulation on dose escalation: case 1 following the 
mFBS 
CASE 1:     
Cohort (n) mFBS  Dose Increment 
Cohort 
Dose D(n) 
1  0 50 
2 1 50 100 
3 0.67 67 167 
4 0.5 83.5 251 
5 0.4 100.2 351 
6 0.33 115.7 466 
7 0.33 153.9 620 
8 0.33 206.7 827 
Note: case 1 all dose were considered feasible, efficacious until cohort 7 (monotonic increments, 
condition: YYYYYYY). The first column reports the cohort number, the second column the mFBS, 
the third column the dose increments derived by the mFBS and the last column the assigned dose 
starting with an initial dose of 50 daily repetitions. Dose is expressed in daily number of task 
repetitions. 
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Case 2 (condition: YNYY, orange line in Figure 5-5)  
Table 5.2 refers to the numerical results on the dose escalation for case 2. The 
feasible doses were highlighted in bold, the first not feasible dose was highlighted 
in red, when the stopping rule was verified the following dose was highlighted in 
grey. 
In detail, the first dose was considered feasible and efficacious thus, following the 
mFBS, the second dose was increased by 100%. The second dose was considered 
not feasible (or efficacious) and therefore, the third dose was decreased by 50% 
of the previous increment following the trial dose de-escalation procedure. This 
new dose (third) was considered feasible and efficacious and thus, the forth dose 
was increased by 67% of the previous increment reaching 92 daily repetitions. 
The following dose (fifth) should have been increased by 50% of the previous 
increments (by 8 repetitions) but a stopping rule was considered because the 
difference between the two doses was less than 10% (see chapter 4 for trial 
algorithm and rules).  
 
Table 5-2: Mathematical simulation on dose escalation: case 2 following the 
mFBS 
CASE 2:  
Cohor
t (n) 
mFBS  
Dose 
Incremen
t 
Cohor
t Dose 
D(n) 
Dose 
Decremen
t 
Cohor
t 
Dose 
D(n) 
Dose 
Incremen
t 
Cohor
t 
Dose 
D(n) 
1  0 50     
2 1 50 100 25    
3 0.67 67 167  75 16.8  
4 0.5 83.5 251   8.4 92 
5 0.4 100.2 351       100 
Note: Case 2 condition: YNYY. The feasible and efficacious dose were highlighted in bold whereas, 
the dose which were not feasible or efficacious were highlighted in red. In grey was highlighted 
the first not included dose. The first left column reports the cohort number, the second column 
the mFBS, the third, fifth, and seventh columns report the dose increments or decrements derived 
by the mFBS and the fourth, sixth, and eighth columns the assigned dose. Dose is expressed in 
daily number of task repetitions. 
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Case 3 (condition: YYNNY, grey line in Figure 5-5)  
Table 5.3 refers to the numerical results on the dose escalation for case 3. In 
detail, the first and second doses were considered feasible and efficacious seeing 
and increment of 100% and 50% respectively for the second and third cohorts.  
The third dose was considered not feasible (167 daily repetitions, highlighted in 
red). Thus, the following (fourth) dose was decreased by 50% of the previous 
increment (134 daily repetitions). This new dose was considered again not 
feasible (or efficacious) (highlighted in red) and the following (fifth) dose was 
decreased by 50% of the previous increment. The fifth dose was considered 
feasible and efficacious but the trial was stopped because the following (sixth) 
cohort would have set at 141 daily repetitions with an increment by 67% of the 
previous increment, but this new dose was above a dose already found unfeasible 
(134 daily repetitions).  
Table 5-3: Mathematical simulation on dose escalation: case 3 following the 
mFBS 
CASE 3:  
Cohor
t (n) 
mFBS  
Dose 
Incremen
t 
Cohor
t 
Dose 
D(n) 
Dose 
Decremen
t 
Cohor
t 
Dose 
D(n) 
Dose 
Incremen
t 
Cohor
t 
Dose 
D(n) 
1  0 50     
2 1 50 100     
3 0.67 67 167 33.5    
4 0.5 83.5 251 16 134   
5 0.4 100.2 351  118 23  
6 0.33 115.7 466       141 
Note: case 3 condition: YYNNYY. The feasible and efficacious dose were highlighted in bold 
whereas, the dose which were not feasible or efficacious were highlighted in red. In grey was 
highlighted the first not included dose. Cohort number is reported in the left column followed by 
the modified Fibonacci sequence, dose increments (or decrements) derived by the mFBS and the 
assigned dose. Dose is expressed in daily number of task repetitions. 
 
Case 4 (condition: YYNYY yellow line in Figure 5-5)  
Table 5-4 refers to the numerical results on the dose escalation for case 4. As the 
previous case the first and second dose were considered feasible and efficacious 
but the third dose was not (highlighted in red). Thus, the following (fourth) dose 
was decreased by 50% of the previous increment (134 daily repetitions) which in 
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this case, was considered feasible and efficacious. Thus, the fifth cohort saw an 
increase of 67% of the previous increment (156 daily repetitions). This new (fifth) 
dose was considered again feasible and efficacious but the trial was stopped 
because the following dose, increased by 50% of the previous increment at 169 
daily repetition was above a dose already considered unfeasible (167 daily 
repetitions). 
Table 5-4: Mathematical simulation on dose escalation: case 4 following the 
mFBS 
CASE 4:  
Cohor
t (n) 
mFBS  
Dose 
Incremen
t 
Cohor
t Dose 
D(n) 
Dose 
Decremen
t 
Cohor
t Dose 
D(n) 
Dose 
Incremen
t 
Cohor
t Dose 
D(n) 
1  0 50     
2 1 50 100     
3 0.67 67 167 33.5    
4 0.5 83.5 251 16 134 23  
5 0.4 100.2 351   11.5 156 
6 0.33 115.7 466       169 
Note: case 4 condition: YYNYY. The feasible and efficacious dose were highlighted in bold 
whereas, the dose which were not feasible or efficacious were highlighted in red. In grey was 
highlighted the first not included dose. Cohorts are reported in the left column followed by the 
modified Fibonacci sequence, dose increments (or decrements) derived by the mFBS and the 
assigned dose. Dose is expressed in daily number of task repetitions. 
 
As a result of this analysis, the gaps between doses and the trials rules seemed 
appropriate for this trial and intervention.  
Furthermore, from these analyses, it was estimated that between 4 to 7 cohorts 
were required for this trial which was likely to suggest a dose between 134 and 
620 repetitions. 
5.2.12 Trial endpoints 
Coherently with the discussions in chapter 3 and chapter 4, the dose endpoints 
for this trial where derived at the end of the trial as: 
1. the maximal tolerable dose (MTD) defined as the highest dose that was 
adhered to by at least two of the three participants in a cohort and for which 
no more than one of the three participants experienced an adverse 
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consequence. The MTD was derived from the analysis on participants’ 
adherence to the assigned daily dose;  
2. the recommended phase II dose (RPTD) and the dose-response 
relationship. The RPTD was derived from the intervention dose-response 
relationship analysis. The RPTD represented the dose at which the motor 
intervention was likely to be feasible with the observed highest patients’ 
benefit (local maxima). 
 
5.3 Outcome measures 
In phase I pharmaceutical trials treatment effect is often estimated by assessing 
changes on a biological level (i.e. changes in the size of the tumor, changes in the 
blood pressure, and changes in the cells count). These changes, commonly used 
as surrogate endpoints for the definitive outcomes (i.e.: increase of the surviving 
rate; reduction of incidence of stroke and heart attack), are measurable in a 
known and often short period of time.  
Similar specific outcomes and background knowledge are not yet available in 
stroke rehabilitation. As a consequence, the selection of the outcome measures 
is often a challenging step in planning a clinical trial [266]. To overcome these 
issues: 
a) the primary outcome focussed on the impairment level as the most 
sensitive to change brought by the intervention [267] and as predictive of 
neurological and functional recovery after stroke [268,269,270].  
b) a battery of secondary measure was used to investigate changes from pre 
to post interventionon an impairment and functional level. Ideally, the 
selected measure battery should: be appropriate to measure a change 
brought by the intervention; be sensitive enough to depict changes; have 
good psychometrics properties; be validate among the studied group of 
people; and assess more than one level as state by the ICF classification 
(impairment, activity and participation) [271,272,273].  
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c) an objective assessment of the changes in the corticospinal pathway was 
included. Neurophysiology changes after the two weeks of intervention 
were explored using a non-invasive neuroimaging tool. This measure was 
thought to be a more sensitive assessment than clinical examination to 
detect brain reorganization and thus recovery [274]. The appropriateness 
and feasibility of this non-invasive tool was explores in dose-finding trial. 
 
Participants’ characteristics were collected to allow descriptive analyses and 
explore potential relationships with outcomes. Patients’ characteristics obtained 
were: age and gender; time since stroke; side of stroke; and dominant side 
affected. 
The trial baseline (pre intervention) and outcome (post-intervention) measures 
sheets are available in Appendix H and Appendix I. 
In the following sub-sections details are provided on all trial measures. 
5.3.1 Dose feasibility measures  
The feasibility of the training dose was defined as participants’ adherence to the 
assigned training daily dose. In detail, the daily dose was defined feasible if 
adherence to the assigned dose was 100% for at least two of the three 
participants in a cohort (≥66% of the cohort) and no more than one participant 
experiences an adverse reaction (≤33% of the cohort) (toxicity).  
To this definition some flexibility was allowed to accommodate the trial 
intervention to participants’ daily life. If participants did not fully adhere to the 
assigned dose for reasons not related to the trial or the training dose (e.g. hospital 
appointment; health issues unrelated with the trial; all day personal 
engagements; etc.) for a maximum of three days on the entire training period, 
they were still considered adherent to the dose. Participants’ adherence was 
recorded in two ways. 
1. Self-reported (SRM) by participants on a daily dose-monitoring form 
(Appendix G). For each training day participants were asked to record the 
following information: the training day date, the number of repetitions 
achieved in that session, and the total time spent on the daily training session 
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specifying whether they split the session or not. If the daily assigned dose was 
not achieved, participants were asked to motivate44.  
2. Electronically by the counter. The counter recorded the number of 
repetitions achieved for each of the daily training session. Data on number 
of repetitions, time and duration of the daily training sessions were stored in 
a SD card enclosed in the counter and are considered as objective measure 
(OBM). 
 
The participation in this trial training was considered with a low risk of serious 
adverse events. However, any physical training could be related to an “over-use” 
syndrome. To control for this possibility participants were asked to note on the 
dose-monitoring form any adverse occurrences such as: discomfort, pain or 
fatigue. These data, alongside with participants’ feedbacks and comments on the 
training dose, were used to support the dose feasibility assessment. Participants 
were contacted by phone at least in two occasion during the trial intervention to 
check on possible complains, needs and to improve dose adherence. If necessary, 
more phone calls were agreed and planned with participants. 
5.3.2 Efficacy measures 
Independent assessors, blinded to allocation of the training dose, undertook all 
pre (baseline) and post intervention (outcome) measures to avoid possible bias. 
Pre intervention measures were administered on the first training day, before the 
intervention. Post intervention measures were taken within one week after the 
last training day for all participants to equalize retention of training effect. 
5.3.3 Primary efficacy measures 
Considering the generalizability of participants’ acquired motor skills, it was 
desirable to assess a task which is similar to the one treated in the rehabilitative 
                                                     
44 Eight pre-formulated possible reasons to not adhere to the assigned daily training dose were 
provided in the form to facilitate participants. Namely: 1) No time/too busy including; 2) I was 
bored; 3) I was tired; 4) I was sick or not feeling well; 5) Pain or discomfort on my affected hand or 
arm; 6) The numbers of repetitions assigned were too much; 7) I cannot do it/I am not able to do 
it; 8) other, please specify. These added information are used on data analysis and conclusions. 
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sessions [63]. It was difficult to find a known, economically accessible, and 
reliable measure tool able to assess the strength in the extensors muscle of the 
hand and arm which were the muscles trained by the trial intervention task. Thus, 
a clinical therapy device, was used to explore the efficacy of the intervention from 
pre to post intervention as a primary efficacy outcome measure. The Cando Digit-
Extend (Figure 5-6)45 finger exerciser46. The Cando Digit-Extend is a professional 
but easy device. It is clinically used to build strength in the intrinsic and extrinsic 
muscle groups in the hand and forearm. This device is equipped with five coded 
resistance bands (see Figure 5-4). 
In this study, the therapy device was used to assess the effect of the intervention 
on participants’ strength and motor learning focussing on the extensor 
mechanism of all fingers and thumb of the paretic hand. 
The measure took place as follow. Participants inserted the fingers and thumb of 
their paretic hand in the plastic frame and opened their hand against a coded 
resistance band. This measure consists of two parts. First, participants were asked 
to extend their fingers and thumb (open and close their paretic hand) against the 
lightest resistance band available (xx-light, colour: beige) as many time as 
possible in one minute (test part A). The achieved number of repetitions was then 
recorded. 
  
                                                     
45 http://prohealthcareproducts.com/exercise-stations-c-6/cando-digi-extend-finger-exerciser-
package-p-1084 (last visited on 12/13). 
46 No relationship were present between the researcher or the University of East Anglia and the 
DIGI-EXTEND® manufacturer. 
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Figure 5-6: Cando Digit-Extent finger exerciser therapy device 
Note: device manufactured by: DIGI-EXTEND®. 
 
The second part of the test assessed the highest level of resistance (colour band) 
against which participants were able to extend their fingers and thumb of their 
paretic hand twice in one minute (test part B). The test started with the beige 
band (lightest band). Zero was assigned if participant was unable to perform the 
movement. One if participant was able to perform one movement; two if 
participant was able to extend twice the fingers and thumb with the band. This 
test was run with all bands using the same point increments. Therefore, the 
maximum score of 10 points was obtained by a participant that was able to 
perform the movements with the blue (strongest) resistance band. 
The training dose was defined efficacious if at least two of the three participants 
in a cohort (≥66% of the cohort) experienced significant positive change in at least 
one of the two parts of the primary measure. A significant positive change in the 
primary measure was arbitrary chosen as equal or above 10%.  
The changes in these measures, as primary efficacy measure, were used to guide 
the dose escalation and de-escalation in subsequent cohorts following the trial 
algorithm as well as used to identify the dose-response curve and derive trial 
endpoints. 
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5.3.4 Secondary efficacy measures 
The Hand grip test assessed changes from pre to post intervention in participants’ 
upper limb strength using the JAMAR Hand Dynamometer (Figure 5-7, left side). 
Measuring power grip strength changes due to motor interventions was 
considered a sensitive method of charting intrinsic neurological recovery and 
functional recovery after stroke [268,269,270]. Participants were asked to grip 
the handle of the dynamometer and squeeze as hard as possible. The Minimally 
Clinically Importance Change (MCIC) for grip strength was evaluated at around 6 
kg in the healthy population [275] and at around 5 kg for stroke survivors [276].  
The Pinch grip test (thumb and first finger) assessed changes in participants’ 
upper limb strength using a JAMAR Hydraulic Pinch gauge (Figure 5-7, right side). 
The Hydraulic dynamometer was considered a reliable, valid and sensitive test to 
establish changes in the upper limb muscles strength and impairment recover 
over time. Participants were asked to pinch, between the thumb and the first 
finger, and squeeze as hard as possible.  
In both strength tests participants were seated on a table with their elbow 
supported at about 40° angle with wrist unsupported [277]. The tests were 
undertaken three times47 and the mean value is used for the analyses. 
  
                                                     
47 The devices were set to “zero” before each trial. 
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Figure 5-7: Hand grip and hand pinch test  
 
Note: this picture shows the hand grip dynamometer on the left side and the hydraulic pinch 
gauge on the right side. Manufacturer: Sammons Preston Rolyam, distributed by: Homecraft, Ltd., 
Nottinghamshare UK. 
 
The modified Box and Block Test (mBBT). The Box and Block Test is a 
performance-based measurement of unilateral gross manual dexterity. The BBT, 
originally developed in 1957 by Hyres and Buhler [278,279], exhibited an 
excellent test-retest reliability (Interclass correlation coefficient ICC= 0.97 for the 
right; and ICC= 0.96 for the left hand) and inter-rater reliability (ICC= 0.99 and 
Spearman rho correlation rho= 0.99) in elderly people with stroke upper limb 
sensorimotor impairments [280,281,282]. The original test was modified for this 
trial to assess manual dexterity but in three different hand positions. The mBBT 
was chosen due to some similarity with the applied repetition task. The control 
of the extensor muscles of the hand is a key element to perform functional 
releasing movements. Thus, it was thought that increasing their strength and 
control in extensor muscle of the hand and arm participants could release objects 
better and quicker.  
Participants undertook three trials using a different object each time: a tennis ball 
referred to as modified Box and Block test 1 (mBBT1); a 2 cm cube referred to as 
modified Box and Block test 2 (mBBT2); and a 5 cm cube referred to as modified 
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Box and Block test 3 (mBBT3) (Figure 5-8). Five minutes rest were allowed 
between each trial to avoid over-tiredness. The number of reaching and releasing 
achieved by all participants in one minute were assessed using the three objects 
at baseline (pre) and post intervention. Participants’ changes were evaluated as 
the difference between these two measure points.  
To undertake the test participants sit on a dining-type chair at a table in front of 
a divided box. They were asked to pick up an object, between the tip of the index 
finger and tip of the thumb of the paretic hand and release the object into the 
other side of the box. This task was repeated as many times as possible in one 
minute. 
A MCIC, for stroke survivors, corresponds with an increment of five blocks 
[282,283,284].  
Figure 5-8: The modified Box and Blocs tests 
Note: the figure shows the modified Box and Block test with the used three objects: a tennis 
ball, a 2 cm cube and a 5 cm cube. 
 
Results from secondary measures were used to test consistency on the dose-
response curve and the RPTD obtained using the primary efficacy measure48. 
                                                     
48 The secondary measures did not guide the trial algorithm for efficacy and thus, the MTD could 
not be derived from these analyses. 
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5.3.5 Non-invasive neuroimaging tool: Transcranial magnetic 
stimulation (TMS) 
The TMS is a non-invasive brain stimulator tool able to enhance understanding of 
the nervous system. It can be used for mapping cortical motor representation in 
the brain [285]. 
Recently, it has been used to investigate the neural mechanisms that underline 
spontaneous and therapy-induced motor recovery after stroke 
[32,60,62,286,287].  
TMS works by passing a transient current through a wire coil placed on the 
subject’s head. The current produces a changing magnetic field in the beneath 
brain area inducing a depolarization of nerves cells. Single-pulse, low intensity 
TMS can stimulate the corticospinal tract directly if applied over the primary 
motor cortex (M1) (trans-synaptically). The response to this stimulus depends on 
the size, shape, orientation, frequency, and intensity of the TMS stimulus [285] 
and it can be recorded using motor evoked potential (MEP) by bipolar surface 
electromyography positioned on target muscles. When TMS is used following 
standard procedures and guidelines it is considered a safe and painless procedure 
[58,288]. Figure 5-9 shows the MEP characteristics when a single TMS pulse is 
recorded from a muscle. The TMS of the M1 can be used to measure several 
parameters of the integrity and responsiveness of the corticospinal pathway. The 
more common studied parameters include: the cortical motor threshold; MEP 
amplitudes and latency; and the central motor conduction time.  
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Figure 5-9: TMS-derived measures of cortical excitability 
Nates: a) background EMG, b) latency, c) peak-to-peak amplitude, d) silent period. Extracted from 
[58]. 
 
The rational to introduce TMS in this trial was to explore if changes in biological 
level could be more indicative than changes in motor function to guide dose 
optimization studies. In other words, if it could be possible to use change in 
corticospinal excitability as biomarkers for the brain functional reorganization. In 
detail, the objective of this measure were to: 
1. explore if it was feasible to apply TMS to a dose-finding study in stroke 
rehabilitation; 
2. explore if there was a change in the corticospinal excitability pre to post 
intervention; 
3. explore if these changes appeared before any behavioural changes could 
be found. In other words, if this measure was more sensitive to change 
than any other measure applied in the trial;  
4. explore if the dose of training was correlated with changes in excitability 
of the corticospinal pathway; 
5. assess if changes in corticospinal excitability related to any other measure 
applied (clinical scores). 
 
Participants’ changes pre to post intervention were explored on: 
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 MEP amplitude. The size of the peak-to-peak MEP amplitude provided 
information on the integrity of the corticospinal tract. MEP were 
measured in response to increasing stimulus intensity (supra-threshold 
TMS at 100% 110%, 120% and 130% of the motor threshold). This enabled 
exploration on the stimulus response curve (sigmoid curve) or 
recruitment curve (RC) which can demonstrate the relationship between 
corticospinal excitability and level of intensity of stimulation [289]. Both 
hemisphere were investigated because people with motor deficits post-
stroke usually presented variability in the excitability of both hemisphere 
with, often, a reduced MEPs amplitude on the affected motor area 
compared with the unaffected side [290].  
 the resting motor threshold (RMT). The RMT is the basic measure of 
exitability of the corticospinal tract and it could provide indication of brain 
plasticity being predominantly influenced by neural excitability and white 
matter changes [286].  
Single pulses of TMS were given over the participants’ brain areas of M1 of the 
stroke and non-stroke hemisphere of three upper limb muscles: the abductor 
pollicis brevis muscle (ABP); the extensor carpi radialis muscle (ECR); and the 
biceps brachii (BB). These muscles were considered the principal muscles 
involved in the trial repetitive task practice. The measures were taken before the 
start of the trial intervention and between a week post interventions. 
Changes in RMT and MEPs amplitudes from pre to post intervention for each 
assessed muscle were analysed to each individual participants and by cohorts, if 
possible.  
In this study a MAGSTIM appliance with a standard figure-of-eight coil was used 
(see Figure 5-10) to assess the changes in excitability of the corticospinal 
pathways pre and post intervention.  
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Figure 5-10: Transcranial magnetic stimulation machine and figure-of-eight coil 
 
 
Prior to performing TMS, a screening questionnaire, available in Appendix J, 
based on guidelines for safety precautions [58,288] was used to assess 
participants’ ability to take part in the measure by the assessors specialised in the 
tool. Participants were excluded if any metal implants, heart pacemaker was 
reported or participants suffer from epilepsy.  
To undertake the test participants were comfortably seated on an armchair with 
both arms in resting position. The RMT was located in the hot spot49. The hot spot 
was defined as the brain area where the minimum TMS intensity required to elicit 
5 MEPs (≥ 50µV) in 10 consecutive stimulus at rest [289]. To identify the hot-
spots, the assessor measured the participants’ head to find the vertex and then 
moved laterally the TMS coil in very small increments [289]. When located on the 
scalp the hot-spot was marked with an indelible ink. This spot was the one used 
to collect all data. Subsequently, five trials were performed at the intensity of 
110%, 120% and 130% to explore muscle recruitment curve. For each studied 
                                                     
49 The “hot spot” was defined as the most active scalp position for the target muscle where the 
minimal intensity is needed to produce an evoked motor response (motor threshold). 
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muscle the coil was placed on the hot-spot tangentially to the participant’s scalp 
and at 45-degrees to the midline, so that the induced current flowed in a lateral-
posterior to medial-anterior direction. 
Surface electrodes in a belly-tendon montage were used for electromyography 
recordings. Disposable CLEARTRACE ECG adult electrodes50 were used for the 
extensor carpi radialis and the biceps brachii muscles. Reusable cup electrodes51 
were used for the abductor pollicis brevis muscles due to their smaller size.  
The participant’s muscle areas were cleaned before positioning electrodes with 
an abrasive skin preparing gel and then, an alcoholic wipe. 
MEPs data were recorded using Windows compatible Signal software. 
 
 
5.4 Analysis 
The main aims of this dose-finding study were to assess the feasibility of a dose-
finding trial design in stroke rehabilitation research and, to explore the relevance 
of data on dose provided by this study.  
The numerical results on dose were not the focus of this study. Instead, the 
results were only used to suggest the appropriateness of this study to provide 
relevant results on dose endpoints and on the dose-response relationship. 
All participants’ data were included in the analysis following an intention to treat 
procedure to consider attrition and non-compliance. This procedure was found 
to increase validity of the trial results [291]. 
5.4.1 Primary analysis: design feasibility  
Trial design feasibility was assessed considering:  
 the feasibility of the multi-stage recruitment procedure, the time required to 
recruit participants, and to complete the study; 
 the accettability to participate and complete the trial (retention rate);  
                                                     
50 ECG electrodes manufactured by: ConMed Corporation. 
51 Cup electrodes manufactured by: Nicolet Biomedical. 
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 the feasibility, appropriateness and face validity52 of the dose-adherence 
monitoring procedures [292];  
 the appropriateness of the outcome-adaptive dose escalation and de-
escalation procedures; 
 ease of use of the trial pre-defined rules; 
 feasibility in identifying the selected dose endpoints: the MTD and the RPTD 
by plotting dose-response curves. 
5.4.2 Relevance of the dose optimisation information provided 
The relevance to stroke rehabilitation of the dose optimisation information 
provided by this trial were explored through: 
 the ability to identify the MTD;  
 the ability to derive a dose-response curve and thus, to estimate the RPTD 
 
Changes from pre to post intervention on the primary measure data were used. 
In accordance with the standard analysis plans applied in pharmaceutical phase I 
dose optimization research [205,209,231], the appropriateness of two 
parametric models – with a linear and a quadratic specification- were used to 
study the association between dose and effect (dose-response curve). The model 
which showed a better fit with the data using a goodness of fit statistics was used 
to identify the RPTD. The RPTD was then the local maxima of this curve. A non-
parametric53 regression was also run [205] to estimate on which parametric 
model was more appropriate. The purpose of this analysis was explorative only. 
The relevance of the trial to inform stroke rehabilitation research and the 
appropriateness of undertaking the planned analyses were the main focus. The 
numerical value of the dose endpoints were not intended to use per se or in 
further studies. 
                                                     
52 Face validity is a content validity. It implied that the applied test appeared to users practical, 
pertinent and related to the aim of the test (Baruch N., 1958). 
53 See chapter 4, section 7 for details. 
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The feasibility of collecting data on training session duration (time) in a dose-
finding design was explored. The duration of the training session is often used in 
stroke rehabilitation as dose of training [31]. Exploring the feasibility to collect 
this data seemed therefore relevant in a dose-finding study as well as helping in 
compare results with other trials. 
The appropriateness of the obtained trial sample size was evaluated in light of 
the literature.  
 
 
5.5 Results  
Table 5-5 reports participants’ baseline characteristics and pre (baseline) and 
post (outcome) scores by cohorts and overall.  
The mean age of the 15 participants (5 cohorts) was 68.4 years (range 48-81), and 
46.7% were women. On average, participants reported a mean of 70 months 
after stroke (range 9-289), with 33.3% having a right-sided paresis.  Overall, mean 
pre intervention (baseline) motor function scores were: 23.3 (SD= 18.9) 
repetitions per minute of fingers and thumb flexion/extension; 12.3 (SD= 8.2) Kg 
for hand grip; 4.6 (SD= 1.8) Kg for pinch grip; 31.7 (SD= 15.4) transfers per minute 
on mBBT1 (with a tennis ball); 32.2 (SD= 16.7) transfers per minute on mBBT2 
(with a 2cm cube); and 33.7 (SD= 17.6) transfers per minute on mBBT3 (with a 
5cm cube).  
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Table 5-5: Participants’ baseline characteristics and pre (baseline) and post intervention (outcome) scores by cohorts 
 Overall Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 
Baseline characteristics             
Age (years): mean (range) 68.4 (48-81) 68.7 (66-71) 71.7 (68-77) 63.3 (54-71) 60.0 (48-75) 74.3 (69-81) 
Months post-stroke: mean (range) 70 (9-289) 37 (9-67) 124 (18–289) 78 (12-120) 65 (11-156)  44 (30-54) 
Female: % 46.7 67 0 33 100 33 
Right side affected: % 33.3 0 33 67 0 67 
Dominant Side affected: % 46.7 0 0 67 100 67 
Baseline scores: mean (SD) 
      
Maximum no. repetition 23.3 (18.9) 17.0 (16.5) 25.0 (11.8) 24.7 (38.5) 17.0 (18.7) 32.7 (3.1) 
Hand grip (Kg) 12.3 (8.2) 7.3 (7.0) 12.0 (8.3) 19.0 (11.9) 11.0 (8.6) 12 (5.6) 
Pinch grip (Kg) 4.6 (1.8) 4.5 (1.8) 5.4 (1.9) 6.1 (2.0) 3.4 (1.1) 3.8 (1.9) 
mBB test1 (transfers/minute) 31.7 (15.4) 24.3 (12.9) 21.0 (8.5) 36.7 (17.2) 33.7 (20) 42.7 (15.8) 
mBB test2 (transfers/minute) 32.2 (16.7) 22.0 (15.1) 28.0 (13.0) 35.0 (13.5) 40.0 (21.6) 36 (24.3) 
mBB test3 (transfers/minute) 33.7 (17.6) 19.7 (15.5) 36.0 (24.3) 34.0 (17.6) 41.3 (19.9) 37.3 (14.6) 
Outcome scores: mean (SD) 
      
Maximun no. repetition 34.3 (28.7) 22.7 (21.2) 38.0 (26.9) 48.7 (55.2) 23.0 (24.2) 14.6 (39.3) 
Hand grip (Kg) 14.5 (10.1) 8.1 (6.2) 18.5 (17.9) 21.1 (9.7) 12.1 (5.3) 12.7 (10.1) 
Pinch grip (Kg) 5.1 (2.5) 4.2 (1.3) 6.2 (3.9) 7.7 (2.8) 3.4 (1.1) 4.2 (0.9) 
mBBT1 (transfers/minute) 38.0 (23.7) 27.7 (22.0) 32.0 (22.7) 40.3 (16.5) 40.7 (39.4) 48.0 (26.9) 
mBBT2 (transfers/minute) 39.9 (23.4) 32.3 (22.2) 34.3 (21.5) 38.7(11.8) 49.7 (37.8) 44.3 (31.9) 
mBBT3 (transfers/minute) 38.9 (19.8) 32.3 (22.9) 32.7 (20.6) 40.0 (16.4) 47.0 (26.0) 42.7 (24.6) 
SD = standard deviation; mBBT1= modified Box and Block test with tennis ball, mBBT2= modified Box and Block test with 2 cm cube, mBBT3= modified Box and Block test with 5 cm cube. 
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5.5.1 Primary analysis: design feasibility  
Feasibility of the multi-stage recruitment procedure & retention rate 
The trial recruitment procedure started after receiving the ethical committee 
consent in March 2014. The trial and recruitment procedure were stopped due 
to suspended activity by the stroke survivors support groups during the months 
of August and December and participants’ holiday.  
The trial data collection ended on January 2015. A following communication to 
the Norfolk NRES Committee East of England declared the end of study on the 
28th of February 2015. Table 5-6 reports the details on the trial time frame and 
on the recruitment procedure.  
Participants were recruited by contacting thirteen stroke survivors’ support 
groups in the East of England region (eleven groups were located in Norfolk, one 
in Suffolk and one in Cambridgeshire area). Two of the thirteen stroke survivor 
groups refused to host a study information presentation. The administrators of 
these two groups reported an unpleasant experience on previous research trials.  
 
Table 5-6 shows the flowchart of the recruitment and consent rate by stroke 
survivors’ support groups. Approximately 185 people attended the trial 
presentations made by the researcher. Of these, 24 people expressed an interest 
and were provided with the ethically-approved information pack. Of the 24 
potential participants, ten (41.7%) were excluded because they did not meet all 
of the study criteria. One eligible subject contacted directly the researcher 
expressing interest in taking part to the study and was included in the trial 
because they met the trial inclusion criteria. All the 15 participants provided 
written informed consent. 
All participants were able to undertake the two weeks of intervention and the 
post intervention measures. Therefore, retention rate was 100%. This was 
perhaps due to the length of the study of two weeks and the effort made on 
engaging participants to the training and overall trial. The importance to adhere 
to the training dose was highlighted to participants in several occasions. 
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Table 5-6: Time frame of the recruitment and trial procedures 
 Mar-14 Apr-14 May-14 Jun-14 Jul-14 Sep-14 Oct-14 Nov-14 Dec-13 Jan-15 Feb-15 
SSG1   1                                      
SSG2 0                                      
SSG3   2                                 
 Cohort 1       training                            
SSG4        2                            
SSG5            1                          
 Cohort 2             training*                     
SSG6              1                   
SSG7               2                     
 Cohort 3                   training                  
SSG8                    1                 
SSG9                        1             
SSG10                           2         
 Cohort 4                           training          
SSG11                                1    
Subject                       1               
 Cohort 5                                   training*        
Notes: figure shows the time of recruitment from the first contact to the second visit for each of the SSG included in the study. The number of participants recruited by SSG 
is highlighted. For each study cohort the training period is highlighted in yellow. Participants of the same cohort started the trial at different days; SSG= Stroke survivor 
support group 
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 Figure 5-11: Flowchart of the recruitment and consent rate by Stroke Survivors’ Support Groups 
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Feasibility, appropriateness, and face validity of the dose-monitoring 
procedure 
All participants provided self-reported information (SRM) on the daily number of 
repetitions achieved completing the dose-monitoring form. Participants also 
reported that the form was easy and practical to follow. The majority of 
participants reported no problems in using the electronic counter and therefore, 
in the collection of the objective measures (OBM). The electronic counter was 
considered by participants a useful method on tracking the high number of task 
repetitions undertaken.  
Overall, the dose-monitoring procedures applied were considered feasible, 
appropriate, and valid.  
However, some issues were raised by few participants on the electronic counter. 
Two participants raised initial concerns on the complexity of the sequential 
procedure needed to store data on the SD card. These issues were resolved after 
few days of practice. One more participant54, reported having difficulties in using 
the counter for the entire duration of the trial period with the comments: “not 
being able to remember” and “getting confused on the correct procedure to 
switch ON and OFF the counter”. Counter data for this participant were sparse 
and often incomplete. Another participant claimed that the display was too small 
causing difficulties and possible errors in recording the daily number of 
repetitions.  
Following the rate of agreements between SRM and OBM was assessed by 
plotting the two measures for each observations (participant x daily observation) 
on a graph (SRM are on the y-axis and OBM are on the x-axis) to check how close 
the observation were to the line of equality. The line of equality (or identity line) 
was represented by the 45º line (OBM=SRM). Figure 5-12 shows an acceptable 
agreement between the SRM and OBM as most observations were close to the 
identity line. The Pearson’s correlation coefficient r was derived to estimate the 
                                                     
54 DF-14. 
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linear correlation between the two measures. The correlation between SRM and 
OBM was r= 0.86, p<0.001. 
Overall, participants tent to slightly self-report more exercise than those actually 
recorded by the counter. Table 5-7 reports the number of repetitions by cohort 
reported by OBM and SRM and the mean difference between these measures55. 
Cohort 4 reported the greatest difference of about -31 repetitions between OBM 
and SRM.  
 
Figure 5-12: Rate of agreement between Self-reported (SRM) and objective 
measure (OBM) measures by cohort for all participants’ daily training 
 
Notes: dots correspond to all training days for each participant enrolled in the trial. Each cohort 
is highlighted with a different colour. Correlation found between measure was r=0.86 (p<0.001). 
SRM= self-reported measure; OBM= objective measure 
 
 
  
                                                     
55 Data on OBM for participant DF-14 (in cohort 5) were available only for five days.  
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Table 5-7: Mean number of repetitions by cohort reported by OBM and SRM 
and the mean difference between these measures. 
Cohort OBM 
(mean) 
SRM 
(mean) 
Mean diff.  (OBM-SR) 
1 44.53 48.00 -3.47 
2 105.57 108.53 -2.97 
3 128.32 128.66 -4.93 
4 154.50 185.87 -31.37 
5 128.70 128.65 0.05 
Note: table shows the average number of OBM (objective measure) and SRM (self-reported 
measure) repetitions reported by cohorts. The differences between the two means are reported 
on the right column, the greater difference is highlighted in red.  
 
 
Appropriateness of the outcome-adaptive dose escalation and dose de-
escalation procedure 
The outcome-adaptive procedure and algorithm were implemented in this trial 
and setting with no emerging issues.  
The starting dose of 50 daily repetitions was found feasible for all three 
participants (cohort 1). 
Application of the mFBS and the dose de-escalation procedure determined 
discernibly different dose for subsequent cohorts (i.e. differences above 10% 
between subsequent cohorts). In detail, the training dose was escalated in the 
three subsequent cohorts, with an increment of 100% (2d1, 100 daily repetitions), 
67% (1.67d2, 167 daily repetitions) and 50% (1.5d3, 251 daily repetitions), 
respectively. The fourth dose (251 daily repetitions) become not feasible for all 
three participants. Consequently, the dose de-escalation procedure was used to 
define the dose for the following (fifth) cohort (decreased by 50% of the previous 
increment, 209 daily repetitions). This new dose level was feasible but then, the 
trial met a stopping rule as the dose for the sixth cohort would have been less 
than 10% difference between the dose above (see chapter 4, section 4.5 for detail 
on stopping rules). 
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Feasibility of the trial predefined rules on dose feasibility and dose 
efficacy, dose checking and trial stopping rules 
The predefined trial rules were all clear, unambiguous and implemented without 
any issue. Checking rules were not required during this study. (See details on trial 
rules in chapter 4) 
Adherence to the target dose was important for the application of the trial rules 
for feasibility and efficacy. Table 5-8 provides details of individuals’ adherence to 
the target dose and change in primary and secondary measures from pre to post 
intervention.  
In summary, all participants in cohorts 1 and 2 adhered to the assigned dose and 
only one participant in cohort 1 did not show at least 10% improvement from pre 
intervention on the selected primary measure (treatment efficacy). Therefore, 
the dose was increased after both cohorts. 
Cohort 3 had a target dose of 167 daily repetitions. One participant of cohort 3 
did not adhere (mean number of repetitions=73) but all three experienced 
improvements well above 10% level on the selected primary measure (range 
60.9% to 600%). The dose was therefore increased to 251 repetitions for cohort 
4 in accordance with the trial predefined rules. 
In cohort 4 all three participants were not adherent to the assigned dose. 
Although they showed improvement well above the 10% level, the dose was 
decreased by 50% of the previous increment for cohort 5 (dose de-escalation 
procedure). 
In cohort 5 only one participant was not adherent to the assigned dose of 209 
daily repetitions and two participants had improvement above the 10% level. One 
participant experienced a negative change above 10% level (-25.0%). 
Following the trial rules, the dose for the subsequent cohort 6 should increase by 
67% of the previous increment equal to 237 daily repetitions. But this difference 
in dose between two subsequent doses (251-237=14 repetitions) is lower than 
10%. Thus, the trial was stopped at cohort 5 because a stopping rule was verified. 
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Table 5-8: Individuals’ adherence to target dose and change in primary and secondary measures from pre to post intervention 
Cohort Participant Target dose 
(repetitions) 
Repetitions 
performed 
(mean by 
OBM) 
Dose 
feasible 
Primary outcome                   
Max number 
repetitions Cando-
Digit Extend                
% change from 
baseline 
Dose 
efficacious 
Hand gripa              
% change 
from 
baseline 
Pinch gripa           
% change 
from 
baseline 
mBBT1b         
% change 
from 
baseline  
mBBT2 b         
% change 
from 
baseline  
mBBT3 b         
% change 
from 
baseline  
1 
DF-01 
50 
51 
Yes 
27.3 
Yes 
45.0 5.9 35.9 46.2 56.8 
DF-02 54 0 75.0 -7.7 -6.7 40.0 100.0 
DF-03 56 44.4 -9.1 -13.2 -15.8 52.9 66.7 
2 
DF-04 
100 
127 
Yes 
17.9 
Yes 
2.3 0.0 10.0 14.3 19.0 
DF-05 100 91.4 103.6 47.6 93.3 37.2 -12.5 
DF-06 100 16.7 0.0 -25.0 23.1 0.0 -26.1 
3 
DF-07 
167 
170 
Yes 
480 
Yes 
39.1 2.4 29.0 48.4 63.0 
DF-08 172 60.9 -5 42.2 1.8 -10.0 0.0 
DF-09 73 600 21.4 34.8 4.3 4.2 4.8 
4 
DF-10 
251 
217 
No 
32.4 
NA 
0 -7.3 59.3 55.2 28.1 
DF-11 163 100 89.8 -18.7 -36.4 -4.3 -2.1 
DF-12 140 35.7 13.1 29.7 7.1 -6.3 10.5 
5 
DF-13 
209 
209 
Yes 
13.9 
Yes 
-5.0 24.7 31.7 26.6 31.5 
DF-14 207 -25.0 30.4 -13.8 -12.8 15.0 0.0 
DF-15 72 76.7 2.7 49.8 6.9 20.8 -3.2 
Notes: OBM= objective measure (electronic counter); mBBT1= modified Box and Block test with tennis ball; mBBT2= modified Box and Block test with 2 cm cube; mBBT3= 
modified Box and Block test with 5 cm cube. (a) = (kg); (b)= transfer per minute
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Feasibility to identify the selected dose endpoints 
The feasibility to identify the MTD and the RPTD by plotting dose-response curves 
is explored in detail in the following section. 
5.5.2 Rehabilitation relevance of the dose optimisation information 
provided 
The MTD was derived from the analysis on dose feasibility. Counter measures 
(OBM) were used to assess participants’ adherence to the assigned daily training 
dose (dose feasibility) because thought to be more objective. 
The OBM was not available for participant DF-14. For this participant SRM were 
used instead as it was showed in section 7.5.1 that these were very close.  
Participants’ adherence rate (R) to the assigned daily dose was derived as the 
absolute value (ABS) of the ratio between the daily achieved dose (Dachieved) by 
participant and the daily assigned dose (Dassigned): 
𝑅 = [𝐴𝐵𝑆 (
  Dassigned−Dachieved
Dassigned
− 1)] × 100 = 𝐴𝐵𝑆 (−
Dachieved
Dassigned
) × 100  
Using this formula, adherence rate was equal to 0 when Dachieved=0 and 100 when 
Dachieved= Dassigned. It should be notices that R could also be greater than 100 if the 
participant exercised more than required (Dachieved>Dassigned).  
Figure 5-13 reports R for each participants in all 5 cohorts, flattened at 100% to 
ease reading of the results56. The mean number of daily repetitions achieved in 
the training period is shown in the graph for those who did not adhere to the 
assigned daily dose.  
  
                                                     
56 Figure 7-1 in the Appendix K reports participants’ adherence rates with no adjustment at 100%. 
The figure also includes the mean number of daily repetitions achieved in the training period of 
two weeks for each participants. 
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Figure 5-13: Participants’ adherence rates (in %) by cohort flattened at 100% 
 
Notes: the vertical bars reports adherence rate to the assigned dose; the x bar reports cohort of 
study and numbers of assigned repetitions (in parenthesis). Figures above the bars shown average 
number of daily repetitions achieved in the training period for participants who did not adhere. 
(*) highlights participants who were considered adherent but did not fully compliant with the 
target dose for reasons not related to the trial or the dose. 
 
The adherence rates (R) for the first two cohorts was 100%. In cohort 3 two 
participants adhered to the assigned dose whereas one participant achieved only 
44% of the assigned dose (assigned dose= 167 repetitions, mean achieved 
repetitions= 73). None of the participants of cohort 4 adhered to the assigned 
dose of 251 daily repetitions, achieving on average 217; 163 and 140 daily 
repetitions, respectively. One participant of this cohort (ID=10) was not adherent 
to the target dose on the first four days of training. Two participants of cohort 5 
adhered to the assigned lowered dose of 209 repetitions. One participant 
achieved only 34% of the assigned daily dose (on average 72 daily repetitions 
achieved). 
In this feasibility study for the model task applied, the maximal tolerable dose 
was found to be about 209 daily repetitions.  
Changes from pre to post intervention on primary and secondary outcome 
measures were used to derive the dose-response relationships and the resultant 
recommended phase II dose of the model task applied. Two parametric models 
(linear and quadratic) and a non-parametric one (see chapter 4 for justification) 
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were fitted on these data. The mathematical models were used to study the trial 
dose-response curve and to graphically show the associations between dose and 
intervention effect. 
 
Primary efficacy measure: the RPTD 
Figure 5-14 shows the dose-response relationships derived using the Cando Digit-
Extensor measure test part A57, using the three statistical models. In the x-axis it 
is reported the overall daily number of repetitions obtained from the OBM (panel 
a), the SRM (panel b) and the trial target repetitions (assigned dose) (Dassigned) 
(panel c). 
Figure 5-14 shows that the three analyses on participants’ changes on the primary 
measure (test part A) provide similar results, no matter the way in which 
repetitions are included in the analysis. 
The mathematical model that fitted the data best was the quadratic one, 
according to the goodness-of-fit statistic (R2). The highest training effect 
observed from this analyses, which represented the vertex of the curve, lied at 
162 daily repetitions. In this feasibility study this dose level would represent the 
potential recommended phase II dose for the model-task applied (RPTD).  
Table 5-9 reports participants’ maximum number of repetitions achieved with the 
Cando Digit-Extensor test part A at pre (baseline) and post intervention 
(outcome). The changes on the measure from baseline for all participants and by 
cohort are reported in the table.  
Participants’ changes on part B58 of the primary measure are reported in Table 
5-10.   
                                                     
57 Changes assessed in the maximal number of repetitions achieved by each participant from pre 
intervention. 
58 Test B on the primary outcome assessed the highest level of resistance against which participants 
were able to extend their fingers and thumb of their paretic hand twice in one minute. 
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Figure 5-14: Trial dose-response relationships of primary measure change from 
baseline and mean number of daily repetitions for all participants in the trial.  
a)  
 
b) 
 
c) 
 
Notes: triangles (Obs.) represent the participants’ mean daily repetitions. The solid, dashed and dotted lines 
refer respectively to the linear, quadratic and non-parametric mathematical models fitted to the data. (a) 
shows the dose-response relationships derived using the OBM (linear r2 = 0.08 and quadratic r2 = 0.15); (b) 
shows the dose-response relationships derived using SRM (linear r2 = 0.04 and quadratic r2 = 0.18); and (c) 
shows the dose-response relationships using the trial assigned dose (linear r2 = 0.00 and quadratic r2 = 0.18). 
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Table 5-9: Changes on part A of the primary outcome from baseline for all 
participants on the trial 
Cohort Participant Baselinea Outcomea Differencea 
from 
baseline 
Mean 
difference 
by cohort 
% change 
from 
baseline 
1 DF-01 33 42 9 
 
27.3 
DF-02 0 0 0 5.67 0.0 
DF-03 18 26 8   44.4 
2 DF-04 28 33 5   17.9 
DF-05 35 67 32 13.00 91.4 
DF-06 12 14 2   16.7 
3 DF-07 5 29 24   480.0 
DF-08 69 111 42 24.00 60.9 
DF-09 0 6 6   600.0 
4 DF-10 37 49 12   32.4 
DF-11 0 1 1 6.00 100.0 
DF-12 14 19 5   35.7 
5 DF-13 36 41 5 
 
13.90 
DF-14 32 24 -8 6.67 -25.00 
DF-15 30 53 23   76.70 
Note: a= maximum number of repetitions 
Table 5-10: Changes on part B of the primary measure from pre (baseline) to 
post intervention (outcome) for all participants in the trial 
Cohort Participant Baselinea Outcomea Difference from 
baselinea 
1 
DF-01 10 10 0 
DF-02 0 0 0 
DF-03 10 10 0 
2 
DF-04 10 10 0 
DF-05 10 10 0 
DF-06 2 2 0 
3 
DF-07 10 10 0 
DF-08 10 10 0 
DF-09 10 4 -6 
4 
DF-10 10 10 0 
DF-11 0 1 1 
DF-12 5 7 2 
5 
DF-13 10 10 0 
DF-14 6 8 2 
DF-15 10 10 0 
 
Notes: a= number of repetitions; negative changes are highlighted in red. Participants who scored 10/10 
points at pre (baseline) and post intervention (outcome) are highlighted in bolt. 
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Nine participants out of fifteen scored ten points, the highest possible value, at 
both assessment points (highlighted in bolt). Eleven participants did not see any 
change between pre and post intervention. One participant (DF-09) saw a 
decrease in the level of resistance achieved after the intervention period 
(highlighted in red). Unfortunately, the low sensitivity to changes and low ceiling 
effect showed by this measure precluded any further analysis on these data.  
Secondary efficacy outcomes 
Aim of this analysis was to explore whether secondary outcomes provided 
different results in the dose-response relationship and, consequently, in the 
RPTD. 
The analysis was made using OBM59 data. SRM data (not reported but available 
on request) confirmed OBM results, in line with what shown for the primary 
measure. 
Upper limb Strength tests 
Participants undertook each strength tests (hand grip and pinch tests) for three 
times. The average of these three trials was used for the analysis. 
Table 5-11 and Table 5-12 show the pre (baseline) and post intervention 
(outcome) scores for the hand grip test and the pinch grip test by all participants 
respectively. Changes from pre intervention are reported as numerical 
differences as well as percentage (%) changes.  
  
                                                     
59 For all participants OBM were used apart from participant DF-14 where SRM data were used 
instead. 
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Table 5-11: Hand grip strength test by all participants in the trial 
Cohort Participant Baselinea 
(mean) 
Outcomea 
(mean) 
Differencea 
from baseline 
 % change 
from baseline 
1 
DF-01 6.7 9.7 3.0 45.0 
DF-02 0.7 1.2 0.5 75.0 
DF-03 14. 7 13.3 -1.3 -9.1 
2 
DF-04 14. 7 15 0.3 2.3 
DF-05 18. 7 38 19.3 103.6 
DF-06 2.7 2.7 0.0 0.0 
3 
DF-07 15.3 21.3 6.0 39.1 
DF-08 32.3 30.7 -1.7 -5 
DF-09 9.3 11.3 2.0 21.4 
4 
DF-10 18.7 18.7 0.0 0 
DF-11 1.7 3.2 1.5 89.8 
DF-12 12.7 14.3 1.7 13.1 
5 
DF-13 9.8 9.3 -0.5 -5.0 
DF-14 7.7 10 2.3 30.4 
DF-15 18.3 18.8 0.5 2.7 
Note: a= Kg 
Table 5-12: Pinch grip strength test by all participants in the trial 
Cohort Participant Baselinea Outcomea Differencea 
from baseline 
 % change 
from baseline 
1 
DF-01 2.8 3.0 0.2 5.9 
DF-02 4.3 4.0 -0.3 -7.7 
DF-03 6.3 5.5 -0.8 -13.2 
2 
DF-04 5.8 5.8 0.0 0.0 
DF-05 7.0 10.3 3.3 47.6 
DF-06 3.3 2.5 -0.8 -25.0 
3 
DF-07 7.0 7.2 0.2 2.4 
DF-08 7.5 10.7 3.2 42.2 
DF-09 3.8 5.2 1.3 34.8 
4 
DF-10 4.7 4.3 -0.3 -7.3 
DF-11 2.7 2.2 -0.5 -18.7 
DF-12 2.8 3.7 0.8 29.7 
5 
DF-13 2.7 3.3 0.7 24.7 
DF-14 6.0 5.2 -0.8 -13.8 
DF-15 2.7 4.0 1.3 49.8 
Note: a= Kg 
Figure 5-15 and Figure 5-16 show the dose-response relationships derived using 
changes from pre to post intervention and OBM on the hand grip strength and 
pinch grip tests respectively.  
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Figure 5-15: Trial dose-response relationships of changes from baseline on the 
hand grip strength test and mean number of daily repetitions for all 
participants.  
 
Notes: triangles (Obs.) represent the participants’ mean daily repetitions observed by OBM. The solid, 
dashed and dotted lines refer respectively to the linear, quadratic and non-parametric mathematical models 
fitted to the data.  
Figure 5-16: Trial dose-response relationships of changes from baseline on the 
pinch grip strength test and mean number of daily repetitions for all 
participants.  
 
Notes: triangles (Obs.) represent the participants’ mean daily repetitions observed by OBM. The solid, 
dashed and dotted lines refer respectively to the linear, quadratic and non-parametric mathematical models 
fitted to the data.  
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The analysis on participants’ upper limb strength changes from pre to post 
intervention from hand grip and pinch grip tests confirmed that a quadratic 
interpolation fitted the dose-response relationship best. The higher outcome, 
curve vertex, was observed as 134 daily repetitions for the Hand Grip test and 
138 daily repetitions for the Pinch Grip test. This would represent the potential 
RPTD for the applied model-task.   
 
Modified Box and Block tests 
Table 5-13 shows the changes from pre (baseline) and post intervention 
(outcome) on the three mBB tests60 for all participants and the mean tests 
changes by cohort. 
Figure 5-17 shows the dose-response relationships derived using participants’ 
changes from baseline on the mBBT1 (panel a), mBBT2 (panel b), and mBBT3 
(panel c), by the mean daily number of repetition from OBM. From this analysis 
it could be observed that the three tests provided seemingly different dose 
response relationships. 
A quadratic form seemed to fit better the dose-response relationship for the 
mBBT1 (panel a), with a higher outcome observed around 130 daily repetitions. 
This would represent the potential RPTD. However, the reduced curvature of the 
quadratic form pointed out the relatively small estimated variation of mBBT1 by 
number of repetitions. This was also confirmed by an almost flat line depicted 
from the linear interpolation61.  
Results from mBBT2 (panel b) showed a non-statistically significant relationship 
of this outcome according the number of repetitions, determining a flat dose-
response relationship. In this case, a linear interpolation fitted better the data, 
but the coefficient associated to the number of repetitions (and then the slope 
of the line) was not significantly different from zero at conventional significance 
                                                     
60 mBBT1=tennis ball test; mBBt2=2 cm cube test; and mBBT3=5 cm cube test. 
61 The coefficient associated to number of repetition of the linear model was not significant at 
conventional levels. 
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level. Since the RPTD would be the minimum dose associated with the highest 
outcome, results would suggest inefficacy of the therapy. 
For the mBBT3 (panel c) a quadratic form obtained the best fit in a statistical point 
of view. The estimated parameter associated with the quadratic term of dose was 
negative, implying a concave down parabola. Since the RPTD would be the 
minimum dose associated with the highest outcome, results would suggest 
inefficacy of the therapy. In support of this result, the estimated slope from the 
linear model was negative, meaning that more therapy was associated with lower 
outcomes.  
A summary of the trial dose endpoints found by primary and secondary outcomes 
is reported in Table 5-14. 
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Table 5-13: Modified Box and Block tests (mBBT1- mBBT2- mBBT3) changes from baseline by all participants and by cohort 
mBBT1a mBBT2 a  mBBT3 a  
Baseline Outcome 
Diff. 
from 
baseline 
 % 
change 
from 
baseline 
mean 
diff. 
by 
cohort 
Baseline Outcome 
Diff. 
from 
baseline 
 % 
change 
from 
baseline 
mean 
diff. 
by 
cohort 
Baseline Outcome 
Diff. 
from 
baseline 
 % 
change 
from 
baseline 
mean 
diff. 
by 
cohort 
39 53 14.0 35.9   39 57 18.0 46.2   37 58 21.0 56.8  
15 14 -1.0 -6.7 3.3 10 14 4.0 40.0 10.3 7 14 7.0 100.0 12.7 
19 16 -3.0 -15.8   17 26 9.0 52.9   15 25 10.0 66.7   
20 22 2.0 10.0   21 24 3.0 14.3   21 25 4.0 19.0  
30 58 28.0 93.3 11.0 43 59 16.0 37.2 6.3 64 56 -8.0 -12.5 -3.3 
13 16 3.0 23.1   20 20 0.0 0.0   23 17 -6.0 -26.1  
31 40 9.0 29.0   31 46 15.0 48.4   27 44 17.0 63.0   
56 57 1.0 1.8 3.7 50 45 -5.0 -10.0 3.7 54 54 0.0 0.0 6.0 
23 24 1.0 4.3   24 25 1.0 4.2   21 22 1.0 4.8   
54 86 32.0 59.3   58 90 32.0 55.2   57 73 16.0 28.1   
33 21 -12.0 -36.4 7.0 46 44 -2.0 -4.3 9.7 48 47 -1.0 -2.1 5.7 
14 15 1.0 7.1   16 15 -1.0 -6.3   19 21 2.0 10.5   
60 79 19.0 31.7   64 81 17.0 26.6   54 71 17.0 31.5   
39 34 -5.0 -12.8 5.3 20 23 3.0 15.0 8.3 27 27 0.0 0.0 5.3 
29 31 2.0 6.9   24 29 5.0 20.8   31 30 -1.0 -3.2   
Notes: participants’ changes from baseline are reported as numerical differences as well as % changes. A = transfer per minute; mBBT1= modified Box and Block test 1 with 
tennis ball; mBBT2= modified Box and Block test 2 with 2 cm cube; mBBT3= modified Box and Block test 3 with 5 cm cube. 
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Figure 5-17: Trial dose-response relationships derived from the three mBB tests  
a) 
 
b) 
 
c) 
 
Notes: triangles (Obs.) represent the participants’ mean daily repetitions by OBM. The solid, dashed and 
dotted lines refer respectively to the linear, quadratic and non-parametric mathematical models fitted to 
the data on mBBTs changes from baseline. (a) shows the dose-response relationships derived from mBB test 
1; (b) shows the dose-response relationships derived from mBB test 2; (c) shows the dose-response 
relationships derived from mBB test 3. 
 
 168 
 
  
Table 5-14: Trial dose endpoints by primary and secondary outcomes 
Outcome MTD RPTD 
Primary outcome      
CandoDigit-Extensora  209 162 
Secondary outcome      
Hand grip testb n.a. 134 
Pinch grip testb n.a. 138 
mBBT1c n.a. 130 
mBBT2 c n.a. NN 
mBBT3 c n.a. NN 
Notes: MTD= maximal tolerable dose; RPTD= recommended dose for further studies; mBBT1= 
modified Box and Block test 1 with tennis ball; mBBT2= modified Box and Block test 2 with 2cm 
cube; mBBT3= modified Box and Block test 3 with 5cm cube; a= Maximum number of repetitions; 
b= Kg; c= transfer per minute; n.a. not applicable. 
 
Non-invasive neuroimaging tool: Transcranial Magnetic Stimulation  
It was possible to retrieve TMS data only for seven participants out of fifteen 
(46.7%). Participants undertaking TMS were spread among cohorts as follow: two 
in cohort 1; two in cohort 2, and one participant in each of the remaining cohorts 
(cohort 3, 4 and 5). Among participants receiving TMS measure, it was well 
tolerated with no reported complains.  
TMS was contraindicate for seven participants and one participant did not 
undertake the measure due to assessor annual leave. Figure 5-18 highlights the 
reasons for not undertaking the measure among the entire trial sample.  
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Figure 5-18: Trial sample undertaking TMS and reasons for not undertake the 
measure 
 
Note: the pie chart highlights the reasons for not undertaking the TMS measure and the number 
of participants for each reasons is in brackets. 
 
As reported from Figure 5-19 to Figure 5-21, data on MEPS amplitude were 
further limited as the TMS stimulus gets bigger (MEP amplitude in response to 
supra-threshold stimulus). This because the resting motor threshold for stroke 
survivors had to be higher because the size of the TMS response is smaller than 
in healthy people [58]. This was observed for all the three examined muscles in 
general, and for the biceps brachii in particular (see Figure 5-19).  
It was therefore, not possible to use TMS data in this dose-finding study. All data 
and analyses on TMS are confined in Appendix L. 
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Figure 5-19: Data availability on biceps brachii muscle MEPS amplitude changes 
from pre intervention by % of the motor threshold stimulus on affected side. 
 
Notes: bars represents availability of TMS data by % of the motor threshold (dark bar sections) 
on the sample of participants undertaking TMS (7 total participants).  
 
 
 
Figure 5-20: Data availability on extensor carpis radialis muscle MEPS amplitude 
changes from pre intervention by % of the motor threshold stimulus on affected 
side. 
 
Notes: bars represents availability of TMS data by % of the motor threshold (dark bar sections) 
on the sample of participants undertaking TMS (7 total participants).  
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Figure 5-21: Data availability on abductor pollicis brevis muscle MEPS amplitude 
changes from pre intervention by % of the motor threshold stimulus on affected 
side. 
 
Notes: bars represents availability of TMS data by % of the motor threshold (dark bar sections) 
on the sample of participants undertaking TMS (7 total participants).  
 
 
 
Training session duration (time) 
Table 5-15 shows the mean duration of the daily sessions in minutes (self-
reported) for all participants and by cohorts. Ten participants (66.7%) exercised 
for less than an hour per day. All three participants of cohort 4, who did not 
adhere to the 251 daily repetitions, spent a lot more than an hour exercising with 
on overall average of 164.5 minutes a day of training.  
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Table 5-15: Mean duration (in minutes) of daily training session by all 
participants and cohorts. 
Cohort 
(dose) Participant 
Mean time 
(mins) Mean time by cohort (mins) 
Chort 1 
(50) 
DF-001 96.5  
DF-002 45.0 56.6 
DF-003 28.3  
Chort 2 
(100) 
DF-004 53.9  
DF-005 28.8 43.8 
DF-006 48.6  
Chort 3 
(167) 
DF-007 56.0  
DF-008 24.0 37.0 
DF-009 30.9  
Chort 4 
(251) 
DF-010 77.3  
DF-011 328.0 164.5 
DF-012 88.1  
Chort 5 
(209) 
DF-013 59.0  
DF-014 82.2 60.1 
DF-015 39.0  
Notes: participants who exercised for less than an hour were highlighted in bold. In red is 
highlighted the cohort which exercise in average more than an hour.  
 
Sample size 
The trial involved five cohorts with a final sample size of 15 participants. These 
numbers are in line with existing literature on dose optimization in 
pharmaceutical research (see chapter 3). The cohorts’ size appeared appropriate 
to guide the trial algorithm through the dose escalation and de-escalation 
procedures.  
 
 
5.6 Discussion 
All the operating characteristics of this feasibility phase I dose-finding trial were 
found feasible using the applied model-task intervention among moderately 
impaired stroke survivors. 
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The multi-stage recruitment was feasible and allow the recruitments of the 
needed sample. However, for the sequential feature of this process, the time 
required for the recruitment should be carefully considered and optimized in 
order to minimize idle times between cohorts. 
The time commitment needed for the trial interim analyses (decision making 
processes between subsequent cohorts) was feasible in a clinical setting and 
doable in the foreseen time frame. 
The dose-monitoring procedures were feasible and able to provide data on 
participants’ achieved training dose. We found a high level of consistency 
between self-reported and objective measures of training dose and therefore 
both were appropriate to monitor it. However, participants welcomed the use of 
an electronic counter to keep track on the number of repetitions undertaken 
during daily training sessions. We do not exclude the possibility that measures 
from the electronic counter were used by participants’ in their self-reported 
activity.  
Although the trial task was a model-intervention task, it was meaningful to 
participants because they could see the relationship to letting go of objects, an 
issue often experienced by stroke survivors and difficult to exercise in the 
everyday activities. This promoted motivation to self-practice, with potential 
beneficial effects in enhancing dose adherence.  
The definition of the training dose (number of daily repetitions x intensity) was 
appropriate and unambiguous. It was feasible to set, manipulate and control all 
the characteristics of the training dose (amount and intensity) and protocol 
(frequency and total length of the training) for all participants. This has limited 
the ambiguity in the dose-response relationship and has enhanced the reliability 
of the dose optimization process. 
The applied predefined trial rules were appropriate to guide the trial algorithm 
to target dose endpoints. The implementation of feasibility rules, alongside with 
efficacy rules appeared meaningful to motor interventions because investigating 
two key aspects of the training dose. The proportions used to define feasible and 
efficacious doses -the dose had to be feasible/effective for at least two of the 
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three participants in a cohort (≥66% of the cohort) with no more than one 
participant experiencing an adverse reaction (≤33% of the cohort)- appeared 
balanced to guarantee meaningful results for motor interventions, and preserve 
participants’ safety.  
The outcome-adaptive dose escalation and de-escalation procedure provided 
discernibly different target doses for subsequent cohorts. Dose increments and 
decrements were adequately spaced to the purposes of this trial. Dose 
increments were larger at the beginning to avoid sub-therapeutic dose and then, 
smaller to target the dose endpoints with more precision. The use of a de-
escalation procedure, not commonly contemplated in pharmaceutical studies 
given the assumption that the outcome is a monotonic increasing function of 
dose, allowed to closely target the dose endpoints. 
Two weeks of training were considered enough to test the feasibility of the 
phase I trial providing indication of the changes brought by the training dose. 
Other evidence reported changes in motor functions from two weeks of therapy 
[257,258,259]. It is possible that two weeks of training could be not enough to 
depict the efficacy of a rehabilitative intervention. However, the changes 
measured in this dose-finding study has to be considered as intermediate 
endpoints promising for further significant changes as it happen in other medical 
fields and pharmaceutical research [230]. 
In this respect it is also important to note that all the outcomes (primary and 
secondary) which assessed changes at the impairment level (strength) showed 
similar dose-response relationship curves. On the other hand, results from the 
modified Box and Blocs tests, which assessed changes in the functional level, 
were less clear. This could imply the limited transferability of the model-task 
intervention on a functional level, or suggesting that a longer training period may 
be required to observe relevant changes on a functional level.  
This trial involved 5 cohorts, with a final sample size of 15 participants. This 
sample size could appear small comparing to trials evaluating the efficacy of 
rehabilitative intervention. Although more confirmatory data are needed, in 
particular on how to obtain homogeneous and balanced cohorts in small sample 
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studies, cohorts of three participants seemed adequate to guide the trial 
algorithm through the dose escalation and de-escalation procedure. This is 
promising for efficient studies in stroke rehabilitation where recruiting large 
samples is challenging. However, the underlying assumption – also common in 
pharmaceutical research - that individual’s responses to the treatment dose are 
fairly similar might deserve further consideration. 
 
This trial was able to provide information on doses. Acknowledging that the 
purpose of this trial was to test the feasibility and informative nature of the 
design and not to evaluate the model-task intervention as a potential 
intervention or to use the numerical data further, sufficient data were provided 
from this trial to derive the targeted dose endpoints (the maximal tolerable dose 
and the recommended phase II dose) and to explore the intervention dose-
response relationship through statistical modelling. Holding the needs for more 
research, due to the piloting nature of this trial, this result seemed promising for 
stroke rehabilitation research to enhance the methodology of the current 
practice that seeks at identify dose-response relationships of motor 
interventions. 
It was also feasible to retrieve data on the mean duration of participants’ daily 
therapy sessions. This would enable comparison with other research and the 
current national clinical guideline for stroke rehabilitation [31].  
LIMITATIONS 
Trial limitations 
The complexity and novelty of dose optimization processes on motor 
intervention have led to the implementation, in this dose-finding study, of a 
model-task intervention enabling high level of control on the applied dose. This 
model could have reduced the transferability of the results when applying “real-
world” rehabilitative interventions and might explain the inconclusiveness of 
results from the secondary outcomes at the functional level (box and blocks 
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tests). Therefore, further research with complex rehabilitative interventions are 
needed. 
Considering the high numbers of daily task repetitions assigned to participants, 
they could have benefit from some days of training preparation to gradually reach 
the assigned dose. This was not planned in this trial and it may have influenced 
participants’ adherence to the dose. 
Cohorts were found not balanced. Heterogeneity was found on participants’ 
limitations, time since stroke and other characteristics. Although the focus of the 
study was to test the feasibility of implementing a dose-finding design to stroke 
rehabilitation research, rather than providing results on relevant doses of the 
model-task intervention, some considerations are needed for further research. In 
fact, this variability on participants’ characteristics is thought to affect results on 
dose and it is difficult to control in 3+3 designs. In dose-finding designs in general 
there is the common assumption that participants respond fairly homogenous to 
treatment. Thus, restriction of trial inclusion criteria seems the vehicle to reduce 
variability on participants’ characteristics, and then to increase the reliability of 
the dose optimization results. The categorization of patients in sub-groups could 
improve the dose-response estimation by taking into account differences due to, 
for example, their presentation, age, time since stroke. The categorization, 
however, is likely to introduce challenges on the recruitment process, increasing 
study recruitment time due to the restriction of inclusion criteria on stroke 
presentation. In this study, 41.7% of the potential participants were excluded 
because they did not meet the inclusion criteria which are now considered as 
over inclusive. 
It could be argued that larger cohorts can improve the confidence in dose-
optimization studies considering the complexity of motor intervention research 
and the heterogeneity on treatment outcomes. However, two aspects should be 
considered. First, a larger cohort size would increase the cost and time required 
for the study. Second, whatever the cohort size, it is advisable to follow a dose 
escalation study with a phase II dose-ranging study. As in pharmaceutical 
research, a dose-ranging study seeks in a larger sample the identification of an 
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optimal dose among a range of doses close to the recommended dose provided 
by the phase I trial [224,225,238]. Further assessment and adjustment on the 
proposed recommended dose can be done at this second stage. Dose-ranging 
studies also entail randomisation procedure and are already implemented for 
dose-optimization in rehabilitation trials [245]. 
Although the trial stopping rules were useful in avoiding the delivery of similar 
doses between subsequent cohorts, it could be argued that a maximal tolerable 
dose which lies between 209 and 25062 was imprecise. The limit of 10% difference 
between subsequent cohorts was therefore over estimated considering the rapid 
increments in the numbers of repetitions assigned by the escalation procedure. 
However, the numerical values provided by the mathematical simulations 
appeared appropriate in relation to the applied intervention, a difference 
between doses which was less than the starting dose seemed not meaningful. 
The implementation of different interventions could benefit from a different 
stopping rule limit. For example, a 10% difference from the last beneficial dose 
could be more appropriate than 10% difference between subsequent cohorts as 
in this study  
Although the trial algorithm considered the use of checking rules to avoid biased 
information by sample characteristics, they were not verified in this trial. More 
research is needed to evaluate whether these trial rules were appropriate or 
needed some revisions. 
Pharmaceutical dose optimization studies assumed that the expected outcome 
are directly measured in a known time frame. This information, often derived 
from preclinical studies, guides the decision on the appropriate length of 
treatment. In stroke rehabilitation this information is not available and 
investigations on the time-curse effect are still limited. The following chapter 
                                                     
62 In our trial the fourth dose of 251 daily repetitions was found not feasible. The fifth cohort was 
de-escalated at exercised at 209 daily repetitions which was found again feasible. The following 
cohort should have exercised at 237 daily repetitions but the difference between the 251 and 237 
is less than 10% and the trial ended. 
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(chapter 6) addressed this lack of data on the appropriate length of rehabilitative 
interventions after stroke implementing a longitudinal63 studies. However, two 
weeks of intervention seemed appropriate to check the feasibility of this study 
providing indication of changes in participants’ motor function. This result was 
in line with previous literature suggesting improvement in motor function in 
response to a two weeks period of training for stroke survivors [257,258,259]. 
Furthermore, two weeks of training could have maximised the adherence to the 
training and the training dose.  
Although, the electronic counter was considered by participants a good support 
to track high number of task repetitions, few issues were acknowledged causing 
some missing or incorrect data recording. These issues were foreseen at the point 
when the counter was constructed and discussed with the technician involved. 
No structural changes were made because considered unfeasible for the 
mechanical laboratory team. 
The trial traveling commitment could have precluded the participation of more 
impaired stroke survivors or those less motivated. This is a limitation common in 
rehabilitation trials. However, the home-based nature of the intervention, the 
availability of the therapist to travel to subjects’ homes to undertake visits and 
assessments and the trial arrangements should have limited this issue. 
Measures limitations 
The use of a clinical therapy device, the Cando Digit-Extend, as a primary 
measure, instead of a more reliable and validated measure among stroke 
population, could be a matter of concern. However, it was not possible to identify 
a known and affordable measure tool able to assess the strength in the extensors 
muscle of the hand and arm. The focus of the study on the methodology, rather 
than on assessing the intervention efficacy guided this decision. 
                                                     
63 A longitudinal study is a study that apply repeated measures of the same variables over a period 
of time. 
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The primary outcome test part B64 showed low sensitivity to changes and low 
ceiling effect which, unfortunately, precluded the use of this data. 
It was feasible to undertake TMS measures for less than half of the sample 
(46.7%). This was due to the technique contraindications, which made the TMS a 
challenging tool to be applied in the stroke population, rather than an issue 
deriving from the dose-finding design itself.  
Due to the feature of dose-finding studies, the availability of measures able to 
early assess treatment outcomes is paramount. Other assessment tools able to 
identify early changes at the biological level brought by the intervention should 
be therefore tested in these designs.  
 
5.7 New circumstances 
At the time this chapter was revised a new study was published by Dite and 
colleagues implementing a 3+3 dose escalation design in stroke rehabilitation 
research [293]. This study used a different design compared to our study. In the 
Dite and colleagues’ study each cohort of three participants were involved for a 
12-week period split into a preparation phase (weeks 1-4), an adaptation phase 
(weeks 5-8) and a dose maximisation phase (weeks 9-12). The dose escalation 
3+3 design was only applied during the second two weeks of the dose 
maximisation phase. Dose escalations were planned a priory for two cohorts and 
the increments were applied among the same cohort at the end of each 
maximisation training week, if participants were able to exercise at the target 
dose and no dose-limiting toxicity were experienced. The dose of exercise per 
week, for all cohorts, was 360 minutes for the preparation phase and 420 minutes 
for the adaptation phase. High-velocity progressive resistance training was added 
in the second week. The starting dose for the maximisation phase was increased 
                                                     
64 Primary outcome test part B assessed the highest level of resistance against which participants 
were able to extend their fingers and thumb of their paretic hand twice in one minute. 
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by 30 minutes for weeks one and two (cohort one exercised for 450 minutes). At 
the beginning of week three of the maximisation phase an increase of 120 
minutes was planned followed by an increase of 60 minutes in week four (total 
of 630 minutes for cohort one). The design was for subsequent cohorts to start 
their dose maximisation phase at the final dose achieved by the preceding cohort 
and then, increase 60 minutes in week two, and 120 minutes in week three and 
four. 
Summarising the major differences between ours and Dite and colleagues’ study 
were that in the cited study: 
 the starting dose was relatively high. As a consequence, only two cohorts 
were undertaken before the maximal tollerable dose was found. A dose-
limiting toxicity was experienced on the first cohort and thus, no 
increment was allowed on the second cohort; 
 at the end of each maximisation week the dose was increased (dose 
escalation between the single cohorts);  
 training protocol comprises of more than one intervention which differs 
among participants and between training weeks; 
 a de-escalation procedure was not considered; 
 checking rules were not applied;  
 the dose escalation plan was not based on clinical efficacy. Therefore, 
unlike our design, this study was only able to indicate the maximal 
tolerable dose. No dose-response information was generated and 
therefore the recommended phase II dose cannot be determined. This 
approach is consistent with pharmacutical studies where the main 
concern is toxicity and there is the assumption that the drug efficacy 
increases monotonically with the dose. This cannot be true for the central 
nervous system and has to be verified for motor interventions.  
In motor interventions, using the maximal tolerable dose for evaluation in 
subsequent clinical efficacy trials could mean that people participate in 
more exercise than they need for production of optimal clinical efficacy. 
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Interestingly, in our study the RPTD was found about 78% of the maximal 
tolerable dose. In health service terms this represents a considerable 
resource saving compared with provision of the maximal tolerable dose. 
Furthermore, some safety issues can arise implementing the maximal 
tolerable dose in subsequent testing. 
Our design therefore may have advantages over the study by Dite and colleagues 
[293].  
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Chapter 6:  
Feasibility of a 
repetitive assessment 
procedure for stroke 
survivors engaged in a 
rehabilitative trial 
 
 
6.1 Introduction 
Chapter 1 highlighted the need of reliable information on the optimal therapeutic 
dose (OTD) and on the appropriate length of motor intervention to enhance 
stroke rehabilitation outcome in a cost effective manner. Chapter 5 drawn 
attention to the need of data on the time-curse effect and on the appropriate 
length of rehabilitative interventions to set dose optimization studies for stroke 
survivors. 
This chapter addressed the feasibility and acceptability of undertaking a 
longitudinal study to investigate how the therapy effect evolves over time and 
therefore, how to derive the appropriate length of training (protocol) (Overall 
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aim 3 and specific objectives). To do so, the observation of within-patients’ 
variations of a given outcome at different time points are required using a 
repetitive assessment procedure. 
In stroke rehabilitation research, repetitive assessment procedures are not 
commonly undertaken [127,130]. The common practice in this field is to assess 
participants’ change on two time points, generally at the beginning (pre 
intervention) and end of the trial (post intervention). The resultant difference in 
outcomes identifies the therapy effect. This rather simplistic approach, however, 
does not enable to discern the appropriate length of the training protocol 
because the trend on therapy effect cannot be explored.  
The implementation of repetitive assessments in a rehabilitation trials is not 
straightforward and needs further study. These procedures can be costly -in 
terms of effort- for both, the stroke survivors and the researcher, and they 
generally require extra financial resources to be devoted to the research.  
The implantation of longitudinal studies is in line with the suggested framework 
for complex interventions which endorsed the use of feasibility studies early in 
the research pathway [138] and with the step-by-step approach required for 
robust scientific evaluation of complex rehabilitation interventions which 
promoted the identification of key information before moving forward in the 
research pathway [74,138,214]. 
 
6.2 Methods 
6.2.1 Research Design 
The reported study was designed as a longitudinal feasibility study embedded in 
a phase II clinical efficacy trial (FeSTivALS). This trial was planned as an embedded 
study for the following three reasons. 
First, the main aim of this study was to test the feasibility of a repetitive 
assessment procedure in stroke rehabilitation and not to test the efficacy of any 
intervention. Thus, it appeared more convenient, in terms of time and financial 
costs, to exploit an already running trial.  
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Second, early efficacy trials seemed to be the most appropriate stage of research 
at which to introduce such a procedure, to maximise research efficacy and 
increase the informative value of the trial. 
Third, the features of FeSTivALS as a randomized, observer-blind trial increased 
the validity of the embedded trial results. FeSTivALS trial was a randomized, 
observer-blind, phase II clinical trial evaluating the efficacy of the Functional 
Strength Training (FST) for upper and lower limbs motor function [294]. The 
flowchart of FeSTivALS trial design and the embedded repetitive assessment 
study (highlighted in blue) is reported in Figure 6-1. 
The embedded longitudinal feasibility study consisted of delivering an additional 
motor assessment (Fugl-Meyer motor functioning assessment) to FeSTivALS trial 
to investigate the intervention response over time.  
The protocol features of FeSTivALS trial (randomization and recruitment 
procedures, participants’ inclusion criterial, trial intervention and research 
setting) were briefly reported to contextualise the embedded study. These were 
already in place when this trial started. For more information on FeSTivALS trial 
refers to Mares et al., 2013 [294]
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Figure 6-1: Flowchart of FeSTivALS trial and the longitudinal embedded study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: the embedded longitudinal study is highlighted in orange 
 
Participant with having had a stroke between 1 & 5 years ago
Baseline measurements
FAC for lower limb function, ARAT for upper limb function, Modified Rivermead 
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Data Collection- 6 weeks
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Data Collection -12 weeks
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Data 
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6.2.2 Recruitment procedure 
Potential participants were identified from three sources: the discharge database 
of one acute stroke service from the local acute hospital, the six-month post-
stroke clinic of the same stroke service, and therapists’ referral. 
A recruitment letter was sent to each potential participant with an expression of 
interest form attached. They were asked to send the expression of interest in 
taking part in the study back, in a stamped addressed envelope or by phone. On 
receipt of an expression of interest form, the researcher from FeSTivALS 
contacted the potential participants to initially screen whether they met the trial 
inclusion criteria. If this was likely then, the same researcher arranged a home 
visit to discuss the practicalities of taking part in the study, to assess inclusion 
criteria and to go through the Participant Information sheet (PIS). After not less 
than 7 days from this visit the potential participants were contacted to check their 
willingness to participate in the study. If they confirm their intention an 
appointment was made with the blind research assessor. During this visit, after 
providing informed consent (IC), participants undertook the measurement 
battery (baseline). A letter was sent to participants’ GP to inform on the patient’s 
participation in the study asking to report back if GP disagreed with patient’s 
participation. A summary of the study was attached to the letter so that GP could 
made an informed decision about the medical suitability of their patient. If no 
reply was received within ten working days, the participant was contacted again 
to agree on date to start the study. The trial recruitment letter, the expression of 
interest form, the PIS, the IC, and the GP letters are confined in Appendix M to R. 
Following baseline measures participants were randomly allocated to either FST 
for their upper limb (FST-UL) or FST for their lower limb (FST-LL). 
6.2.3 Randomization procedure 
Random group allocation was determined by a telephone call to an independent 
randomization service within the Norwich Clinical Trials Unit. The baseline scores 
for the Functional Ambulation Category (FAC) and Action Research Arm Test 
(ARAT) were used to minimize any imbalance in allocation of participants to 
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either FST-UL or FST-LL [294,295]. Minimisation of baseline imbalance between 
treatment groups was based on the Pocock and Simon’s range method [296]. 
6.2.4 Participants 
Inclusion criteria: 
 adults aged 18+ years; 
 six months to five years after either an infarct or haemorrhagic stroke in 
the anterior circulation; 
 able to walk four steps with the continuous support from one person 
and/or assistive device, but unable to step on and off a step 7.5cm high 
more than fourteen times in fifteen seconds with either their affected or 
unaffected leg (the step test) [297];  
 have sufficient voluntary activity in the paretic upper limb to move the 
paretic hand from a position on their lap to the table top in front of them, 
but unable to pick up four £1 coins individually from a table top and stack 
them evenly in a pile;  
 able to follow a 1-stage command with the non-paretic upper limb i.e. 
sufficient communication/orientation to undertake the trial 
interventions. 
Exclusion criteria: 
 diagnosed with a known pathology contraindicating participation in FST; 
 receiving formal upper or lower limb physical therapy. 
6.2.5 Sample size estimates 
Given the feasibility nature of FeSTivALS trial a power calculation was not 
possible. However, it was estimate a target of 58 stroke survivors65.  
                                                     
65 26 participants per group would have 90% power at 5% significance to detect: a change of 1 
point on the FAC, assuming a standard deviation of 1, and a change of 5.7 points on the ARAT, 
assuming a standard deviation of 5.7. By allowing for an estimate 10% attrition rate the final 
recruitment targeted of FeSTivALS was set at 58 stroke survivors. For more detail refers to Mares 
et al., 2013. 
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On the same line, a power calculation was not feasible for the embedded 
longitudinal study given its feasibility nature and the use of an additional measure 
to FeSTivALS trial (not the primary outcome measure). However, to provide and 
idea of the needed sample size for future studies implementing the Fugl-Meyer 
motor functioning assessments as a primary outcome, a power analysis was 
derived from the literature. Assuming a clinical relevance of 10% difference on 
the Fugl-Meyer motor functioning assessments score [298], a standard deviation 
of 3.2 [299], and a loss of patients at follow-up of 10%, 20 patients would be 
sufficient in each group to have an 80% chance of detecting a statistically 
significant difference in improvements between the two groups. 
6.2.6 Ethics 
Ethical approval for FeSTivALS trial was granted by the Norfolk Ethics Committee 
(reference number 09 H0308 147). FeSTivALS trial was also registered on the 
Current Controlled Trials database (ref:  ISRCTN71632550).  
Ethical approval for the repetitive assessment procedure was provided as a 
substantial amendment (amendment number 7) by the Cambridgeshire 2 
Research Ethics Committee (ref: 09 H0308 147).  
All relevant documents are included in Appendix S. 
6.2.7 Intervention  
Functional Strength Training (FST) was an exercise-based therapy implemented 
to enhance cortical reorganization to recover functional skills lost after stroke. It 
was a hands-off progressive resistive exercise involving repetitive daily functional 
activities directed by the therapist. 
FST for the lower limb (FST-LL) focussed on functional activities involving the 
lower limb such as: 
- standing up and sitting down; 
- ascending and descending stairs and/or using a block for step up/step down 
exercise; 
- practice of balance activity including one-leg standing; 
- walking whilst avoiding and/or stepping over obstacles. 
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FST for the upper limb (FST-UL) focussed on improving the production of 
appropriate force in the shoulder, arm and hand to improve functional 
movements. Example of FST-UL were: 
- reaching, picking up a jug containing water and pouring contents into a 
container; 
- picking up a container and removing the screw lid; 
- reaching down to a foot and then using both hands to lace up a shoe; 
- picking up and then moving everyday objects of various weights and sizes to 
position them in a different locations of diverse heights. 
 
In FeSTivALS trial training progression was informed by the Oxford program [300] 
through increasing the amount of resistance (external resistance bands and/or 
weights), increasing task difficulty and increasing the number of repetitions. 
Participants were randomised to either FST-UL or FST-LL for one hour a day, on 
four days a week, for six weeks. 
6.2.8 Research setting 
FeSTivALS trial intervention, trial measurement battery, as well as the additional 
weekly assessments of this embedded trial took place in participants’ homes with 
the supervision of a research therapist.  
6.2.9 Outcome measures 
FeSTivALS trial outcome measures 
FeSTivALS primary efficacy outcome measures were the Functional Ambulation 
Category (FAC) [301] for the lower limb, and the Action Research Arm Test (ARAT) 
[302] for the upper limb collected at baseline (pre intervention), after the six 
weeks of intervention (post intervention) and a six weeks after the end of the 
intervention (follow-up). 
The FAC is a functional walking test that evaluates ambulation ability using a six 
point scale [303], largely used with patients with stroke in research and clinical 
practice. Mehrholz et al. (2007) examined the FAC psychometric properties in 
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hemiparetic patients after stroke. They found that it has an excellent reliability, 
good concurrent and predictive validity, and good responsiveness [304]. 
The ARAT is an arm-specific measure of functional ability which has been found 
appropriate and largely used with stroke survivors [305]. The ARAT showed high 
inter-rater and test-retest reliability as well as content validity and construct 
validity [306].  
Secondary outcome measures were also collected (see Mares et al. (2013) for 
details [294]). 
Embedded trial: repeated measures  
A fundamental and challenging step in implementing this embedded study was 
the identification of an appropriate outcome measure.  
The measure needed to show several qualities. First, it needed to be able to 
detect changes brought by the trial intervention and thus, needed to assess 
functional tasks that were likely to be improved by a strengthening programme –
like the FST- in both the upper and lower limbs.  
Second, it should have good psychometric properties verified in the stroke 
population. Such as, validity, responsiveness and, most important for the 
repetitive nature of this procedure, reliability [266]. Reliability refers to the 
measure ability to provide results that are consistent and able to differentiate 
between participants. These characteristics are refereed as the test-retest (or 
intra-rater) reliability and the interrater reliability [307]. 
Third, to avoid potential learning effect with the trial primary efficacy measure 
[63,308], the measure for this embedded longitudinal study differed from the 
ones already implemented in the main trial.  
Fourth, it should not be too long or require too much physical effort. In fact, it 
would not be desirable that participants become fatigued because of the length 
of time and effort required to complete the repeated assessment. 
Finally, a pragmatic factor to consider was that the research therapist should be 
able to carry the equipment to undertake the measure alongside with other 
equipment needed to deliver the therapy during the home therapy sessions. 
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As a result of these key considerations, for this longitudinal embedded trial the 
Fugl-Meyer assessment (FMA) of paretic upper and lower limb [298] was chosen 
as additional repetitive assessment. 
FMA showed good psychometric properties [309]. It has been validated among 
stroke survivors and is one of the most often used tool to evaluate stroke 
patients, in particular for upper limb extremity [309,310]. This give consistency of 
outcome measure across research.  
Platz et al. (2005) rated the test-retest reliability of the upper limb motor score 
as excellent among patients with neurological conditions (Interclass correlation 
coefficient (ICC) is 0.97) [306]. Duncan et al. (1983) examined the test-retest and 
interrater reliability of the FMA among stroke survivors and found an excellent 
correlation (Intra-rater Pearson’s correlation coefficients: (r) is 0.98-0.99 for the 
total score, r = [0.995-0.996] for the upper extremity and r = 0.96 for the lower 
extremity; interrater r [0.98-0.995] for the upper extremity and r = [0.89-0.95] for 
the lower limb) [311]. 
The FMA is divided into five domains: motor function, sensory function, balance, 
joint range motion, and joint pain. Each domain contains multiple items, each 
scored on a 3-point ordinal scale (0=not able to perform; 1=partially performed; 
2=fully performed). To limit the burden on participants, which were already 
engaged in a highly demanding physical intervention, only the motor function and 
reflex domain items were tested (see Table 6-1). The average time needed to 
administer the motor and reflex sections of the FMA was estimated between 15-
30 minutes. The FMA protocol is available in Appendix T.  
The FMA was undertaken weekly by therapists who were trained on the 
assessment beforehand. This time point appeared able to provide enough 
information to explore the therapy time course relationship as well as not too 
disruptive on the main trial. As standard procedure, the FMA for upper and lower 
limbs was taken on the same day every week before the intervention. 
The FMA minimal clinically important difference (MCID) in stroke survivors has 
been estimated around 5.25 points [312,313] on the upper limb, and as 10% 
increments on the lower limb portion of the test [309]. 
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Data were collected on a standardised FMA score sheet (see Appendix U) for each 
participant at each measure point assessment. Space for comments were 
available if needed in the score sheet. Blinding assessors was not possible 
because the therapist delivering the trial intervention also undertake the weekly 
assessment. The therapists’ code was recorded in the FMA score sheet. People 
involved in the analysis were not involved in the outcome measures.  
Other data available for all participants included in FeSTivALS trial were: 
participant’s age, gender, time after stroke, side of stroke, and duration of each 
training session, missing of daily training session, and reasons for variation on the 
planned dose of daily training or for missing sessions.  
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Table 6-1: Fugl-Meyer Assessment: motor domain items 
Upper Extremity (66 points)  Lower Extremity (34 points) 
Shoulder retraction  Hip flexion 
Shoulder elevation  Hip extension (supine) 
Shoulder abduction  Hip adduction (supine) 
Shoulder abduction to 90 degrees  Knee flexion (supine) 
Shoulder adduction/internal rotation  Knee flexion (sitting) 
Shoulder external rotation  Knee flexion (standing) 
Shoulder flexion 0–90 degrees  Knee extension (supine) 
Shoulder flexion 90–180 degrees  Ankle dorsiflexion (supine) 
Elbow flexion  Ankle dorsiflexion (sitting) 
Elbow extension  Ankle dorsiflexion (standing) 
Forearm supination  Ankle plantar flexion (supine) 
Forearm pronation  Heel-shin speed 
Forearm supination/pronation (elbow at 0 
degrees)  Heel-shin tremor 
Forearm supination/pronation (elbow at 90 
degrees, shoulder at 0 degrees)  Heel-shin dysmetria 
Hand to lumbar spine  Knee reflex 
Wrist flexion/extension (elbow at 0 degrees)  Hamstring reflex 
Wrist flexion/extension (elbow at 90 
degrees) Ankle reflex 
Wrist extension against resistance (elbow at 
0 degrees)  
Wrist extension against resistance (elbow at 
90 degrees)  
Wrist circumduction  
Finger flexion  
Finger extension  
Extension of MCP joints, flexion of PIPs/DIPs  
Thumb adduction  
Thumb opposition  
Grasp cylinder  
Grasp tennis ball  
Finger-nose speed  
Finger-nose tremor  
Finger-nose dysmetria  
Finger flexion reflex  
Biceps reflex  
Triceps reflex   
Note: see Fugl-Meyer et al. (1975) for details and scoring instructions. From: 
Gladstone D. et al. (2002).  
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6.3 Analysis 
All participants’ data were included in the analysis following an intention to treat 
procedure. This increased trustfulness of the trial results on study feasibility 
[291].  
In this longitudinal study the feasibility of undertaking repetitive assessment 
procedure during a clinical efficacy trial was assessed using participants’ 
adherence to the weekly measure (attrition rate). The possible impact of the FMA 
on the delivering of the trial intervention was also explored assessing if: i) the 
number of missing trial sessions, and ii) the amount of therapy (in minutes) 
undertaken by participants differed between the groups who did (assessed 
group) and the group who did not (not-assessed group) the additional FMA 
assessment. 
The patients’ responses over time –the time course relationships- were explored 
to support the appropriateness of the data collection on the decision on the 
appropriate length of the intervention. The relevance of data collection on the 
intervention time curve effect was explored by measuring the difference 
between FMA score at each weekly assessment, with confident interval (CI) 
constructed at 95%. Data were analyzed as a group effect over time for 
participants allocated to upper and lower limb training, as well as for each 
included participant.  
The appropriateness of undertaking repetitive assessment in a weekly bases was 
explored based on the ability to construct the patients’ responses over time with 
the retrieved data. 
All analyses were undertaken using Stata 13 statistical software. 
 
6.4 Results 
6.4.1 Recruitment procedure 
Figure 6-2 shows the flowchart of the recruitment and consent rate of FeSTivALS 
trial. A total of 52 participants were randomised to take part in FeSTivALS trial.  
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Figure 6-2: Flowchart of FeSTivALS trial recruitment and consent process. 
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entries 
n = 1085 
Not meeting 
inclusion criteria 
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Sent letter 
n = 434 
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n = 270 
Randomised 
n = 52  
(11 in the embedded 
study) 
 
Other referrals 
n = 42 
Completed 
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n = 24  
(14 in the 
embedded study) 
 
Allocated to lower limb 
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n = 25  
(11 in the embedded 
study) 
Completed 
outcome measures 
n = 21  
(11 in the 
embedded study) 
 
Completed follow up 
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n = 24 
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(14 in the embedded 
study) 
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Withdrew 
n = 1 
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From when this longitudinal embedded study started 25 participants were 
randomised and undertook the additional weekly FMA. Fourteen of them were 
allocated to FST-UL and eleven were allocated to FST-LL (highlighted in bolt). 
One participant (ID=135), randomised to receive FST-LL, did not receive the FMA 
due to time constrain imposed by the day centre where he was living. He was 
allowed to receive a maximum of one hour training session from the researcher 
therapist. Intention to treat principles were followed and this participant is 
included in the analysis. 
Table 6-2 shows participants’ characteristics at baseline (pre intervention) for all 
participants included in the longitudinal embedded study and disaggregated by 
their allocated intervention group (FMA_FST-UL; FMA_FST-LL). 
On average, sample participants had a mean age of 71.5 years, observed after 1.7 
months after stroke. The mean score for the upper limb (UL) part of the FMA was 
27.1 (total possible score for UL section= 66). For the lower limb (LL) part of the 
FMA was 16 (total possible score for LL section = 34). All characteristics were 
almost balanced across the two groups. 
Table 6-2: Summarised baseline characteristics for all participants who 
undertake the longitudinal study and by training groups 
 
 
Subjects' characteristics 
Overall FMA 
(n=25) 
FMA_FST-UL 
(n=14) 
FMA_FST-LL 
(n=11) 
 Mean SD  Mean SD  Mean SD 
Age (years) 71.5 12.2 70 13.7 73.2 10.6 
Female (%) 0.2 0.4 0.3 0.5 0.2 0.4 
Right side affected (%) 0.4 0.5 0.4 0.5 0.5 0.5 
Time after stroke (months) 1.7 1.1 1.6 1 1.8 1.3 
FMA(UL) score 27.1 21.8 35.5 15.4 23.6 20.5 
FMA(LL) score 16 12 13.7 12 24.2 7 
FAC score 2 1.4 1.8 1.5 2.3 1.3 
ARAT score 16.6 12.3 17.8 13.6 15.3 11 
Notes: SD= Standard Deviation; FAC= Functional ambulatory category; ARAT= Action research 
arm test; FMA (UL) score Fugl-Meyer motor function assessment; FMA (LL)= Lower limb score 
Fugl-Meyer motor function assessment; FMA_FST-UL= participants undertaking Fugl-Meyer 
motor function assessment and allocated to receive upper limb therapy; FMA_FST-LL= 
participants undertaking Fugl-Meyer motor function assessment and allocated to receive lower 
limb therapy. 
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Table 6-3 shows FeSTivALS participants’ characteristics at baseline for both, the 
group who did the weekly FMA in addition to the trial intervention (assessed 
group) (FMA_FST) and the group who did only the FeSTivALS trial intervention 
(non-assessed group) (FST).  
All characteristics were balanced at baseline (pre intervention) across the two 
groups except for time since stroke and functional measures where statistically 
significant differences were found (p<0.05). Overall, the group who undertook 
only the trial intervention (FST group) had a mean of 3.6 months after stroke; the 
group who undertook the additional assessment plus the trial intervention 
(FMA_FST group) had a mean of 1.7 months after stroke. The FST group achieved 
better FAC measure but had a lower ARAT measure compared to the FMA_FST 
group. 
Table 6-3: Summarised baseline characteristics for all FeSTivALS participants by 
groups who undertake FST only (FST) (non-assessed group) and who undertake 
weekly FMA in addition to FST (FMA_FST) (assessed group) 
 
 
FST  
(n=26) 
FMA_FST  
(n=25) 
Subjects' characteristics Mean SD Mean SD 
Age (years) 65 13.5 71.5 12.2 
Female (%) 0.4 0.5 0.2 0.4 
Right side affected (%) 0.5 0.5 0.4 0.5 
Time since stroke (months) 3.6* 1.5 1.7 1.1 
FAC score 2.9* 1.3 2 1.4 
ARAT score 14.5* 14.1 16.6 12.3 
Notes:  SD= Standard Deviation; FST= Functional strength training; FMA_FST= group undertaking 
Fugl-Meyer assessment before trial intervention; (*) significant difference <0,05. 
 
 
6.5 Feasibility of the repetitive assessments procedure 
6.5.1 Attrition rate 
Feasibility of undertaking repetitive assessment procedure during a stroke 
rehabilitation clinical efficacy trial was assessed controlling for participants’ 
adherence to the weekly assessments (FMA). 
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Table 6-4 shows participants’ adherence to the weekly assessments and trial 
intervention to all participants and by their allocated group (FST-UL; FST-LL). In 
detail: 
 seven participants (28%) completed all the weekly assessments (highlited in 
green). Four participants were on the intervention upper limb group (FST-UL) 
and three on the intervention lower limb group (FST-LL);  
 ten participants (40%) missed one weekly measure. Six participants were on 
the FST-UL group and four on the FST-LL group. The reasons for missing the 
measure were: trial management66 (8% of the total sample of 25 participants) 
(ID=139; 140); personal reasons not related to the trial (12% of the total 
sample of 25 participants) (ID=137; 147; 149); the research therapist 
considered participants too tired or weak to undertake the measures without 
affecting the delivery of the trial intervention (20% of the total sample of 25 
participants) (ID=131; 134; 136; 143; 152); 
 seven participants (28%) missed three or more assessments. Four belonged 
on the FST-UL group and three on the FST-LL group. The reasons for missing 
the measure were: lack of therapy time (12% of the total sample of 25 
participants) (ID=145; 148; 151); personal reasons not related to the trial (8% 
of the total sample of 25 participants) (ID=132; 150); participants were 
considered too weak to do the measure and the training on the same training 
day (8% of the total sample of 25 participants) (ID=127; 129). 
 one participant (4%) (ID=135) did not take the measures for restriction on the 
allowed therapy time by his care home.  
  
                                                     
66 The therapists had not enough time to undertake both, the measure and the therapy so the 
priority was on delivering the study intervention. 
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Table 6-4: Participants’ adherence to the weekly FMA and trial intervention by 
allocated group 
Allocated 
therapy 
Patient’s Identifier  
ID 
week of observation 
1 2 3 4 5 6 
UL 
128 V V V V V V 
129 V V X X X X 
131 V V V V V X 
132 V X X X X X 
134 V V V V X V 
137 V X V V V V 
138 V V V V V V 
141 V V V V V V 
142 V V V V V V 
143 V X V V V V 
145 V X X X X X 
147 V V X V V V 
151 V X X X X V 
152 V V X V V V 
LL 
127 V X V X X X 
130 V V V V V V 
135 X X X X X X 
136 V V X V V V 
139 V V V X V V 
140 V V X V V V 
144 V V V V V V 
146 V V V V V V 
148 V V X X X V 
149 V V V X V V 
150 V V X X X X 
Notes: weekly sessions highlighted in light green (v) correspond to sessions where participant 
undertook both FMA and trial intervention successfully. The orange (x) highlights the session 
where participants had the trial intervention but not the FMA; whereas, the red (x) correspond 
to sessions where participants didn’t undertake either FMA or trial intervention. 
 
For this embedded longitudinal study one weekly assessment was planned for the 
6 weeks of trial intervention. Considering the 25 enrolled participants, a total of 
150 in assessments were planned. Of these overall 150 assessments, 105 (70%) 
were successfully undertaken (in light green) and 45 (30%) were missed (in 
red/orange). Considering now only the missing sessions, in 25 cases (55.5% of the 
total missing) the entire training session was missed. The therapist was unable to 
see participants, or participants were not available for reasons not related with 
the trial. In the remaining twenty cases (13.3% of the total sessions) (in orange) 
participants did not undertake only the FMA while, the trial intervention was 
successfully undertaken. Among these cases the reasons for not undertaking the 
FMA were: 
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- lack of therapist time or constraints imposed by the participant’ care setting 
(nine cases, 45%);  
- participants’ personal reasons not related with the trial (four cases, 20%);  
- participants considered too weak to do the motor assessment without 
affecting the trial intervention (seven cases, 35%).  
6.5.2 Impact of the FMA on the trial intervention  
The possible impact of the FMA on the trial intervention was explored comparing 
the groups who did the weekly FMA in addition to the trial intervention (assessed 
group) (FMA_FST) and the group who did only the FeSTivALS trial intervention 
(non-assessed group) (FST) on: 
1. the number of missing therapy sessions;  
2. the average daily amount of therapy (in minutes) undertaken by participants.  
 
Table 6-5 shows the average missing sessions for the non-assessed group (FST) 
and the assessed group (FMA_FST). The allocated intervention group (UL/LL) is 
also highlighted in the table.  
 
Table 6-5: Average missing sessions by the groups who did only the trial 
intervention (non-assessed group) (FST) and the group who did the additional 
weekly assessment and the trial intervention (assessed group) (FMA_FST) and 
by allocated intervention (UL/LL). 
Group Overall UL LL 
FST (mean) (n=24) 3.2 3.1 3.4 
FMA_FST (mean) (n=25) 4.1 4.7 3.3 
Notes: FST= non-assessed group; FMA_FST= assessed group undertaking FMA before 
intervention; UL = allocated upper limb trial intervention; LL = allocated lower limb trial 
intervention 
 
Overall, the non-assessed group (FST) missed less sessions, 3.2 sessions on 
average, compared to the participants in the assessed group (FMA_FST) who 
missed 4.1 sessions on average. 
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While acknowledging the small sample, further analyses were reported on the 
average of missing session by subgroups. 
The average missing session rate slightly changed in favour of the assessed group 
(FMA_FST) if the participants who missed sessions for reasons not related with 
the trial intervention were excluded from the analysis: three participants in the 
assessed group (FMA_FST) compared to one in the non-assessed group (FST). 
With this new condition, on average, the assessed group (FMA_FST) missed 1.1 
session against an average of 2.8 for the non-assessed group (FST). 
Let now consider the allocated intervention groups. The non-assessed group 
allocated to upper limb training (FST) missed - on average - 3.1 therapy sessions 
against 4.7 sessions missed by the assessed group (FMA_FST). The non-assessed 
group allocated to lower limb training (FST) missed - on average- 3.4 sessions 
against 3.3 sessions missed by the assessed group (FMA_FST).  
 
Table 6.6 visually shows the daily adherence to the therapy sessions for the FST 
and FMA_FST groups, by allocated intervention (UL/LL). Missing training sessions 
were highlighted in red and marked with an “x”. Participants who completely 
adhered to the training session during the six weeks period were highlighted in 
green. In the table were reported the percentage of participants undertaking the 
daily training session for all training period by group who did and did not the FMA 
assessment. 
One participant in the non-assessed group (FST) and five participants in the 
assessed group (FMA_FST) completely adhered to the training session during the 
six weeks training period (green line in Table 6.6).  
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Table 6-6: Adherence to the daily trial intervention for all FeSTivALS participants by groups who did and did not the FMA and by allocated training (UL, LL). 
  Week1 Week2 Week3 Week4 Week5 Week6 Total 
 ID Day1 Day2 Day3 Day4 Day1 Day2 Day3 Day4 Day1 Day2 Day3 Day4 Day1 Day2 Day3 Day4 Day1 Day2 Day3 Day4 Day1 Day2 Day3 Day4 missing 
FST-U
L G
ro
u
p
 
102 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x 1 
103 √ x √ √ √ √ √ √ √ √ x x x x √ x √ x x x √ x x x 12 
106 √ √ √ √ x x x x x √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 5 
108 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x √ √ 1 
111 √ √ 0 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x √ √ √ √ 2 
112 x √ √ √ √ √ √ √ x √ x √ √ √ x √ √ √ √ √ √ √ √ x 5 
115 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x √ √ √ √ √ √ √ x 2 
116 √ √ √ √ √ √ √ √ √ √ √ √ √ x √ √ √ √ √ √ √ √ √ √ 1 
118 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x √ √ √ √ √ x √ √ 2 
119 √ √ x √ √ √ √ √ √ √ √ √ √ √ √ √ x √ √ √ √ √ √ √ 2 
120 √ √ √ √ √ √ √ √ x √ √ √ √ √ √ √ √ √ √ √ √ x x x 4 
121 √ √ √ √ √ x √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 1 
123 √ √ √ x x √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 2 
FST-LL G
ro
u
p
 
101 √ √ √ √ √ √ √ √ x √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 1 
104 √ √ √ √ x √ √ √ √ √ √ √ √ x x x √ √ √ √ √ √ √ √ 1 
107 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x √ 1 
109 √ √ √ √ x √ √ √ √ √ √ x √ √ √ √ √ x √ √ √ √ x √ 4 
110 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x √ x √ √ √ √ √ 2 
113 x x √ √ √ √ √ √ x √ x √ √ √ x √ √ √ √ √ √ √ √ √ 5 
114 √ √ √ √ √ √ √ √ x √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 1 
117 x √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 1 
122 √ √ √ √ √ √ √ x x √ √ x x √ x x x x x x x x x x 14 
124 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 0 
125 √ √ √ √ √ x √ √ x √ √ x x √ √ √ √ √ √ √ √ √ √ √ 4 
 Daily % 87.5 91.7 91.7 95.8 83.3 87.5 95.8 91.7 66.7 100 87.5 83.3 87.5 87.5 83.3 79.2 87.5 87.5 87.5 87.5 95.8 79.2 79.2 75  
FM
A
_FST-U
L G
ro
u
p
 
128 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 0 
129 x √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x x x x √ √ x 6 
131 x x √ √ √ √ √ √ √ √ √ √ x √ √ √ √ √ x √ √ √ √ x 4 
132 √ √ √ √ √ √ x x x x x x x x x x x x x x x x x x 18 
134 √ √ √ x √ √ √ √ √ √ √ √ x x √ √ √ x x x √ √ √ x 7 
137 √ √ √ x √ √ √ x x √ √ √ √ √ √ √ √ √ √ √ √ √ √ x 4 
138 √ √ √ x √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x 2 
141 √ √ √ √ √ √ √ √ √ x x √ √ √ √ √ √ √ √ √ √ √ √ √ 2 
142 √ √ √ x √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x √ √ √ x 3 
143 √ √ √ x √ √ x √ √ √ √ √ √ √ √ x √ x √ x √ √ √ x 6 
145 √ √ x √ √ √ √ √ √ √ √ x √ √ √ x x x x x x x x x 11 
147 √ √ √ √ √ x √ √ x √ √ √ √ √ √ √ √ √ √ √ √ √ √ x 3 
151 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 0 
 152 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 0 
FM
A
_FST-LL G
ro
u
p
 
127 √ √ √ √ x √ √ √ √ √ √ √ x √ √ √ √ √ √ √ √ √ √ √ 2 
130 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 0 
135 √ √ x √ √ √ √ √ x x √ √ x √ √ √ √ √ √ √ √ √ √ x 5 
136 √ √ √ √ √ √ √ √ √ √ x √  √ √ √ √ √ √ √ √ √ √ √ 1 
139 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x √ √ √ √ √ √ x 2 
140 √ √ √ √ √ √ √ √ x √ √ √ √ √ √ √ √ √ √ √ x √ x √ 3 
144 √ √ √ x √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x 2 
146 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 0 
148 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ x x √ √ x √ √ √ √ 3 
149 √ √ √ x √ √ √ √ √ √ √ √ √ x √ √ √ √ √ x √ √ x x 5 
150 √ √ √ x √ √ √ √ √ x x x √ √ √ x x x x x x x x x 13 
 Daily % 91.7 95.8 91.7 66.7 95.8 91.7 91.7 91.7 79.2 83.3 83.3 87.5 79.2 87.3 95.8 79.2 79.2 58.3 58.3 62.5 79.2 87.5 79.2 16.7  
Note: ID= participant’ identification code; x= missing training session; √= completed training session; FST= group undertaking trial intervention alone; FMA_FST= group undertaking Fugl-Meyer assessment before 
trial intervention; UL = allocated upper limb trial intervention; LL = allocated lower limb trial intervention; the light green band correspond to a participant who was compliant to a full week of training; the sessions 
highlighted in red correspond to a missed trial intervention session. The percentage of participants undertaking the daily training session is reported by group who did and did not the FMA assessment.
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Table 6-7 shows the mean daily amount of therapy in minutes in the six weeks 
of training period for all sample by the assessed group (FMA_FST) and the 
non-assessed group (FST) and by allocation intervention group (UL/LL). A 
significant positive difference in the mean duration of daily therapy of 5.5 
minutes was found in favour of the non-assessed group (FST). If the groups 
were disaggregated between those participants who receive upper (UL) or 
lower (LL) limb interventions, this difference remained highly statistically 
significant (at 1% level) only for the group who received UL training, with a 
mean of 7.7 minutes of more therapy.  
 
Table 6-7: Participants’ mean daily duration of therapy and standard 
deviation (SD) by the group who did the additional weekly assessment and 
the trial intervention (assessed group) (FMA_FST) and the groups who did 
only the trial intervention (control group) (FST) and by allocated 
intervention treatment (UL/LL) 
GROUP FMA_FSTa 
(mean) 
SD FSTa  
(mean) 
SD Diff. 
UL 36.2 (n=14) 20.7 43.9 (n=13) 19.8 7.7* 
LL 36.7 (n=11) 20.7 39.5 (n=11) 16.6 2.8 
Overall 36.4 (n=25) 20.3 41.9 (n=24) 19 5.5* 
Note: a= therapy duration in minutes UL= allocated upper limb trial intervention; LL= allocated lower 
trial limb intervention; FST= group undertaking trial intervention alone; FMA_FST= group undertaking 
Fugl-Meyer assessment before trial intervention; SD= standard deviation; (*) significant difference at 
0.00001. 
 
6.6 Informative nature of the repeated assessment 
procedure 
The patients’ response to the trial therapy was calculated at each week (six 
assessment points) of the intervention period, in terms of overall FMA value 
computed among all participants, by allocated intervention group. 
Upper limb score 
 205 
Table 6-8 shows, for participants allocated to receive FST-UL, the average 
value of FMA upper limb score (FMA-UL) at each measure time point.  
 
Table 6-8: Mean FMA upper limb score (FMA-UL) and standard deviation for 
participants allocated to receive FST-UL at each weekly assessment.  
Weekly 
assessment  
FMA-UL 
(mean) 
 SD 
 
Participants assessed  
by week 
1 35.5 15.4 14 
2 39.6 15.1 9 
3 38.6 15 8 
4 42.6 14.4 10 
5 45.8 13.6 9 
6 48.9 11.3 10 
Note: FMA-UL= Fugl-Meyer upper limb motor assessment score; SD=standard deviation; 
column on the right reports the number of participants assessed each week. 
 
The mean value of FMA-UL observed at week 1 (pre intervention) was 35.5 
points and 48.9 at week 6. The difference from week 1 was of 13.4 points, 
which was well above the 5.25 points MCID for the upper limb section of this 
measure. 
Participants’ attrition rate to the weekly assessments is reported in the right 
column of the table. Fourteen participants were enrolled and assessed at 
week 1. Four participants (28.6% of the original sample) were not observed at 
week 6.  
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Figure 6-3: Mean FMA-UL score trends over time for participants allocated 
to receive FST-UL (treatment group) and for participants allocated to receive 
FST-LL used as control groups 
 
Note: x-axis=training weeks; y-axis= mean FMA-UL score observed in the group receiving FST-
UL (treatment group) and in the group receiving FST-LL (control group). Vertical bars 
represent 95% confident interval (95% CI). 
The red line in Figure 6-3 shows the mean of FMA upper limb score (FMA-UL) 
over the six weeks of therapy for the participants allocated to receive FST-UL 
(treatment group), with a confidence interval (CI) constructed at 95%. For 
comparison purpose, the same trend is also reported for the group of 
participants receiving FMA upper limb but, allocated to receive therapy for 
their lower limb (FST-LL) only (dash black line, defined as control group). It 
appeared that the upper limb therapy enhanced motor functions steadily for 
all training period of six weeks (red line). This could not be seen in the control 
group (dash black line), providing an indication that the improvement in upper 
limb functions was mainly due to the intervention. Besides, results pointed 
out that a stop in the improvement (therapy effect) was not reached at the 
end of the six week, providing an indication that further improvement could 
have been obtained with a longer therapy period. Subjects’ trends over time 
are available in Appendix V. 
This analysis also shown that a weekly assessment procedure provided 
enough and appropriate data to explore the intervention effect over time on 
upper limb.  
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Lower limb score 
Table 6-9 shows the average value of FMA lower limb score (FMA-LL) at each 
measure time point for participants allocated to receive FST-LL.  
Table 6-9: Mean FMA lower limb score (FMA-LL) and standard deviation for 
participants allocated to receive FST-LL at each weekly assessment. 
Weekly  
assessment 
FMA-LL  
(mean) 
SD 
 
participants assessed  
by week 
1    24.2 7 10 
2    24.4 7.5 9 
3    25.3 6 6 
4    27.6 5.5 5 
5    28 4.8 7 
6    26 7.8 8 
Note: FMA-UL= Fugl-Meyer upper limb motor assessment score; SD=standard deviation; 
column on the right reports the number of participants assessed each week. 
 
Ten participants were enrolled to receive FST-LL and assessed by the FMA-LL 
at week one. The mean value of FMA-LL observed at week 1 (pre intervention) 
was 24.2 points and 26 at week 6, with an overall increase of less than 2 
points. This increase was lower than the 10% increment required for the MCID 
for the lower limb section of this measure. 
Participants’ attrition rate to the weekly assessments is reported on the right 
column of the table. Two participants (about 20% of the original sample) were 
not observed at week 6. 
The red line in Figure 6-5 shows the mean of FMA lower limb score (FMA-LL) 
over the six weeks of therapy for the participants allocated to receive FST-LL, 
with a confidence interval (CI) constructed at 95%. Figure 6-5 and Table 6-9 
show that the therapy response over time for the group undertaking FST-LL 
had a slight increasing trend, with a better outcome saw at week 5. After week 
5 a decrease of 2 points score was seen. As before, the same trend is also 
reported for the group allocated to receive therapy for their upper limb (FST-
UL) (dash black line) and used as control group, confirming difficulties in 
deriving definitive conclusions. Subjects’ trends over time are available in 
Appendix V. 
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Figure 6-4: Mean FMA-LL score trends over time for participants allocated to 
receive FST-LL (treatment group) and for participants allocated to receive 
FST-UL used as control groups 
 
Note: x-axis=training weeks; y-axis= mean FMA-LL score observed in the in the group 
receiving FST-LL (treatment group) and in the group receiving FST-UL (control group). Vertical 
bars represent 95% confident interval (95% CI). 
 
 
6.7 Discussion 
This analysis pointed out the feasibility of applying a weekly assessment 
procedure in stroke rehabilitation clinical research.  
About 68% of the sample (17 participants) successfully undertook the weekly 
assessments procedure or missed only one assessment. Among the remaining 
eight participants who had missed more than three assessments, only two 
were unable to undertake the weekly assessment while being able to perform 
the trial intervention. Therefore, attrition (the loss of eligible participants 
during the trial) seemed mainly related to the delivery of the trial intervention 
rather than on the added repetitive assessments. However, the repetitive 
assessment increased the burden of the trial. A significant positive difference 
in the mean duration of the daily intervention therapy was found in favour of 
the non-assessed group (the group who did only the intervention therapy). It 
also appeared that the length and physical effort required to undertake the 
additional Fugl-Meyer assessment could have impacted on the delivery of the 
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trial intervention for the weakest and frailer participants or, could have 
impacted on the amount of therapy that the therapists were able to deliver. 
Some adjustments of the undertaken assessment (e.g. using a less demanding 
assessment, or an assessment integrated into the therapy) might help in 
reducing these disadvantages. Examples of assessments integrated into the 
therapy could see the use of the Box and Blok test (or its modifications) for 
the upper limb and the five-minutes walking test or the “time up and go” test 
for the lower limb. 
 
On a methodological point of view, this study was able to provide relevant 
information on stroke rehabilitation therapy effect over time. In detail, it was 
possible to derive longitudinal data potentially useful in determining the 
appropriate length of the applied intervention. The Fugl-Meyer assessment 
seemed to show that the therapy has enhanced motor function steadily over 
the six weeks of upper limb training protocol without reaching a reduced 
effect size. 
Furthermore, this study indicated the potential of this repetitive procedure to 
undertake sub-group analysis. Disaggregating the data by groups of 
participants who have received upper limb intervention and those who have 
received lower limb interventions it was possible to illustrate a statistical 
significant difference on the mean duration of daily therapy only for the group 
receiving upper limb intervention.  
STUDY STRENGTHS 
This study highlighted the feasibility of applying multiple assessment 
procedure in stroke clinical research. The upcoming benefit of this procedure 
was the possibility to explore participants’ therapy response over time, 
informing on the appropriate length of intervention. This procedure could 
deliver more cost-effective therapies but also it could provide relevant 
information of participants’ response to specific therapies. For example this 
procedure could allow an early identification of the subgroup(s) of 
participants that could benefit more from the applied therapy or dose. The 
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development of rehabilitative programme to fit individual’s needs is 
welcomed to the research community [67,131] and the application of 
repetitive assessments is a promising way to go forward. However, further 
research on this direction is required. 
A further advantage of applying a multiple assessment procedure is a 
potential reduction of the bias induced by the loss of end-point data 
(attrition), often seen in clinical trials. With this procedure, the loss of one (or 
more) assessment point still allows data analysis, under less stringent 
assumptions than random attrition. For instance, if the latest observation 
becomes missing, the previous one (or the subsequent one) can be used 
instead to infer on the missing value. This would not be possible in a pre and 
post observation design where subjects with missing post observation (or pre 
observation) data will inevitably be eliminated from the analyses.67  
LIMITS OF THE STUDY  
The small number of participants enrolled in this study could have impacted 
on the trial results. However, such a sample size is common with several 
feasibility studies [247,314] and in line with other feasibility studies (i.e. 
[315,316,317]). Besides, it was sufficient to derive participants and groups 
therapy effect curves over time. Appendix W gives the sample size calculation 
assuming that the Fugl-Meyer assessment was used as a primary outcome 
measure. 
Another concern was the documented differences in baseline (pre 
intervention) characteristics found among participants who undertook only 
the trial intervention and participants who undertook the additional 
assessment before the trial intervention. This could have influenced our 
estimated impact of the Fugl-Meyer assessment. Unbalanced groups, 
however, was driven by the nature of this trial (i.e. an embedded study). The 
randomization procedure was only undertaken for allocating participants to 
                                                     
Strictly speaking, we referred here to the “listwise deletion” method for handling missing 
data. According this method, an entire observation is excluded from analysis if any single value 
is missing.  
 211 
the intervention groups and not for allocating those undertaking/not-
undertaking the repetitive assessments. However, the main aim of this 
embedded study was to assess the feasibility of a repetitive assessment 
procedure in stroke clinical research, rather than providing data on the 
appropriate length of therapy.  
Finally, the length and physical effort required to undertake the additional 
Fugl-Meyer assessment could have increased the burden associated with the 
trial. The decision to test only the motor function domains of the Fugl-Meyer 
was made to limit this burden, while preserving the scope of the trial 
assessment.  
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Chapter 7:  
Conclusions and 
implications for 
future research 
 
 
This research work reflected the attempt to make a contribution to the 
complex and challenging field of dose optimization in motor interventions, by 
fulfilling the knowledge gap on optimal intervention doses and protocols in 
stroke rehabilitation clinical research.  
To fulfill this research breakthrough, three main aims were set: 
1. to identify dose optimization approaches and designs that were 
suitable for use in stroke rehabilitation research; 
2. to test the feasibility of a novel phase I dose optimization trial design 
for motor interventions after stroke; and  
3. to assess the feasibility and acceptability of undertaking repetitive 
assessments to identify the appropriate length of stroke rehabilitative 
interventions in a clinical efficacy trial.  
This chapter offers a discussion of the methodology used for this thesis 
and the results achieved. The project is ultimately placed within the wider 
context of stroke rehabilitation research. 
The following section starts discussing how well the aims and objectives 
of this research project have been addressed. 
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1. Identification of suitable dose optimisation approaches and designs 
The first aim of this research project was to identify dose optimization 
approaches suitable for use in stroke rehabilitation research. To do so, dose 
optimization approaches applied in exercise-based training research were 
investigated with a systematic review (Chapter 2). Results from this review 
highlighted that, despite the existence of a large number of studies pooled by 
guidelines on recommended training doses, only a small number of these 
studies investigated the intervention dose-response relationship to identify 
appropriate dose or protocol endpoints. Furthermore, even those studies 
which investigated the appropriate dose or protocol, they often applied sub-
optimal designs and approaches towards dose optimization. 
The lack of reliable and efficient dose optimization designs in exercise-based 
training literature drew the attention to pharmaceutical research which was 
identified as the field applying the “gold” standard dose optimization designs 
and approaches. A narrative systematic review on pharmaceutical dose 
optimization clinical research was undertaken (Chapter 3) and showed that, 
in this field, there is a clear, standardised and efficient research pathway 
towards the identification of optimal drugs doses and protocols. In brief, the 
first dose optimization studies are the so called dose-finding studies. These 
studies are small and used as precursor of clinical efficacy studies to suggest 
appropriate doses early in the research pathway. They are often followed by 
dose-ranging studies which aim at confirming and adjusting the optimal 
therapeutic dose and protocol in wider samples.  
The information gathered from the reviews on dose optimization approaches 
in exercise-based training and pharmaceutical literature were then used to 
devise the novel phase I dose optimization trial design for motor intervention. 
Specifically, among the dose optimization designs applied in pharmaceutical 
research, a phase I 3+3 rule-based, outcome-adaptive dose-finding design was 
chosen to be adapted for use in stroke rehabilitation research. The 
development of this novel design was undertaken in the methodological 
chapter of this thesis (Chapter 4). 
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2. Testing feasibility and informative nature of a dose-finding trial design 
The second aim of this research project was to test the feasibility and 
informative nature of the newly devised dose-finding design for motor 
interventions after stroke. In detail, the feasibility of the 3+3 dose-finding 
design and all its characteristic features were tested with moderately 
impaired stroke survivors undertaking an upper limb model-task intervention 
(Chapter 5). 
All the operating characteristics of this novel trial design were found feasible 
with the selected group of stroke survivors.Cohorts of three participants were 
found to be adequate and efficient to guide the devised trial algorithm 
through the dose escalation and de-escalation procedures. The final sample 
size of 15 participants was appropriate and in line with existing literature on 
dose optimization in pharmaceutical research. The multi-stage recruitment 
allowed the recruitment of the needed sample in the foreseen time frame. 
The trial stopping rules were useful to avoid the delivery of similar doses 
between cohorts and to guarantee participants’ safety. The relatively short 
length of the study (2 weeks), and the considerable effort made on engaging 
participants to the training and overall trial, allowed to achieve 100% of 
retention rate. The data collected from this trial enabled the use of standard 
statistical models for pharmaceutical dose-finding trials for their analysis. The 
use of these statistical models were found relevant for stroke rehabilitation 
research, allowing preliminary study on the training dose-response 
relationship. Acknowledging that the purpose of this trial was to test the 
informative nature of the design, and not to use the numerical data on the 
optimal dose further, the analysis enabled the derivation of the maximal 
tolerable dose as 209 repetitions and the recommended phase II dose as 162 
repetitions of the applied model-task intervention. 
Some refinements to the reported dose-finding design should be considered 
for further studies to enhance the appropriateness of dose optimization 
process on motor interventions. Firstly, the issues of heterogeneity on 
participants’ characteristics among cohorts, highlighted in this trial, should be 
limited considering the possible interrelationship between optimal training 
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dose and subject’ characteristics. Although the cohorts’ heterogeneity did not 
affect the results of this trial on the feasibility of implementing a dose-finding 
design to stroke rehabilitation research, it could compromise results on doses. 
Secondly, the stopping rule limit of 10% difference between subsequent 
cohorts used in this trial could be overestimated when applied to a different 
intervention. Therefore, considering the rapid increments in the numbers of 
repetitions assigned by the escalation procedure, a 10% difference from the 
last beneficial dose between subsequent cohorts could be used instead. 
Thirdly, although the electronic counter was considered by participants as a 
good support to track high number of task repetitions, few issues were 
acknowledged with the implemented device causing some missing or 
incorrect data recording. A different or refined system to objectively record 
participants’ achieved number of repetitions is therefore advisable. Finally, 
the use of a reliable and validated primary outcome measure should be used 
in further studies to increase reliability of results on dose. 
3. Testing feasibility and acceptability of repetitive assessments in a 
clinical trial 
To fulfill the third aim of this research, a repetitive assessment was embedded 
in a stroke rehabilitation clinical efficacy trial (Chapter 6). The results of this 
longitudinal study showed that it was feasible and acceptable to deliver a 
weekly repetitive assessments procedure in stroke rehabilitation efficacy 
trials without affecting the trial intervention outcomes. The data retrieved 
were sufficient to study the treatment effect over-time and to provide 
indication on the appropriate length of the applied intervention. 
Acknowledging that this trial was explorative on the feasibility to apply 
repetitive assessments in stroke rehabilitation research, it was able to indicate 
that participants receiving the trial upper limb intervention enhanced their 
motor functions steadily over the six weeks of intervention. This result could 
imply that more than six weeks of the trial upper limb intervention may be 
required to reach maximal therapy effect. Whereas, for participants receiving 
trial lower limb intervention, the peak of improvement was reached after five 
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weeks of intervention, although there was not a statistically significant 
difference. 
The analysis on the impact of the additional repetitive assessment seemed to 
suggest that the assessment used in this trial, the Fugl-Meyer assessment, 
increased the burden of the trial. In fact, the length and physical effort 
required to undertake the additional Fugl-Meyer assessments appeared to 
have impacted on the delivery of the trial intervention for the weakest and 
frailer participants or, on the amount of therapy that the therapists were able 
to deliver. Some adjustments on the undertaken assessment (e.g. using a less 
demanding assessment, or an assessment integrated into the therapy) are 
therefore advisable to limit these upcoming issues. 
 
 
How this thesis has contributed to stroke rehabilitation 
research 
The systematic review in exercise-based training literature undertook in this 
thesis had the innovative value to explore the methodological aspects of dose 
optimization in the primary trials upon which the guidelines and 
recommendations on appropriate dose of training were based. 
Understanding the designs and the approaches applied to dose optimization 
gave indication on the strength of results and recommendations on training 
dose and protocol. The studies’ risk of bias assessment applied in this review 
focused on the dose optimization protocols, providing further information on 
the strength of results on optimal doses and protocols. The taxonomic study 
conducted in this review on the definition and use of the training dose and its 
components, alongside with the assessment of the current recommendations 
on training dose and protocol provided useful indication for further research 
trajectories for motor interventions. 
Results from the systematic review in exercise-based training literature 
highlighted that only dose-ranging approaches had been applied to identify 
the appropriate training dose and protocol. These designs only allowed the 
limited investigation of pre-defined numbers and levels of dose. As a result, 
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the study's ability to investigate the dose-response relationships, and the 
ability to identify the appropriate dose of training was confined to the 
appropriateness of the tested doses. Dose-ranging approaches are therefore, 
inefficient and inadequate to improve the current gap of knowledge on the 
dose-response relationship in stroke rehabilitation research. This review also 
highlighted some important aspects to preserve reliability of data during dose 
optimization processes of motor interventions. Firstly, the importance of 
finding a meaningful definition of the “training dose”, which accounted for its 
multifactorial aspects. Secondly, the need to use a standardised and 
consistent terminology on dose to contrast the existing heterogeneity on the 
way key concepts of the training dose and protocol were defined. Finally, the 
need to use adequate and controlled procedures when manipulating the 
components of the training to increase reliability of the results on appropriate 
dose. Moreover, this review helped in understanding how the different 
components of the training dose and protocol were manipulated and which 
controls were undertaken in the existing practice of dose optimization in 
exercise-based training research.  
The second review undertaken in this research project, a narrative systematic 
review on dose optimization approaches applied in pharmaceutical clinical 
research, was also the first of its kind with the specific aim of providing key 
features to inform dose optimisation methods for stroke rehabilitation 
research. Results from this review found that, in pharmaceutical clinical 
research dose-finding designs were commonly viewed as the best designs to 
target dose endpoints in the early stage of the research, given their adaptive 
nature in exploring the dose-response relationship and their elevate 
efficiency. Furthermore, this review highlighted that each stage of the 
pharmaceutical dose optimization research pathway saw the implementation 
of different approaches to answer different questions on dose as well as 
target different dose endpoint(s). The implementation of a standardised 
pathway to dose optimization increases the reliability of the research results 
allowing more control on the applied research procedure(s). This control has 
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the scope to preserve patients’ safety, as well as monitor efficiency of the 
research. 
The information gathered from the two aforementioned reviews helped to 
devise a novel dose-finding trial design expressly designed for use in stroke 
rehabilitation research. The methodological work behind this research thesis 
adopted, for the first time, a pharmaceutical dose-finding design to the 
specificities of the stroke rehabilitation field. The features of the developed 
dose-finding design reflected the attempt to establish a standardised and 
efficient procedure to dose optimization for motor interventions in general, 
and stroke rehabilitation research in particular.  
During the writing-up period of this thesis, Dite and colleagues published a 
study implementing a different form of a pharmaceutical dose escalation 
design applied to stroke rehabilitation research [293]. However, the design 
implemented in Dite and colleagues’ study raised concerns that brought 
critical difficulties in the evaluation of their results.  
The dose-finding design presented in this research work differed significantly 
from that of Dite and colleagues’ study and presented some methodological 
advantages. For instance, in the dose-finding trial used in this thesis, the 
training dose was consistent within participants of the same cohort and only 
one parameter of the dose, the amount of training, was manipulated among 
subsequent cohorts. This procedure was used to increase the understanding 
of the underline active training parameter(s) able to maximise therapy effect, 
besides enhancing the clarity on the dose-response relationship results. In 
Dite and colleagues’ study the training protocol comprised more than one 
intervention which differed among training weeks and within participants. 
Additionally, dose increments were allowed within cohorts. This approach 
could bring uncertainty on the dose-response relationship and on the true 
effect of dose.  
In the study reported in this thesis, an analysis on the recommended phase II 
dose was introduced, alongside with the study on the maximal tolerable dose, 
which is more common in pharmaceutical studies. This additional analysis 
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acknowledged that, in motor interventions, the interest is on the intervention 
effect, rather than on the dose toxicity. A dose-escalation procedure was also 
planned in this study allowing for a non-increasing dose-response 
relationship. This could help to closely target the recommended dose of 
motor interventions. In Dite and colleagues’ study, the dose escalation plan 
was not based on clinical efficacy. Consequently, the dose-response 
relationship could not been studied and, the recommended phase II dose 
could not be determined. As in pharmaceutical dose-finding studies, in Dite 
and colleagues’ study the dose-limiting tolerance (dose toxicity) was the 
guiding parameter for the dose-escalation procedure. A dose-escalation 
procedure was not planned. Following this approach, they made the 
assumption that the intervention efficacy increased monotonically with the 
dose and, therefore, the appropriate dose to use corresponded to the 
maximal tolerable dose. This assumption, however, has not been verified yet 
for motor interventions. Some safety issues can also arise implementing the 
maximal tolerable dose in subsequent trials. Interestingly, in the study 
reported in this thesis, the recommended dose was about 78% of the maximal 
tolerable dose. In clinical practice, this result could bring concerns for safety, 
as well as representing a considerable resources saving for the health system 
compared with the provision of the maximal tolerable dose. 
Two checking rules were implemented in the study reported in this thesis to 
limit the issue of heterogeneity on participants’ presentation and therapy 
response when using small sample size of participants as the ones commonly 
employed in dose-finding designs. In Dite and colleagues’ study the possible 
issue brought by the small cohorts’ size was addressed only by restricting the 
study inclusion criteria. This approach could improve the reliability of trial 
results on dose due to heterogeneity among and across cohorts but could 
reduce the generalisability of the results. Furthermore, if inclusion criteria 
were set too restrictive, the time and resources needed for the recruitment 
process could increase dramatically. 
Unlike the study reported in this research project, in Dite and colleagues’ 
study the starting dose was relatively high, which did not allowed any increase 
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of the dose. Only two cohorts were enrolled before the identification of the 
maximal tolerable dose. 
To allow for a high level of control and restriction on both the trial 
intervention and the training dose, the dose-finding study reported in this 
thesis applied a model-task intervention. In a pharmaceutical dose-finding 
study, apart from the dose, the delivered treatment is identical across 
participants and among groups. The model-task intervention imitated this 
high controlled research setting. This approach, while increasing the reliability 
of results, could limit the generalisability of the results. In this respect, the 
study implemented by Dite and colleagues is promising when assessing the 
feasibility of dose-finding pharmaceutical approaches with complex stroke 
rehabilitation interventions. Both trials devised in this thesis and in Dite and 
colleagues’ study should be seen as a call for further research to explore the 
use and relevance of dose optimization procedures in pilot studies 
implementing complex stroke rehabilitative therapies. 
As the first project of its kind, the initial results of the study reported in this 
thesis successfully show the implementation of a dose-finding design derived 
from pharmaceutical literature to stroke rehabilitation research. This could 
make a step forward in the stroke rehabilitation research pathway tackling 
the issue of dose optimization for motor interventions. As shown in this study, 
the implementation of standardised dose-finding designs in stroke 
rehabilitation research is likely to provide empirical robust evidence to 
substantiate claims for appropriate dose of physical therapy proven to be 
feasible, safe and able to maximise motor recovery. The use of early dose-
finding studies can help minimise the proliferation of inconclusive or 
divergent clinical studies, as studies will use more appropriate doses and 
hence increase their ability to find a significant difference. As an example, in 
2008, a phase II study assessed the safety and feasibility of a very early 
mobilization (VEM) approach at high dose after stroke [79]. In 2011, Cunning 
et al. indicated that high dose of VEM was more effective than standard care 
mobilization in improving sooner, independent walking but failed to show 
statistical significant post-intervention differences in clinical scores [318]. 
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Recently, the AVERT trial challenged these results [82] by finding that 
participants enrolled to receive a very early, high dose mobilization 
intervention did significantly worse than participants receiving early, lower 
dose mobilization. These findings were in line with our results which 
suggested that the more effective dose might be smaller than the maximal 
dose that participants were able to sustain and may warn against the use of 
high intensive training protocol before more evidence is available.  
The use of small cohorts’ sizes, typical of these designs, is likely to increase 
efficiency of stroke rehabilitation research and any other research that faces 
daunting challenges in the recruitment of participants and the associated 
costs. 
The second study implemented in this research project assessed another 
uncommon optimization procedure in stroke rehabilitation research: the 
feasibility and its informative nature to deliver a repetitive assessments 
procedure. The use of repetitive assessment procedures, in early efficacy 
trials, could improve research outcomes by guiding the implementation of 
appropriate duration of the training intervention and therefore maximising 
the treatment efficacy, as currently happening in other medical research fields 
[130,131]. It is also worth highlighting that the implementation of repetitive 
assessment procedures can bring two additional advantages. Firstly, it can 
help in reducing the attrition bias, i.e. the bias induced by the loss of end-point 
data, often seen in clinical trials. With a repetitive assessments procedure, the 
loss of one (or more) assessment point(s) still allows data analysis. Secondly, 
it gives the possibility to analyse data on the therapy time course effect 
dividing participants in sub-groups depending on their abilities or 
characteristics. This could help to early identify participants that could benefit 
more (or less) from the applied therapy or dose tailoring personalised 
rehabilitation plans. As reported by Kwakkel and Dobkin, as well as being 
widely acknowledged by the research community, the development of 
rehabilitative programme to fit individual’s specific needs is a goal to enhance 
stroke rehabilitation outcomes [67,131].  
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Further developments 
The future steps of this research could see the implementation of the phase I 
3+3 dose-finding design and the multiple assessments procedure to stroke 
rehabilitation research to seek confirmatory results. In detail, the dose-finding 
design will be set using a complex rehabilitative intervention providing 
information on the feasibility and relevance of this dose-finding design in the 
“real world” clinical research setting. 
Whereas, a less wearying assessment could be implemented in a longitudinal 
study to gain further confirmatory results on the feasibility and tolerability of 
this repetitive assessments procedure in early efficacy rehabilitative trials 
with stroke survivors. 
 
 
In conclusion, this methodological thesis has contributed to move the dose 
optimization process in stroke rehabilitation research forward. It showed that 
fixed designs and posterior analyses might not be the best approaches to 
maximise trial efficacy and to investigate the appropriate training dose and 
protocols. Interim analyses and flexible designs can be used instead to target 
the appropriate dose and length of training and to improve research 
efficiency.  
The feasibility and relevance for stroke rehabilitation research of new and 
efficacious methodologies able to identify the appropriate dose and length of 
therapy presented in this thesis provided the groundwork for further research 
in this field.  
The regular and standardised implementation of the dose optimization 
designs reported in this research thesis could improve the future of stroke 
rehabilitation research. The implementation, early on in the research 
pathway, of reliable doses which have been proven to be feasible, effective 
and safe could enhance patients’ motor recovery maximising training effect 
and increase research efficiency reducing the chance to deliver sub-
therapeutic or dangerous doses in costly phase II efficacy trials.   
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Appendix A : 
Electronic search strategies for dose optimization 
approaches in Exercise-based training 
 
MEDLINE SEARCH STRATEGY 
1. exp Exercise Therapy/ 
2. exercise/ or resistance training/ 
3. *Motor Activity/ 
4. *Robotics/ or robot-assisted therapy.mp. 
5. (dose* adj2 relationship).ti,ab. 
6. dose-response.ti,ab. 
7. dose-finding.ti,ab. 
8. ((dose or dosage or intensit* or frequenc* or duration* or time or amount or 
power or how much or repetition* or set* or load* or volume or work) adj3 
(training or therap* or protocol* or activit* or program* or exercise*)).ti,ab. 
9. 1 or 2 or 3 or 4        
10. 8 or 5 or 6 or 7      
11. 10 and 9       
12. ((functional or motor) adj2 (abilit* or recovery)).mp. [mp=protocol 
supplementary concept, rare disease supplementary concept, title, original title, 
abstract, name of substance word, subject heading word, unique identifier] 
13. (musc* adj (strength or abilit* or function* power or work or torque or 
force)).ti,ab. 
14. *"Quality of Life"/ 
15. *Heart Rate/ 
16. exp cardiovascular physiological processes/ or exp hemodynamics/ or exp 
respiratory physiological phenomena/ 
17. exp Oxygen Consumption/ or oxygen uptake.mp. 
18. 17 or 15 or 16      
19. "Activities of Daily Living"/ 
20. functional limitation.ti,ab. 
21. ((motor or muscular) adj performance).ti,ab. 
22. 14 or 12 or 13 or 21 or 19 or 20    
23. 18 or 22       
24. 22 and 11                    
25. evaluation.mp. 
26. effec*.mp. [mp=protocol supplementary concept, rare disease supplementary 
concept, title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
27. controlled clinical trial.mp. 
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28. (((controlled before and after) or cohort or case-control or longitudinal or 
observational or case or qualitative) adj3 stud*).mp. 
29. *program evaluation/ 
30. program evaluation.tw. 
31. intervention studies/ 
32. experiment*.tw. 
33. (time adj series).tw. 
34. (pre test or pretest or (post test or postest)).tw. 
35. impact.tw. 
36. intervention*.tw. 
37. chang*.tw. 
38. compar*.tw. 
39. (controlled before and after stud*).mp. 
40. comparative study.sh. 
41. exp Evaluation Studies/ 
42. follow up studies.sh. 
43. prospective studies.sh. 
44. (control* or prospective* or volunteer*).ti,ab. 
45. 44 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 
or 38 or 39 or 40 or 41 or 42 or 43 
46. 24 and 45     
47. 22 and 11     
48. 47 and 45     
49. limit 48 to yr="2007 -Current"   
 
 
EMBASE SEARCH STRATEGY 
1. Exercise therapy/ 
2. exp exercise/ or weight training/ 
3. Physical fitness/ 
4. resistance training/ 
5. *Robotics/ or robot-assisted therapy.mp. 
6. 1 or 2 or 3 or 4 or 5 
7. ((dose or dosage or intensit* or frequenc* or duration* or time or amount or 
power or how much or repetition* or set* or load* or volume or work) adj3 
(training or therap* or protocol* or activit* or program* or exercise*)).ti,ab. 
8. (musc* adj (strength or abilit* or recovery or function* power or work or torque 
or force)).ti,ab. 
9. exp Oxygen Consumption/ or oxygen uptake.mp. 
10. ((motor or muscular) adj performance).ti,ab. 
11. functional limitation.ti,ab. 
12. evaluation.mp. 
13. effec*.mp. [mp=protocol supplementary concept, rare disease supplementary 
concept, title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
14. controlled clinical trial.mp. 
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15. (((controlled before and after) or cohort or case-control or longitudinal or 
observational or case or qualitative) adj3 stud*).mp. 
16. program evaluation.tw. 
17. experiment*.tw. 
18. (time adj series).tw. 
19. (pre test or pretest or (post test or postest)).tw. 
20. impact.tw. 
21. intervention*.tw. 
22. chang*.tw. 
23. compar*.tw. 
24. (controlled before and after stud*).mp. 
25. comparative study.sh. 
26. follow up studies.sh. 
27. prospective studies.sh. 
28. (control* or prospective* or volunteer*).ti,ab. 
29. dose-finding$.ti,ab. 
30. dose-ranging.ab,ti. 
31. dos$ relationship.ti,ab. 
32. dose-response.ti,ab. 
33. hemodynamic processes/ or blood pressure/ or cardiac output/ or heart rate/ 
or regional blood flow/ or vascular resistance/ or vasodilation/ 
34. oxygen consumption/ 
35. Heart rate/ 
36. "Activities of daily living"/ or Disability evaluation/ 
37. quality of life.mp. 
38. ((functional or motor) adj (abilit* or recovery)).ti,ab. 
39. Program evaluation/ 
40. intervention studies.ti,ab. 
41. research design/ or case report/ or clinical trials/ or randomized controlled 
trials/ or comparative study/ 
42. 7 or 29 or 30 or 31 or 32 
43. 6 and 42 
44. 8 or 10 or 11 or 36 or 37 
45. 9 or 33 or 34 or 35 
46. 43 and 45 
47. limit 46 to yr="2007 -Current" 
 
CHINAL SEARCH STRATEGY 
1. (MH "Exercise+") 
2. (MM "Therapeutic Exercise") or ("robot-assisted therapy") 
3. exercise therapy 
4. (MM "Physical Education and Training") OR (MM "Recreation") OR (MM 
"Sports") OR (MM "Leisure Activities") OR (MH "Physical Fitness+") 
5. 1 or 2 or 3 or 4      
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6. dose-finding 
7. dose-response 
8 .(MM "Dose-Response Relationship") 
9. dose relationship 
10. 6 or 7 or 8 or 9 
11. training* N3 dose or training* N3 dosage or training* N3 intensit* or training* 
N3 frequenc* or training* N3 duration or training* N3 amount or training* N3 
power or training* N3 how much or training* N3 repetition* or training* N3 set* 
or training* N3 load* or training* N3 volume 
12. therap* N3 dose or therap * N3 dosage or therap * N3 intensit* or therap * N3 
frequenc* or therap * N3 duration or therap * N3 amount or therap * N3 power 
or therap * N3 how much or therap * N3 repetition* or therap * N3 set* or therap 
* N3 load* or therap * N3 volume or therap* N3 work or therap* N3 time 
13. protocol* N3 dose or protocol* N3 dosage or protocol* N3 intensit* or 
protocol* N3 frequenc* or protocol* N3 duration or protocol* N3 amount or 
protocol* N3 power or protocol* N3 how much or protocol* N3 repetition* or 
protocol* N3 set* or protocol* N3 load* or protocol* N3 volume 
14. activit* N3 dose or activit* N3 dosage or activit* N3 intensit* or activit* N3 
frequenc* or activit* N3 duration or activit* N3 amount or activit* N3 power or 
activit* N3 how much or activit* N3 repetition* or activit* N3 set* or activit* N3 
load* or activit* N3 volume  
15. program* N3 dose or program* N3 dosage or program* N3 intensit* or 
program* N3 frequenc* or program* N3 duration or program* N3 amount or 
program* N3 power or program* N3 how much or program* N3 repetition* or 
program* N3 set* or program* N3 load* or program* N3 volume 
16. exercise* N3 dose or exercise* N3 dosage or exercise* N3 intensit* or 
exercise* N3 frequenc* or exercise* N3 duration or exercise* N3 amount or 
exercise* N3 power or exercise* N3 how much or exercise* N3 repetition* or 
exercise* N3 set* or exercise* N3 load* or exercise* N3 volume 
exercise* N3 work or program* N3 work or activit* N3 work or protocol* N3 work 
or training* N3 work or exercise* N3 time or program* N3 time or activit* N3 time 
or protocol* N3 time or training* N3 time 
17. 16 or 15 or 14 or 13 or 12 or 11 or 10      
18. 5 and 17       
19. Muscle N1 performance or Muscular N1 performance 
20. musc* N1 strength or musc* N1 abilit* or musc* N1 torque or musc* N1 force 
or musc* N1 work or musc* N1 power or musc* N1 function* or musc* N1 
recovery  
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21. (MH "Oxygen Consumption+") OR (MH "Heart Function Tests+") 
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Circulation, 3086-3094. No outcome of Interest. 
535. Wittmann, M., S. Spohn, et al. (2007). "[Patient education in COPD during inpatient 
rehabilitation improves quality of life and morbidity]." Pneumologie 61(10): 636-642. No dose-
responce ralationship investigated. 
536. Wong, P. L., A. Chaouachi, et al. "Effect of preseason concurrent muscular strength and 
high-intensity interval training in professional soccer players." Journal of Strength and 
Conditioning Research 24 (3): 653-660. No dose-responce ralationship investigated. 
537. Woo, J., A. Hong, et al. (2007). "A randomised controlled trial of Tai Chi and resistance 
exercise on bone health, muscle strength and balance in community-living elderly people." 
Age & Ageing 36(3): 262-268. No dose-responce ralationship investigated. 
538. Xiaolin, Y., R. Telama, et al. (2008). "The Longitudinal Effects of Physical Activity History on 
Metabolic Syndrome." Medicine & Science in Sports & Exercise 40(8): 1424-1431. No dose-
responce ralationship investigated. 
539. Yamauchi, J., S. Nakayama, et al. (2009). "Effects of bodyweight-based exercise training on 
muscle functions of leg multi-joint movement in elderly individuals." Geriatrics & gerontology 
international 9(3): 262-269. No dose-responce ralationship investigated. 
540. Yang, A.-L., S.-D. Lee, et al. (2007). "Effects of exercise intervention on patients with stroke 
with prior coronary artery disease: aerobic capacity, functional ability, and lipid profile: a pilot 
study." Journal of Rehabilitation Medicine 39(1): 88-90.Single dose. 
541. Yang, P., B. C. Frier, et al. (2007) "Respiratory muscle training and the performance of a 
simulated anti-G straining maneuver." Aviation, space, and environmental medicine, 1035-
1041. No outcome of Interest. 
542. Yasuda, T., S. Fujita, et al. (2010) "Effects of low-intensity bench press training with 
restricted arm muscle blood flow on chest muscle hypertrophy: a pilot study." Clinical 
physiology and functional imaging. Single dose. 
543. Yeo, W. K., C. D. Paton, et al. (2008). "Skeletal muscle adaptation and performance 
responses to once a day versus twice every second day endurance training regimens." Journal 
of Applied Physiology 105(5): 1462-1470. No outcome of Interest. 
544. Yip, Y. B., J. W. H. Sit, et al. (2007). "Effects of a self-management arthritis programme with 
an added exercise component for osteoarthritic knee: randomized controlled trial." Journal of 
Advanced Nursing 59(1): 20-28. Single dose. 
545. Yong Tai, W., R. Bernard, et al. (2008). "Fundamental Locomotive Activity Time Efficiency 
With Differently Positioning Drive-Axis Wheelchairs Among Elders." Adapted Physical Activity 
Quarterly 25(4): 322-334. No dose-responce ralationship investigated. 
546. Yoshizawa, M., S. Maeda, et al. (2009). "Effect of 12 weeks of moderate-intensity 
resistance training on arterial stiffness: a randomised controlled trial in women aged 32-59 
years." British Journal of Sports Medicine 43(8): 615-618. Single dose. No outcome of Interest. 
547. Young, W., R. Gulli, et al. "Acute effect of exercise on kicking accuracy in elite Australian 
football players." Journal of Science & Medicine in Sport 13(1): 85-89. No outcome of Interest. 
548. Yousefi, B., V. Tadibi, et al. (2009) "Exercise therapy, quality of life, and activities of daily 
living in patients with Parkinson disease: a small scale quasi-randomised trial." Trials, 67. Single 
dose. 
549. Zheng, A., R. Sakari, et al. (2009) "Effects of a low-frequency sound wave therapy 
programme on functional capacity, blood circulation and bone metabolism in frail old men 
and women." Clinical Rehabilitation, 897-908. no met inclusion criteria 
550. Zwick, R. H., O. C. Burghuber, et al. (2009). "[The effect of one year outpatient pulmonary 
rehabilitation on patients with COPD]." Wiener Klinische Wochenschrift 121(5-6): 189-195. 
Single dose. 
ARTICLES EXCLUDED BY ABSTRACT BECAUSE PRESENT IN THE CORE REVIEWS: 
1. Candow, D. G. and D. G. Burke (2007) "Effect of short-term equal-volume resistance 
training with different workout frequency on muscle mass and strength in untrained men 
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and women." Journal of strength and conditioning research / National Strength & 
Conditioning Association, 204-207. 
2. de Vos NJ, Singh NA, et al. (2008). "Effect of power-training intensity on the contribution 
of force and velocity to peak power in older adults." J Aging Phys Act 16(4): 393-407. 
3. Humburg, H., H. Baars, et al. (2007) "1-Set vs. 3-set resistance training: a crossover study." 
Journal of strength and conditioning research / National Strength & Conditioning 
Association, 578-582. 
4. Nakamura, Y., K. Tanaka, et al. (2007). "Effects of exercise frequency on functional fitness 
in older adult women." Archives of Gerontology & Geriatrics 44(2): 163-173. 
5. Rønnestad, B. R., W. Egeland, et al. (2007) "Dissimilar effects of one- and three-set 
strength training on strength and muscle mass gains in upper and lower body in untrained 
subjects." Journal of strength and conditioning research / National Strength & 
Conditioning Association, 157-163. 
6. Bottaro, M., S. N. Machado, et al. (2007). "Effect of high versus low-velocity resistance 
training on muscular fitness and functional performance in older men." European Journal 
of Applied Physiology 99(3): 257-264. 
 
STUDIES EXCLUDED VIA FULL-TEXT: 
1. Alcaraz, P. E., J. Sánchez-Lorente, et al. (2008) "Physical performance and cardiovascular 
responses to an acute bout of heavy resistance circuit training versus traditional strength 
training." Journal of strength and conditioning research / National Strength & Conditioning 
Association, 667-671. Different modalities of training. 
2. Arnardottir, R., G. Boman, et al. (2007). "Interval training compared with continuous 
training in patients with COPD." Respiratory Medicine 101(6): 1196-1204. No population 
of interest. (not healthy adult mixed age 43-80y. 
3. Askim T, Morkved S, et al. (2010). "Effects of a community-based intensive motor training 
program combined with early supported discharge after treatment in a comprehensive 
stroke unit: a randomized, controlled trial." Stroke 41(8): 1697-1703. Different training 
modalities. 
4. Behm DG, Reardon G, Fitzgerald J, Drinkwater E. (2002) "The effect of 5, 10, and 20 
repetition maximums on the recovery of voluntary and evoked contractile properties". J 
Strength Cond Res. 2002 May;16(2):209-18. No dose optimization trial. 
5. Bemben, D. A. and M. G. Bemben "Dose-response effect of 40 weeks of resistance training 
on bone mineral density in older adults." Osteoporosis International 22 (1): 179-186. No 
outcome of Interest. Single dose. 
6. Byl NN, Pitsch EA, et al. (2008). "Functional Outcomes Can Vary by Dose: Learning-Based 
Sensorimotor Training for Patients Stable Poststroke." Neurorehabilitation and Neural 
Repair 22(5): 494-504. No ExBT. 
7. Buford, T. W., S. J. Rossi, et al. (2007) "A comparison of periodization models during nine 
weeks with equated volume and intensity for strength." Journal of strength and 
conditioning research / National Strength & Conditioning Association, 1245-1250. 
Different training modalities. 
8. Cheema, B., H. Abas, et al. (2007). "Randomized controlled trial of intradialytic resistance 
training to target muscle wasting in ESRD: the Progressive Exercise for Anabolism in Kidney 
Disease (PEAK) study." American Journal of Kidney Diseases 50(4): 574-584. no meet 
inclusion criteria. 
9. Combs, S. A., M. D. Diehl, et al. "Boxing training for patients with Parkinson disease: a case 
series." Physical Therapy 91(1): 132-142. Single dose. 
10. Cooke EV, Tallis RC, et al. (2010). "Efficacy of functional strength training on restoration of 
lower-limb motor function early after stroke: phase I randomized controlled trial." 
Neurorehabilitation & Neural Repair 24(1): 88-96 Different training modalities  
11. Dromerick, A. W., C. E. Lang, et al. (2009). "Very Early Constraint-Induced Movement 
during Stroke Rehabilitation (VECTORS): A single-center RCT." Neurology 73(3): 195-201. 
Different modalities of training, same dose. 
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12. Delecluse C, Coppenolle HV, Willems E, Leemputte MV, Diels R, Goris M. Influence of high-
resistance and high-velocity training on sprint performance. Medicine & Science in Sports 
& Exercise. 1995;27(8):1203-9. Different therapies. 
13. Dolezal BA, Potteiger JA. Concurrent resistance and endurance training influence basal 
metabolic rate in nondieting individuals. Journal of Applied Physiology. 1998 August 1, 
1998;85(2):695-700.  Different therapies. 
14. DONNELLY JE, JACOBSEN DJ, HEELAN SNYDER KS, al. E. The effects of 18 months of 
intermittent vs continuous exercise on aerobic capacity, body weight and composition, 
and metabolic fitness in previously sedentary, moderately obese females. Int J Obesity 
Relat Metab Disord. 2000;24:566-72. Different therapies. 
15. Ebben WP, Kindler AG, Chirdon KA, et al (2004). "The effect of highload vs. high-repetition 
training on endurance performance". Journal of Strength and Conditioning Research, 
2004, 18(3), 513–517 Different training modalities 
16. Farthing J, Chilibeck P (2003). "The effects of eccentric and concentric training at different 
velocities on muscle hypertrophy". European Journal of Applied Physiology. 89(6):578-86. 
Different Therapies. 
17. Fry AC, Kraemer WJ, Weseman CA, et al. (1991). The effects of an off-season strength and 
conditioning program on starters and non-starters in women's intercollegiate volleyball. J 
Appl Sport Sci Res 5:174-81. Single dose. 
18. Hoffman JR, Ratamess NA, Cooper JJ, Kang JIE, Chilakos ART, Faigenbaum AD. (2005). 
Comparison of Loaded and Unloaded Jump Squat Training on Strength/Power 
Performance in College Football Players. The Journal of Strength & Conditioning Research. 
19(4):810-5. Different therapies. 
19. Kang, J., E. Chaloupka, et al. (2009). "Regulating intensity using perceived exertion: effect 
of exercise duration." European Journal of Applied Physiology 105(3): 445-451. No dose-
responce ralationship. 
20. Katula, J. A., W. J. Jack, et al. (2008). "Enhancing quality of life in older adults: A comparison 
of muscular strength and power training." Health and Quality of Life Outcomes 6(45). Trials 
included in a larger pilot study (Marsh,2009). 
21. Kawamori N, Crum AJ, Blumert PA, Kulik JR, Childers JT, Wood JA, et al. (2005) Influence 
of Different Relative Intensities on Power Output During the Hang Power Clean: 
Identification of the Optimal Load. The Journal of Strength & Conditioning Research. 
19(3):698-708. No dose investigated. 
22. Kimura, A. (2008). "Cut-off Point of Physical Activity for Elderly Hemiplegics with 
Deconditioning." Rigakuryoho Kagaku 23(3): 375-382. Language restriction on full text. 
23. Kraemer WJ, Ratamess N, Fry AC, et al. (2000) Influence of resistance training volume and 
periodization on physiological and performance adaptations in college women tennis 
players. Am J Sports Med. 28:626-33. Different therapies. 
24. Landin, D. and A. G. Nelson (2007) "Early phase strength development: a four-week 
training comparison of different programs." Journal of strength and conditioning research 
/ National Strength & Conditioning Association, 1113-1116.Same dose Diff order. 
25. Langhammer, B., B. Lindmark, et al. (2007) "Stroke patients and long-term training: is it 
worthwhile? A randomized comparison of two different training strategies after 
rehabilitation." Clinical Rehabilitation, 495-510. Different modalities of training. 
26. Langhammer, B., J. K. Stanghelle, et al. (2008) "Exercise and health-related quality of life 
during the first year following acute stroke. A randomized controlled trial." Brain injury : 
[BI], 135-145. Different modalities of training. 
27. LaRoche, D. P., C. A. Knight, et al. (2007). "Explosive force and fractionated reaction time 
in elderly low- and high-active women." Medicine and Science in Sports and Exercise 39 
(9): 1659-1665. Same Dose applied 
28. Marsh, A. P., M. E. Miller, et al. (2009). "Lower extremity muscle function after strength or 
power training in older adults." Journal of Aging & Physical Activity 17(4): 416-443. 
Different modalities of training. same dose (speed of movement). 
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29. Martin, C. K., T. S. Church, et al. (2009). "Exercise dose and quality of life: a randomized 
controlled trial." Archives of Internal Medicine 169(3): 269-278. No outcome of Interest. 
30. Marx JO, Ratamess NA, Nindl BC, et al (2001). Low-volume circuit versus high-volume 
periodized resistance training in women. MEDICINE & SCIENCE IN SPORTS & EXERCISE 
4:635-643 Different modalities of training. 
31. Mazzetti S, Douglass M, Yocum A, Harber M. (2007) Effect of Explosive versus Slow 
Contractions and Exercise Intensity on Energy Expenditure. Medicine & Science in Sports 
& Exercise. 39(8):1291-301 No outcome of Interest. 
32. McBride JM, Triplett-McBride T, Davie A, Newton RU (2002). "The effect of heavy- vs  light-
load jump squats on the development of strength, power, and speed". Journal of Strength 
and Conditioning Research, 2002, 16(1), 75–82 No population of interest. (Athlete). 
33. Monteiro, A. G., M. S. Aoki, et al. (2009) "Nonlinear periodization maximizes strength gains 
in split resistance training routines." Journal of strength and conditioning research / 
National Strength & Conditioning Association, 1321-1326. . Different training modalities. 
34. Mookerjee S, Ratamess N. (1999) Comparison of Strength Differences and Joint Action 
Durations Between Full and Partial Range-of-Motion Bench Press Exercise. The Journal of 
Strength & Conditioning Research. 13(1):76-81 Different training. 
35. Neils CM, Uderman BE, Brice GA, Winchester JB, McGuigan MR (2005). Influence of 
contraction velocity in untrained individuals over the initial early phase of resistance 
training. J Strength Cond Res;19(4):883-7 Different modalities of training. 
36. Orr R, DeVos NJ, Singh NA, et al (2006). Power training improves balance in healthy older 
adults. J Gerontol A Biol Sci Med Sci. 61(1):78-85. Duplicate. 
37. Ostrowski KJ, Wilson GJ, Weatherby R, Murphy PW, Lyttle AD (1997). "The effect of weight 
training volume on hormonal output and muscular size and function". Journal of strength 
and conditioning research 11(1):148-154. No outcome of Interest. 
38. Reid, K. F., D. M. Callahan, et al. (2008). "Lower extremity power training in elderly subjects 
with mobility limitations: A randomized controlled trial." Aging - Clinical and Experimental 
Research 20 (4): 337-343. Different modalities of training. same dose (speed of movement). 
39. Rhea MR, Phillips WT, Burkett LN, Ball SD, al. e. (2002) A comparison of linear and daily 
undulating periodized programs with equated volume and intensity for strength. J 
Strength Cond Res. 16(2):250-5 Same dose. 
40. Sforzo GA, Touey PR. (1996) Manipulating Exercise Order Affects Muscular Performance 
During a Resistance Exercise Training Session. The Journal of Strength & Conditioning 
Research. 10(1):20-4. Same dose. 
41. Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. (2002) Exercise 
Type and Intensity in Relation to Coronary Heart Disease in Men. JAMA: The Journal of the 
American Medical Association, 288(16):1994-2000. Vague dose. 
42. Tanimoto M, Sanada K, et al. (2008). "Effects of whole-body low-intensity resistance 
training with slow movement and tonic force generation on muscular size and strength in 
young men." J Strength Cond Res. 22(6): 1926-1938. Single dose. 
43. Tanimoto, M., H. Arakawa, et al. (2009). "Changes in Muscle Activation and Force 
Generation Patterns During Cycling Movements Because of Low-Intensity Squat Training 
With Slow Movement and Tonic Force Generation." Journal of Strength & Conditioning 
Research 23(8): 2367-2376. No outcome of Interest. 
44. Tanimoto, M., H. Kawano, et al. (2009) "Low-intensity resistance training with slow 
movement and tonic force generation increases basal limb blood flow." Clinical physiology 
and functional imaging, 128-135. Single dose. 
45. Thomas GA, Kraemer WJ, Spiering BA, Volek JS, Anderson JM, Maresh CM. (2007) Maximal 
Power At Different Percentages of One Repetition Maximum: Influence of Resistance and 
Gender. The Journal of Strength & Conditioning Research. 21(2):336-42. Not controlling 
for dose. 
46. Tran QT, Docherty D, Behm D (2006). The effects of varying time under tension and volume 
load on acute neuromuscular responses. Eur J Appl Physiol. 98(4):402-10. Different 
training modalities. 
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47. Willardson JM and B. LN (2008). "The effect of different rest intervals between sets on 
volume components and strength gains." J Strength Cond Res. 22(1): 146-152. No 
population of interest. (Athlete) 
48. Willardson, J. M., J. Emmett, et al. (2008) "Effect of short-term failure versus nonfailure 
training on lower body muscular endurance." International journal of sports physiology 
and performance, 279-293. No outcome of Interest. 
49. Gillam GM. (1981). "Effects of frequency of weight training on muscle strength 
enhancement". The Journal of sports medicine and physical fitness 21(4):432-6. NO Full-
txt available. 
50. Sipe, C. L. (2008) "The effects of strength and power training on functional abilities in older 
adults." (Dissertation project). 
51. Stone MH, Johnson RL, Carter DR (1979). "A short term comparison of two different 
methods of resistance training on leg strength and power". Journal of strength and 
conditioning research NO Full-txt available. 
52. Stone MH, Potteiger JA, Pierce KC, et al (2000). "Comparison of the effects of three 
different weight-training programs on the one repetition maximum squat". Journal of 
strength and conditioning research 14(3) NO Full-txt available. 
53. Paoli A, Pacelli F, et al. (2010). "Effects of three distinct protocols of fitness training on 
body composition, strength and blood lactate." J Sports Med Phys Fitness` 50: 43-51.NO 
Full-txt available.  
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Appendix D : Narrative systematic review on dose 
optimization approaches in pharmaceutical clinical 
research 
REFERENCE LIST OF EXCLUDED ARTICLES AT FULL-TEXT REVIEW STAGE 
1. Wong, S. F. (2009). "New dosing schedules of Dasatinib for CML and 
adverse event management." Journal of Hematology and Oncology 2(10). 
NOT DOSE OPTIMIZATION STUDY 
2. Mulhall, J. P., S. Bukofzer, et al. (2001). "An open-label, uncontrolled dose-
optimization study of sublingual apomorphine in erectile dysfunction." 
Clinical Therapeutics 23 (8): 1260-1271. NOT DOSE OPTIMIZATION STUDY 
3. Murphy, W. K., F. V. Fossella, et al. (1993). "Phase II study of taxol in 
patients with untreated advanced non-small-cell lung cancer." Journal of 
the National Cancer Institute 85(5): 384-388. NOT DOSE OPTIMIZATION 
STUDY 
4. Plaxe, S. C., J. A. Blessing, et al. (2002). "Phase II trial of pyrazoloacridine 
in patients with persistent or recurrent endometrial carcinoma: A 
Gynecologic Oncology Group study." Gynecologic Oncology 84 (2): 241-
244. NOT DOSE OPTIMIZATION STUDY 
5. Pavlu, J. and D. Marin (2009). "Dasatinib and chronic myeloid leukemia: 
Two-year follow-up in eight clinical trials." Clinical Lymphoma and 
Myeloma 9 (6): 417-424. NOT DOSE OPTIMIZATION STUDY 
6. Porsteinsson, A., R. Sperling, et al. (2011). "Imaging and cerebrospinal 
fluid biomarker results of a phase II dose-ranging study of ELND005 
(Scyllo-inositol) in mild-to-moderate Alzheimer's disease." Alzheimer's 
and Dementia Conference: Alzheimer's Association International 
Conference, AAIC 11 Paris France. Conference Start: 20110716 
Conference End: 20110721. Conference Publication: (var.pagings). 7 (4 
SUPPL. 1): S695. NOT DOSE OPTIMIZATION STUDY 
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7. Reuben, D. B., S. H. Hirsch, et al. (2005). "The effects of megestrol acetate 
suspension for elderly patients with reduced appetite after 
hospitalization: A phase II randomized clinical trial." Journal of the 
American Geriatrics Society 53 (6): 970-975. NOT DOSE OPTIMIZATION 
STUDY 
8. Rhee, P., J. Morris, et al. (2000). "Recombinant humanized monoclonal 
antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: 
Results of a phase II clinical trial." Journal of Trauma - Injury, Infection and 
Critical Care 49 (4): 611-620. NOT DOSE OPTIMIZATION STUDY 
9. Shanafelt, T. D., T. G. Call, et al. (2009). "Phase I trial of daily oral 
polyphenon E in patients with asymptomatic rai stage 0 to II chronic 
lymphocytic leukemia." Journal of Clinical Oncology 27 (23): 3808-3814. 
NO INCLUSION CRITERIA 
10. Thall, P. F., H. G. Sung, et al. (2001). "Dose-finding based on feasibility and 
toxicity in T-cell infusion trials." Biometrics 57 (3): 914-921. NOT DOSE 
OPTIMIZATION STUDY 
11. Sinnige, H. A. M., J. Buter, et al. (1993). "Phase I-II study of the addition of 
alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic 
interaction of alpha-2a interferon and leucovorin." European Journal of 
Cancer Part A: General Topics 29 (12): 1715-1720. NOT DOSE 
OPTIMIZATION STUDY 
12. Smith, A. M., T. Justin, et al. (2000). "Phase I/II study of G17-DT, an anti-
gastrin immunogen, in advanced colorectal cancer." Clinical Cancer 
Research 6 (12): 4719-4724. NOT DOSE OPTIMIZATION STUDY 
13. Shuin, T., Y. Kubota, et al. (1994). "A phase II study of prophylactic 
intravesical chemotherapy with 4'-epirubicin in recurrent superficial 
bladder cancer: comparison of 4'-epirubicin and adriamycin." Cancer 
Chemotherapy & Pharmacology 35 Suppl: S52-56. NOT DOSE 
OPTIMIZATION STUDY 
14. Trachtman, H., F. C. Fervenza, et al. (2011). "A phase 1, single-dose study 
of fresolimumab, an anti-TGF-B antibody, in treatment-resistant primary 
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focal segmental glomerulosclerosis." Kidney International 79 (11): 1236-
1243. . NOT DOSE OPTIMIZATION STUDY 
15. Tsukiyama, I., S. Katano, et al. (2001). "Multi-institutional phase I and II 
trial of simultaneous intracavitary hyperthermia and brachytherapy for 
advanced esophageal cancer." Journal of Brachytherapy International 17 
(4): 299-308. NOT DOSE OPTIMIZATION STUDY 
16. Kendra, K., R. Plummer, et al. (2011). "Phase I dose-finding study for 
pazopanib (P) and paclitaxel (T) in combination in the first-line setting in 
patients (pts) with advanced solid tumours." European Journal of Cancer 
Conference: 2011 European Multidisciplinary Cancer Congress Stockholm 
Sweden. Conference Start: 20110923 Conference End: 20110927. 
Conference Publication: (var.pagings). 47: S146. Not full-text available 
17. Murphy, J. R. and D. L. Hall (1997). "A logistic dose-ranging method for 
phase I clinical investigations trials." Journal of Biopharmaceutical 
Statistics 7 (4): 635-647. Not full-text available 
18. Pena-Rossi, C., S. Schreiber, et al. (2008). "Clinical trial: A multicentre, 
randomized, double-blind, placebo-controlled, dose-finding, phase II 
study of subcutaneous interferon-beta-1a in moderately active ulcerative 
colitis." Alimentary Pharmacology and Therapeutics 28 (6): 758-767. Not 
full-text available 
19. Perera, P. M. S., S. F. Jayamanna, et al. (2009). "A phase II clinical trial to 
assess the safety of clonidine in acute organophosphorus pesticide 
poisoning." Trials 10 (pp 73)(1745). Not full-text available 
20. Perez, E. A., T. Coe, et al. (1996). "Phase I study of paclitaxel with oral 
etoposide in advanced solid tumors." Cancer Journal 2 (5): 286-290. Not 
full-text available 
21. Planting, A. S., M. E. van der Burg, et al. (1993). "Phase I/II study of a short 
course of weekly cisplatin in patients with advanced solid tumours." 
British Journal of Cancer 68(4): 789-792. Not full-text available 
22. Portnow, J., S. Koehler, et al. (2010). "A phase I study of bortezomib (BTZ) 
and temozolomide (TMZ) in patients with advanced solid tumors." Journal 
of Clinical Oncology. Conference 28(15 SUPPL. 1). Not full-text available 
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23. Recchia, F., G. Saggio, et al. (2006). "Dose-finding study of docetaxel 
added to ifosfamide and cisplatin followed by concomitant capecitabine 
and radiotherapy in the treatment of locally advanced squamous cell 
carcinoma of the head and neck." Anticancer Research 26 (3 B): 2317-
2324. Not full-text available 
24. Reckamp, K. L., M. Koczywas, et al. (2010). "Randomized, placebo-
controlled, phase II trial of EGFR and COX-2 inhibition in advanced non-
small cell lung cancer." Journal of Clinical Oncology. Conference 28(15 
SUPPL. 1). Not full-text available 
25. Reddy, G. K., L. Shivakumar, et al. (2007). "Preliminary results of a phase 
II dose-finding study of subcutaneous Hematide in patients with cancer 
receiving chemotherapy." Supportive Cancer Therapy 4 (2): 74-75. Not 
full-text available 
26. Reinhart, K., T. Gluck, et al. (2004). "CD14 receptor occupancy in severe 
sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 
monoclonal antibody (IC14)." Critical Care Medicine 32 (5): 1100-1108. 
Not full-text available 
27. Rhee, E. J., W. Y. Lee, et al. (2010). "A multicenter, randomized, placebo-
controlled, double-blind phase II trial evaluating the optimal dose, efficacy 
and safety of LC 15-0444 in patients with type 2 diabetes." Diabetes, 
Obesity and Metabolism 12 (12): 1113-1119. Not full-text available 
28. Richardson, P. G., R. J. Soiffer, et al. (2010). "Defibrotide for the Treatment 
of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after 
Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding 
Trial." Biology of Blood and Marrow Transplantation 16 (7): 1005-1017. 
Not full-text available 
29. Rixe, O., S. X. Franco, et al. (2009). "A randomized, phase II, dose-finding 
study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in 
patients with pretreated metastatic breast cancer." Cancer 
Chemotherapy and Pharmacology 64 (6): 1139-1148. Not full-text 
available 
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30. Robert, F., M. P. Ezekiel, et al. (2001). "Phase I study of anti-epidermal 
growth factor receptor antibody cetuximab in combination with radiation 
therapy in patients with advanced head and neck cancer." Journal of 
Clinical Oncology 19 (13): 3234-3243. Not full-text available 
31. Rocca, A., R. Maltoni, et al. (2010). "A phase IB dose-finding trial of 
liposomal doxorubicin in combination with capecitabine in patients with 
pretreated metastatic breast cancer." Cancer Chemotherapy and 
Pharmacology 65 (5): 871-876. Not full-text available 
32. Rodgers, K. E., J. Oliver, et al. (2006). "Phase I/II dose escalation study of 
angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in 
patients with newly diagnosed breast cancer." Cancer Chemotherapy and 
Pharmacology 57 (5): 559-568. Not full-text available 
33. Roila, F., J. Rolski, et al. (2009). "Randomized, double-blind, dose-ranging 
trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for 
the prevention of cisplatin-induced nausea and vomiting." Annals of 
Oncology 20 (11): 1867-1873. Not full-text available 
34. Rose, P. G. (2005). "Pegylated liposomal doxorubicin: Optimizing the 
dosing schedule in ovarian cancer." Oncologist 10 (3): 205-214. Not full-
text available 
35. Rose, P. G., J. A. Blessing, et al. (2003). "A phase II study of docetaxel in 
paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic 
Oncology Group study." Gynecologic Oncology 88 (2): 130-135. Not full-
text available 
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Date of visit |__|__|-|__|__|-|__|__|__|__| (DD-MM-YYYY)           Participant Initials |__|__|__|  
Participant Number |__|__|-|__|__|__|__|  
 
CONSENT FORM 
Dose-finding Trial 
Establishing a feasible optimal therapeutic dose using a new 
methodology for stroke rehabilitation 
 
Name of Researcher: ___________________________________ 
 
Name of Participant:  ___________________________________ 
 
NB. If the potential participant is unable to write, please find an 
independent witness who may complete this form as verbal consent is 
given by the potential participant.  The independent witness should read 
each of the 5 items to the potential participant and if the participant 
agrees, the independent witness should initial each of the boxes with 
his/her own initials.   
The purpose of the independent witness is to physically complete this 
consent form on the instruction of a participant in the instance that the 
participant cannot do so for him or herself due to a physical inability to 
hold and or use a pen, or in the instance in which attempting to do so 
would or appears to cause distress to the participant.  The independent 
witness cannot provide consent on behalf of a participant. 
An independent witness must: 
 Not be part of the research team 
 Not be managed by a member of the research team 
 
2 copies of this form must be completed (No photocopies):  
 1 copy for participant 
 1 copy for researcher site file 
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Appendix I : Dose finding Outcome W3 
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Appendix K : Participants’ adherence rates 
Figure 7-1: Participants’ adherence rates (in %) by cohort and participants’ 
mean number of daily repetitions 
 
Notes: the vertical bars reports adherence rate; the x bar reports cohort of study and numbers 
of assigned repetitions (in parenthesis). Figures above the bars shown average number of daily 
repetitions achieved in the training period. 
(*) Participants who were considered adherent but did not fully compliant with the target dose 
for reasons not related to the trial or the dose. 
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Appendix L : TMS results 
Change on MEP amplitude 
Following the data on MEP amplitude in response to a 100% of the motor 
threshold are reported at pre and post intervention points for all the three 
assessed muscle for all participants on affected and unaffected side. 
Acknowledging the relationship between MEP amplitude and stimulus 
intensity, the changes in MEP amplitude in response to a 110%, 120% and 130% 
of the recruitment curve (RC) are reported. 
Biceps brachii 
Table 7-1 shows MEP amplitude at 100% of the RC at pre and post intervention 
on BB muscle for all participants on affected and unaffected side. Changes of 
amplitude from pre to post intervention are reported in the table as well as in 
Figure 7.18.  
Table 7-1: MEP amplitude at 100% of the recruitment curve (RC) on biceps 
brachii muscle (BB) at baseline (pre intervention) and outcome (post 
intervention) for all participants on affected and unaffected side. 
BB 100% RC             
  Affected side Unaffected side 
Cohort 
(dose) Participant Baselinea Outcomea Changea Baselinea Outcomea Changea 
1(50) DF01 0.3730 0.3613 -0.0117 0.2275 0.1968 -0.0308 
1(50) DF02 0.1764 0.2197 0.0433 1.0918 3.2598 2.1680 
2(100) DF04 0.4263 0.6714 0.2451 0.2046 0.4761 0.2715 
2(100) DF05 1.9540 0.7539 -1.7690 0.1914 0.5503 0.3589 
3(167) DF07 . 0.3657 . 0.1606 0.1421 -0.0186 
4(251) DF11 . 0.2183 . 0.0781 0.1367 0.0586 
5(209) DF13 0.0757 0.5752 0.4995 0.1333 0.9575 0.8242 
Notes: (a)=  MEP amplitude in mVolts. The dots represent when a resting motor threshold could 
not be obtained. 
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As expected, from this table I can see that there is individual heterogeneity in 
excitability and MEP amplitude between brain sides as well as between 
participants. More consistent responses are found in the unaffected side.    
Figure 7-2: Changes in MEP amplitude from pre to post intervention on biceps 
brachii muscle (BB) at 100% of the RC for all participants on affected and 
unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude 
for each participants from pre to post intervention for affected (light blue bars) and unaffected 
(dark blue bars) side. 
 
Consistently with Table 7-1, Figure 9-2 shows that some participants increased 
and some decreased in the affected side (light blue bars). Whereas, more 
consistency was found in the unaffected side (bark blue bars). 
Table 7-2 shows changes in MEP amplitude at 110% 120% and 130%of the RC 
from pre to post intervention on BB muscle for all participants on affected and 
unaffected side. 
  
-2.5
-1.5
-0.5
0.5
1.5
2.5
3.5
DF01 DF02 DF04 DF05 DF07 DF11 DF13
A
m
p
lit
u
d
e 
(m
V
)
BB MEPs amplitude change at 100% RC
(pre - post intervention)
Affected side Unaffected side
 340 
Table 7-2: Changes in MEPs amplitude at 110%, 120%and 130% of the RC at 
baseline (pre intervention) and outcome (post intervention) on biceps brachii 
muscle (BB) for all participants on affected and unaffected side. 
BB  
      
  
Affected side Unaffected side 
Cohort 
(dose) 
Participant 
Change 
at 
110% 
RCa 
Change 
at 
120% 
RCa 
Change 
at 130% 
RCa 
Change 
at 
110% 
RCa 
Change 
at 
120% 
RCa 
Change 
at 130% 
RCa 
1(50) DF01 . . . -0.192 -0.015 . 
1(50) DF02 . . . -0.687 0.229 -1.34326 
2(100) DF04 0.331 0.139 . 1.356 1.278 1.256836 
2(100) DF05 -0.415 0.354 4.970703 0.412 0.635 . 
3(167) DF07 . . . -0.082 -0.308 -0.6084 
4(251) DF11 . . . 0.073 . . 
5(209) DF13 0.754 . . 0.795 1.491 . 
Notes: (a)= MEP amplitude in mVolts. The dots represent when a resting motor threshold could 
not be obtained. 
 
From this table it can be seen that there are individual differences in excitability 
and MEP amplitude between brain sides as well as between participants. More 
consistent responses are found in the unaffected side.  
Figure 7-3, Figure 7-4 and Figure 7-5 show the changes in the BB muscle at 
110%, 120% and 130% of the RC for all participants respectively.  
As with Table 7-2, Figure 7-3 to Figure 7-5 show that in both sides some 
participants increased and some decreased. More consistent responses are 
found in the unaffected side. As expected, as the stimulus (%RMT) increases 
less muscle responses are seen in the affected side. This is because the motor 
threshold had to be higher.
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Figure 7-3: Changes in MEPs amplitude from pre to post intervention on biceps brachii 
muscle (BB) at 110% of the RC for all participants on affected and unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude for each 
participants from pre to post intervention for affected (light blue bars) and unaffected (dark blue bars) 
side. 
 
Figure 7-4: Changes in MEPs amplitude from pre to post intervention on biceps brachii 
muscle (BB) at 120% of the RC for all participants on affected and unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude for each 
participants from pre to post intervention for affected (light blue bars) and unaffected (dark blue bars) 
side.
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Figure 7-5: Changes in MEPs amplitude from pre to post intervention on 
biceps brachii muscle (BB) at 130% of the RC for all participants on affected 
and unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude 
for each participants from pre to post intervention for affected (light blue bars) and unaffected 
(dark blue bars) side. 
Extensor carpi radialis 
Table 7-3 shows MEPs amplitude at 100% of the RC from pre to post 
intervention on ECR muscle for all participants on affected and unaffected side. 
Changes of amplitude from pre to post intervention are reported in the table 
and in Figure 7-6.  
Table 7-3: MEPs amplitude at 100% of the recruitment curve (RC) at baseline 
(pre intervention) and outcome (post intervention) on extensor carpi radialis 
muscle (ECR) for all participants on affected and unaffected side. 
ECR 100% RC             
  Affected side Unaffected side 
Cohort 
(dose) Participant Baselinea Outcomea Changea Baselinea Outcomea Changea 
1(50) DF01 0.712 0.738 0.026 0.190 0.172 -0.018 
1(50) DF02 0.863 . . 1.098 2.487 1.389 
2(100) DF04 1.213 0.237 -0.976 1.016 0.724 -0.292 
2(100) DF05 1.040 0.842 -0.198 0.448 0.293 -0.155 
3(167) DF07 0.230 0.224 -0.007 0.620 0.280 -0.339 
4(251) DF11 1.009 0.838 -0.171 0.200 0.401 0.201 
5(209) DF13 0.329 0.398 0.070 0.584 0.626 0.042 
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Notes: (a)=  MEP amplitude in mVolts. The dots represent when a resting motor threshold could 
not be obtained. 
As expected, from this table it can be seen that there were more responses and 
more consistency on ECR muscle than on BB muscle. However, some 
heterogeneity in the changes on excitability between participants are reported. 
 
Figure 7-6: Changes in MEPs amplitude from pre to post intervention on 
extensor carpi radialis muscle (ECR) at 100% of the recruitment curve (RC) for 
all participants on affected and unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude 
for each participants from pre to post intervention for affected (light blue bars) and unaffected 
(dark blue bars) side. 
 
Table 7-3 and Figure 7-6 shows that again, some participants increased and 
some decreased brain excitability. More consistency in the responses between 
hemisphere sides is found in ECR muscle than BB muscle. 
Table 7-4 shows changes in MEP amplitude at 110% 120% and 130%of the RC 
from pre to post intervention on ECR muscle for all participants on affected and 
unaffected side. 
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Table 7-4: Changes in MEPs amplitude at 110%, 120%and 130% of the RC at 
baseline (pre intervention) and outcome (post intervention) on extensor carpi 
radialis muscle (ECR) for all participants on affected and unaffected side. 
ECR        
  
Affected side Unaffected side 
Cohort 
(dose) 
Participant 
Change 
at 110% 
RCa 
Change 
at 120% 
RCa 
Change 
at 130% 
RCa 
Change 
at 110% 
RCa 
Change 
at 120% 
RCa 
Change 
at 130% 
RCa 
1(50) DF01 . . . -0.107 -0.157 . 
1(50) DF02 . . . 1.439 -0.036 0.355 
2(100) DF04 -0.955 0.237 0.804 -0.016 -0.08 0.533 
2(100) DF05 -0.923 -0.769 -1.063 -1.097 -1.333 -1.821 
3(167) DF07 -0.222 -0.375 0.036 -0.278 0.023 -0.03 
4(251) DF11 0.104 -0.405 -0.054 0.172 0.278 0.07 
5(209) DF13 0.462 0.744 -1.172 -0.379 0.201 0.012 
Notes: (a)=  MEP amplitude in mVolts. The dots represent when a resting motor threshold could 
not be obtained. 
From this table, as before, it can be seen that there are individual differences 
in excitability and MEP amplitude between brain sides as well as between 
participants. More consistent responses are found in the unaffected side.   
Figure 7-7, Figure 7-8, and Figure 7-9 show the changes in the ECR muscle at 
110%, 120% and 130% of the RC for all participants respectively.  
Figure 7-7: Changes in MEPs amplitude from pre to post intervention on 
extensor carpi radialis muscle (ECR) at 110% of the recruitment curve (RC) for 
all participants on affected and unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude 
for each participants from pre to post intervention for affected (light blue bars) and unaffected 
(dark blue bars) side. 
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Figure 7-8: Changes in MEPs amplitude from pre to post intervention on 
extensor carpi radialis muscle (ECR) at 120% of the recruitment curve (RC) for 
all participants on affected and unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude 
for each participants from pre to post intervention for affected (light blue bars) and unaffected 
(dark blue bars) side 
 
Figure 7-9: Changes in MEPs amplitude from pre to post intervention on 
extensor carpi radialis muscle (ECR) at 130% of the recruitment curve (RC) for 
all participants on affected and unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude 
for each participants between baseline to outcome measures for affected (light blue bars) and 
unaffected (dark blue bars) side. 
  
-1.5
-1.0
-0.5
0.0
0.5
1.0
DF01 DF02 DF04 DF05 DF07 DF11 DF13
A
m
p
lit
u
d
e 
(m
V
)
Axis Title
ECR MEPs amplitude change at 120%
(pre - post intervention)
Affected side Unaffected side
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
DF01 DF02 DF04 DF05 DF07 DF11 DF13
A
m
p
lit
u
d
e 
(m
V
)
Axis Title
ECR MEPs amplitude change at 130% 
(pre - post intervention)
Affected side Unaffected side
 346 
As with Table 7-4,   
Figure 7-7 to 7-25 show that in both sides some participants increased and 
some decreased. Variability on the changes is found between individual’s 
affected (light blue bar) and unaffected side (dark blue side) as well as between 
participants. More consistent responses are found in the unaffected side. As 
expected, as the stimulus (%RMT) gets bigger less muscle responses are seen 
in the affected side. This is because the motor threshold had to be higher. 
 
Abductor pollicis brevis  
Table 7-5 shows MEPs amplitude at 100% of the RC from pre to post 
intervention on APB muscle for all participants on affected and unaffected side. 
Changes of amplitude from pre to post intervention are reported in the table 
as well as in Figure 7-26.  
Table 7-5: MEPs amplitude at 100% of the recruitment curve (RC) at baseline 
(pre intervention) and outcome (post intervention) measure points on 
abductor pollicis brevis (APB) for all participants on affected and unaffected 
side. 
APB 100% RC             
  Affected side Unaffected side 
Cohort 
(dose) Participant Baselinea Outcomea Changea Baselinea Outcomea Changea 
1(50) DF01 0.676 0.580 -0.096 1.528 0.516 -1.012 
1(50) DF02 . 0.373 . 4.265 2.513 -1.752 
2(100) DF04 3.141 2.277 -0.864 1.800 0.877 -0.922 
2(100) DF05 3.093 4.158 1.065 1.122 0.507 -0.615 
3(167) DF07 0.628 1.214 0.586 0.388 2.647 2.259 
4(251) DF11 0.549 . . 0.308 . . 
5(209) DF13 1.546 1.556 0.010 0.379 0.621 0.242 
Notes: (a)=  MEP amplitude in mVolts. The dots represent when a resting motor threshold could 
not be obtained. 
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Figure 7-10: Changes in MEPs amplitude from pre to post intervention on 
abductor pollicis brevis (APB) at 100% of the recruitment curve (RC) for all 
participants on affected and unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude 
for each participants from pre to post intervention for affected (light blue bars) and unaffected 
(dark blue bars) side. 
 
Consistently with the Table 7-5, Figure 7-10 shows variability on the changes on 
APB muscle at 100% of the RC between individual’s affected (light blue bar) and 
unaffected side (dark blue side) as well as between participants. More 
consistent responses were found in the unaffected side. 
As for ECR, from this table it can be seen that there was more consistent 
responses on APB muscle that on BB muscle. 
Table 7-6 shows changes in MEP amplitude at 110% 120% and 130%of the RC 
from pre to post intervention on APB muscle for all participants on affected and 
unaffected side.
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Table 7-6: Change in MEPs amplitude at 110%, 120% and 130% of RC at 
baseline (pre intervention) and outcome (post intervention) on abductor 
pollicis brevis (APB) for all participants on affected and unaffected side. 
APB       
  Affected side Unaffected side 
Cohort 
(dose) 
Participant 
Change 
at 110% 
RCa 
Change 
at 120% 
RCa 
Change 
at 130% 
RCa 
Change 
at 110% 
RCa 
Change 
at 120% 
RCa 
Change 
at 130% 
RCa 
1(50) DF01 -0.677 . . -0.805 -1.756 . 
1(50) DF02 . . . -0.632 -1.161 -1.79 
2(100) DF04 -1.442 -2.16 -1.412 -0.167 0.319 1.184 
2(100) DF05 0.988 0.169 1.78 -1.763 -0.96 . 
3(167) DF07 -1.466 -2.209 -2.148 -0.668 -4.374 -3.845 
4(251) DF11 . . . . . . 
5(209) DF13 0.569 0.748 0.573 -0.177 0.027 0.537 
Notes: (a)=  MEP amplitude in mVolts. The dots represent when a resting motor 
threshold could not be obtained. 
 
From this table, as before, it can be seen that there are individual 
differences in excitability and MEP amplitude between brain sides as well 
as between participants. More consistent responses are found in the 
unaffected side. Figure 7-11, Figure 7-12 and Figure 7-13 show the 
changes in the APB muscle at 110%, 120% and 130% of the RC for all 
participants respectively.  
Figure 7-11: Changes in MEPs amplitude from pre to post intervention on 
abductor pollicis brevis (APB) at 110% of the recruitment curve (RC) for all 
participants on affected and unaffected side. 
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Notes: the bars represents the difference in excitability identified by changes in MEP amplitude for 
each participants from pre to post intervention for affected (light blue bars) and unaffected (dark 
blue bars) side. 
Figure 7-12: Changes in MEPs amplitude from pre to post intervention on 
abductor pollicis brevis (APB) at 120% of the recruitment curve (RC) for all 
participants on affected and unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude for 
each participants from pre to post intervention for affected (light blue bars) and unaffected (dark 
blue bars) side. 
Figure 7-13: Changes in MEPs amplitude from pre to post intervention on 
abductor pollicis brevis (APB) at 130% of the recruitment curve (RC) for all 
participants on affected and unaffected side. 
 
Notes: the bars represents the difference in excitability identified by changes in MEP amplitude for 
each participants from pre to post intervention for affected (light blue bars) and unaffected (dark 
blue bars) side. 
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As with Table 7-6, Figure 7-11 to Figure 7-29 show variability on the changes on 
APB muscle between individual’s affected side (light blue bar) and unaffected side 
(dark blue side) as well as between participants. As before, more consistent 
responses are found in the unaffected side and as the stimulus (%RMT) gets bigger 
less muscle responses are seen. This is because the motor threshold had to be 
higher.  
 
Summary of changes in MEPs amplitude 
From Figure 9-2 to Figure 7-13 it can be seen that variability in the changes in MEP 
amplitude is found between affected and unaffected side among participants in 
all the three assessed muscles. This demonstrates intra-participant variability in 
MEP amplitude changes after the two weeks of intervention.  
Inter-participants variability is also highlighted from results. Some participants had 
an increased amplitude MEPs and an increased resting motor threshold after the 
two weeks of the task training. This would suggest an increased excitability and 
brain plasticity among them. However, some patients experienced a decrease in 
excitability which cannot be fully explained. The heterogeneity on changes was 
found across all muscle and thus, it can be representative of the all motor system. 
Variability on the cortical spinal pathway excitably could be due to many factors. 
The variability in the technique and the diminished presence and quality of MEPs 
in stroke patients can explain in part these results [58,319]. Moreover, differences 
between people may contribute to this variability in TMS responses. Patients’ 
characteristics such as, age and genetic factors [21,320,321,322], location, size, 
severity, and time since the brain injury can all influence the TMS results 
[56,62,286]. The trial sample was heterogenic in several characteristics such as, 
age and time since stroke. The difference in cortical representation between 
proximal and distal muscles and the difference in TMS response according to the 
muscle under investigation are other important factors in interpreting these 
results. Martin et al. (2006) found that distal upper limb muscles were more 
susceptible and stable in responding to repeated pulse of TMS [323]. In line with 
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these results, in our study ECR and APB muscles (proximal muscles) provide more 
consistent changes than BB muscle (distal muscle) in MEPs amplitude. 
Overall, pre to post intervention individual changes in MEPs amplitude were 
observed in both affected and unaffected brain sides in the three muscles assessed 
expressing intra-participant variability. This is consistent with studies that found 
changes also in contralesional (unaffected) hemisphere excitability as a result of 
over-recruitment68 and reduced inhibitory pathways [324,325]. Changes in the 
unbalanced brain excitability can contribute to improvements of motor function 
[326]. I speculate that the variability of inhibition and excitation I have found could 
be a sign that the brain is trying to reorganise the lost balance between 
hemispheres and some plasticity is happening as a result of the intervention. 
 
Change on RMT 
Table 7-7 shows the RMT from pre to post intervention on BB muscle for all 
participants for affected and unaffected side. Changes in RMT from pre to post 
intervention are reported in the table as well as in Figure 7-30. 
                                                     
68 I.e. recruitment of brain circuits on the unaffected side normally involved in other functions are 
used to supply the deficit in the affected hemisphere. 
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Table 7-7: Resting motor threshold (RMT) differences between the baseline 
(pre intervention) and outcome (post intervention) on biceps brachii muscle 
(BB) for all participants for affected and unaffected side.  
BB 
  
Affected side Unaffected side 
Coho
rt 
(dose
) 
Participa
nt 
Baselin
e 
Outcom
e 
Chang
e 
Baselin
e 
Outcom
e 
Chang
e 
1(50) 
DF-01 80 95 15 79 79 0 
DF-02 94 79 -15 60 68 8 
2(100
) 
DF-04 72 69 -3 61 63 2 
DF-05 46 53 7 69 64 -5 
3(167
) 
DF-07 . 74 . 54 56 2 
4(251
) 
DF-11 94 85 -9 86 72 -14 
5(209
) 
DF-13 48 51 3 47 48 1 
Notes: motor threshold in mVolts. The dots represent when a resting motor threshold could 
not be obtained. 
Figure 7-14: Changes in rest motor thresholds (RMT) from pre to post 
intervention on biceps brachii muscle (BB) for all participants for affected and 
unaffected side. 
 
Notes: the bars represent changes in resting motor threshold from pre to post intervention in 
BB muscle in both affected (light blue bars) and unaffected (dark blue bars) arms. 
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As Table 7-7, Figure 7-14 shows variability in direction of RMT changes from pre 
to post intervention for BB muscle for all participants. It can be seen that there 
is individual variability between affected (light blue bars) and unaffected side 
(dark blue bars) as well as between participants. Some participants increased 
the motor threshold and others decreased the motor threshold in both arms 
providing inconsistent changes in RMT between participants 
Table 7-8 shows the RMT from pre to post intervention on ECR muscle for all 
participants for affected and unaffected side. Changes in RMT from pre to post 
intervention are reported.  
Table 7-8: Resting motor threshold (RMT) differences between the baseline 
(pre intervention) and outcome (post intervention) on extensor carpi radialis 
muscle (ECR) for all participants for affected and unaffected side.  
ECR 
  Affected side Unaffected side 
Cohort 
(dose) 
Participant Baseline Outcome Change Baseline Outcome Change 
1(50) 
DF-01 78 97 19 72 74 2 
DF-02 97 . . 57 50 -7 
2(100) 
DF-04 64 50 -14 52 55 3 
DF-05 48 41 -7 59 54 -5 
3(167) DF-07 52 57 5 41 52 11 
4(251) DF-11 68 60 -8 64 64 0 
5(209) DF-13 42 45 3 36 38 2 
Notes: (motor threshold in mVolts. The dots represent when a resting motor threshold could 
not be obtained. 
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Figure 7-15: Changes in resting motor threshold (RMT) from pre to post 
intervention on extensor carpi radialis muscle (ECR) for all participants for 
affected and unaffected side. 
 
Notes: the bars represent changes in resting motor threshold from pre to post intervention in 
BB muscle in both affected (light blue bars) and unaffected (dark blue bars) arms. 
 
As with Table 7-8, Figure 7-15 shows variability in direction of RMT changes 
from pre to post intervention for ECR muscle for all participants. It can be seen 
that there is individual variability between affected (light blue bars) and 
unaffected side (dark blue bars) as well as between participants. Some 
participants increased the motor threshold and others decreased the motor 
threshold in both arms. 
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Table 7-9 shows the RMT from pre to post intervention on APB for all 
participants for affected and unaffected side. Changes in RMT between 
baseline and outcome measures are reported in the table as well as in Figure 7-
32. 
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Table 7-9: Resting motor threshold (RMT) differences between the baseline 
(pre intervention) and outcome (post intervention) on abductor pollicis brevis 
muscle (APB) for all participants for affected and unaffected side.  
Abductor Pollicis Brevis           
  Affected side Unaffected side 
Cohort 
(dose) 
Participant Baseline Outcome Change Baseline Outcome Change 
1(50) 
DF-01 76 81 5 75 77 2 
DF-02 . 83  68 47 -21 
2(100) 
DF-04 54 54 0 50 51 1 
DF-05 40 41 1 58 68 10 
3(167) DF-07 57 57 0 46 45 -1 
4(251) DF-11 80 . . 65 . . 
5(209) DF-13 41 38 -3 36 35 -1 
Notes: motor threshold in mVolts. The dots represent when a resting motor threshold could 
not be obtained. 
Figure 7-16: Changes in resting motor threshold (RMT) from pre to post 
intervention on abductor pollicis brevis muscle (APB) for all participants for 
affected and unaffected side. 
 
Notes: the bars represent changes in resting motor threshold from pre to post intervention in 
BB muscle in both affected (light blue bars) and unaffected (dark blue bars) arms. 
Figure 7-16 shows variability in direction of RMT changes from pre to post 
intervention for APB muscle for all participants undertaking TMS. As with  
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Table 7-9, it can be seen that there is individual variability between affected 
(light blue bars) and unaffected side (dark blue bars) as well as between 
participants. Some participants increased the motor threshold and others 
decreased the motor threshold in both arms. 
Appendix M : Trial recruitment letter 
 
 
 
 
 
 
 
Date 
 
Dear XXX, 
 
I am writing to tell you about research being carried out in 
Norfolk by Dr Jane Cross and a team of researchers at The 
University of East Anglia. 
Dr Cross and her team are seeing whether a new 
physiotherapy treatment is effective for people who have a 
stroke. They want to find out whether doing 6 weeks of a new 
therapy called “Functional Strength Training” can help people 
Recipients address 
Norfolk and Norwich University 
Hospital 
Colney Lane 
Norwich 
NR4 7UY 
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to use their arm and leg better for daily activities such as 
walking and getting dressed.  
 
The Research team are asking people who have had a 
stroke within the last 5 years to take part. In all the 
researchers are looking for 58 people who have weakness in 
their arm and leg caused by their stroke. Your details were 
identified from your in-patient stay after having your stroke.  
 
What would I have to do? 
Taking part in the study would mean having physiotherapy 
for your arm or leg for 4 days a week for 6 weeks. Each 
training session will be an hour long. You might practise tasks 
for the arm such as reaching for objects, unscrewing lids 
and pouring water; or tasks for the leg such as climbing 
stairs, standing, and walking. We would need to assess 
your arm and leg before and after the 6 weeks of therapy.  
All the therapy and assessments would be in your home 
with a research physiotherapist. We may also ask questions 
about how you found the therapy and whether it was what you 
were hoping for.  
 
Am I the right person for this research? 
Are you walking as well as you had done before the 
stroke? 
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Are you able to use your arm as well as you had done 
before the stroke? 
If your answer is NO to both these questions then you may be 
able to be included in this research. 
 
Taking part in this research is entirely voluntary. You will not 
be out of pocket if you decide you would like to take part.   
 
Please return the reply slip in the stamped address 
envelope to show whether or not you would like to have more 
information about the study.  
If you would like to talk to somebody before deciding, please 
contact Kath Mares on 01603 593099 or 07827 840497.  
If the research team has not heard from you within 2 weeks we 
will send you one reminder by post.  
 
Thank you for taking the time to consider this invitation 
Yours sincerely 
                              
 
  
 
Dr Phyo Myint 
Consultant in Elderly 
Medicine 
Norfolk and Norwich 
University Hospital  
Dr Kneale Metcalf 
Consultant in Elderly 
Medicine 
Norfolk and Norwich 
University Hospital  
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Appendix T FMA Protocol 
FUGL-MEYER Motor Assessment 
Equipment: 
Tennis ball     
Plastic mug diameter 8cm 
Pen      
Paper 
Stopwatch     
Reflex hammer 
Chair with back 
 
General Rules: 
 Subject should be verbally instructed as well as with a demonstration of the test; 
 Subject should perform with the non-affected side first; 
 Do not assist subject, however if the initial position cannot actively attained by the subject the 
limb may be passively placed therein; 
 verbal encouragement is permitted; 
 movement may be repeated up to 3 times to enable observation. 
 
UPPER EXTREMITY 
I. SHOULDER / ELBOW / FOREARM: subject in sitting position aiming for 90° hip and 90° 
knee flexion. 
 Chair: ............................................................................ description   
  .............................................................................................................. 
  .............................................................................................................. cm 
  
1.1. Reflex activity: test non-affected side first 
0 = No reflex activity  ...............................................................................  
 2  = reflex activity present 
 
a.  
1.2. Volitional movement  
  0  = cannot be performed  
1 = detail performed partially 
 2  = detail performed faultlessly 
  
1.2.1. Within synergies 
Flexor synergy: Starting position: Hand from contralateral knee (shoulder adduction/ internal rotation, 
elbow extension, forearm fully pronated) to ipsilateral ear (shoulder abduction at 
least 90°/ external rotation, elbow flexion, forearm supination).  
Instruction: Touch your ear with your .... hand 
 Extensor synergy: Starting position: Hand from ipsilateral ear to contralateral 
knee. 
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 Instruction: Move your hand from your ear to your opposite knee .... 
  
1.2.2. ............................................................................... Mixing 
synergies Hand resting on lap. 
 Hand to lumbar spine: Starting position: subject has to move forward on the 
chair and support for balance may be given.  
 Instruction: Put your hand behind your back 
 Cannot be performed (hand in front of ASIS) ...................................... 0 
 Hand behind ASIS (no compensation) .................................................. 
 .............................................................................................................. 1 
 Hand to lumbar spine higher than ASIS (no compensation) ................ 2 
  
 Shoulder flexion 0-90°: Starting position: elbow at 0°, forearm mid-position 
 Instruction:  Lift your arm straight up, keeping your thumb pointing up 
 Immediate abduction or elbow flexion ................................................ 
 ............................................................................................................ 0 
 Abduction or elbow flexion during the movement .............................. 1 
 Elbow completely extended ................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 2 
  
 Forearm Pro/supination: Starting position: elbow 90°, shoulder 30-90° flexion 
 Instruction: Turn your palm face up and down 
 Cannot be performed ........................................................................... 
 .............................................................................................................. 
 ............................................................................................................ 0 
 Limited pronation/supination, maintains position .............................. 1 
 Full pronation/supination, maintains position ..................................... 
 .............................................................................................................. 2 
  
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1.2.3. ............................................................................... Without 
synergies 
 Shoulder abduction 0-90°: Starting position: elbow at 0°, forearm pronated 
 Instruction: Lift your arm out to the side 
 Immediate supination or elbow flexion ............................................... 
 ............................................................................................................ 0 
 Supination or elbow flexion during movement ................................... 
 ............................................................................................................ 1 
 Abduction 90°, maintains extension and pronation ............................ 
 ............................................................................................................ 2 
  
 Shoulder flexion 90-180°: Starting position: elbow at 0°, forearm mid position 
 Instruction: Lift your hands towards the ceiling, keep your elbow straight and 
thumb pointing up 
 Immediate abduction or elbow flexion ................................................ 
 ............................................................................................................ 0 
 Abduction or elbow flexion during movement .................................... 
 ............................................................................................................ 1 
 Complete flexion, maintains elbow extension ..................................... 
 .............................................................................................................. 2 
  
 Pronation/supination: Starting position: elbow at 0°, shoulder 30-90° flexion 
 Instruction: Turn your palm face up and down, with your elbow straight 
 Cannot be performed ........................................................................... 
 .............................................................................................................. 
 ............................................................................................................ 0 
 Limited pronation/supination, maintains extension ............................ 1 
 Full pronation/supination , maintains elbow extension ...................... 
 ............................................................................................................ 2 
  
1.1. Normal reflex activity: tested only if full score (6 points) achieved on part 1.2.3. 
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 Test as in section 1.1 
 Biceps, triceps, finger flexors 
 0  = No full point section 1.2.3. or 2 of 3 reflexes markedly hyperactive 
      1  = 1 reflex markedly hyperactive or at least 2 reflexes lively 
    2  = maximum of 1 reflex lively, none hyperactive 
 
WRIST Support may be provided at the elbow to take or hold the position, no 
support at wrist, check the passive range of motion prior testing. 
1. Stability at 15° dorsiflexion: Starting position: elbow at 90°, 
forearm pronated 
 Instruction: Lift your hand and hold it there, keep your elbow bent 
 Less than 15° active dorsiflexion .......................................................... 
 .............................................................................................................. 0 
 Dorsiflexion 15°, no resistance  ............................................................ 
 .............................................................................................................. 
 .............................................................................................................. 1 
 Maintains position against light resistance .......................................... 
 .............................................................................................................. 
 ............................................................................................................ 2 
2. Repeated dorsifexion / volar flexion: Starting position: elbow 
at 90°, forearm pronated, slight finger flexion 
 Starting position: Lift your hand up and down, keeping your elbow bent 
 Cannot performed ................................................................................ 
 .............................................................................................................. 
 .............................................................................................................. 0
 ..............................................................................................................  
 Limited active range of motion ............................................................ 
 .............................................................................................................. 
 .............................................................................................................. 1 
 Full active range of motion, smoothly .................................................. 
 .............................................................................................................. 
 .............................................................................................................. 2 
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3. Stability at 15° dorsiflexion: Starting position: elbow at 0°, forearm 
pronated, shoulder 30° flexion 
 Instruction: Lift your hand and hold it there, keep your elbow straight 
 Less than 15° active dorsiflexion .......................................................... 
 .............................................................................................................. 0 
 Dorsiflexion 15°, no resistance ............................................................. 
 .............................................................................................................. 
 ............................................................................................................ 1 
 Maintains position against light  resistance ......................................... 
 .............................................................................................................. 
 ............................................................................................................ 2 
4. Repeated dorsifexion / volar flexion: Starting position:  elbow at 0°, 
forearm pronated, slight finger flexion, shoulder 30° flexion 
 Instruction: Lift your hand up and down, keep your elbow straight 
 Cannot performed ................................................................................ 
 .............................................................................................................. 
 .............................................................................................................. 0
 ..............................................................................................................  
 Limited active range of motion ............................................................ 
 .............................................................................................................. 
 .............................................................................................................. 1 
 Full active range of motion, smoothly .................................................. 
 .............................................................................................................. 
 .............................................................................................................. 2 
5. Circumduction: Starting position: should first perform with non 
affected arm 
 Instruction: Move your hand around with smooth alternating movements, 
keep your arm still and your elbow bent 
 Cannot perform volitionally ................................................................. 
 .............................................................................................................. 
 ............................................................................................................ 0 
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 Jerky movement or incomplete ............................................................ 
 .............................................................................................................. 
 ............................................................................................................ 1 
 Complete and smooth circumduction .................................................. 
 .............................................................................................................. 
 .............................................................................................................. 2 
  
  
II. HAND support may be provided at the elbow to take or 
hold the position, no support at wrist, check the passive 
range of motion prior testing 
a. Mass flexion Starting position: from full active or passive extension 
        Instruction:  Make a fist 
       No flexion ........................................................................................ 
 .............................................................................................................. 
 .............................................................................................................. 
 ............................................................................................................ 0 
       Some but not full finger flexion ...................................................... 
 .............................................................................................................. 
 .............................................................................................................. 1 
       Full flexion .......................................................................................  
 .............................................................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 
 ............................................................................................................ 2 
b. Mass extension Starting position: from full active or passive flexion 
 Instruction:  Stretch out your hand 
       No extension possible ..................................................................... 
 .............................................................................................................. 
 .............................................................................................................. 0 
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       Some but not full finger extension ................................................. 
 .............................................................................................................. 
 ............................................................................................................ 1 
       Full extension .................................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 
 ............................................................................................................ 2 
c. Distal finger Grasp flexion in PIP and DIP extension in MCP 
 Instruction: Grip my finger and hold 
       Cannot be performed ...................................................................... 
 .............................................................................................................. 
 .............................................................................................................. 0 
       Can held position but weak ............................................................. 
 .............................................................................................................. 
 .............................................................................................................. 1 
       Can held against resistance ............................................................. 
 .............................................................................................................. 
 .............................................................................................................. 
 ............................................................................................................ 2 
  
d. Thumb adduction Grasp   Instruction: Grip the paper between your 
thumb and hand 
       Cannot be performed ...................................................................... 
 .............................................................................................................. 
 .............................................................................................................. 0 
       Can held paper but not against tug ................................................ 
 .............................................................................................................. 
 ............................................................................................................ 1 
       Can held paper against tug ............................................................. 
 .............................................................................................................. 
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 .............................................................................................................. 
 ............................................................................................................ 2 
e. Thumb to index finger Grasp Instruction: Hold the pencil between thumb 
and index 
       Cannot be performed ...................................................................... 
 .............................................................................................................. 
 .............................................................................................................. 0 
       Pencil can be held but not against tug ............................................ 
 .............................................................................................................. 
 ............................................................................................................ 1 
       Pencil held against tug .................................................................... 
 .............................................................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 2 
f. Cylinder Grasp: plastic mug diameter 8cm 
 Instruction: Hold the mug – keep it there 
       Cannot be performed ...................................................................... 
 .............................................................................................................. 
 .............................................................................................................. 0 
       Mug can be held but not against tug .............................................. 
 .............................................................................................................. 
 ............................................................................................................ 1 
       Mug held against tug....................................................................... 
 .............................................................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 2 
g. Spherical Grasp: Tennis ball 
 Instruction: Hold the ball – keep it there 
       Cannot be performed ...................................................................... 
 .............................................................................................................. 
 .............................................................................................................. 0 
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       Ball can be held but not against tug ............................................... 
 .............................................................................................................. 
 ............................................................................................................ 1 
       Ball held against tug ........................................................................ 
 .............................................................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 2 
  
III. COORDINATION and SPEED after one trial with non-
paretic arm, blind-folded, tip of the index finger from 
knee to nose, 5 times as fast as possible. Each test is 
timed. 
 In case of complete paralysis, observe for any indication of tremor and 
dysmetria that may be evident elsewhere (face, vive). If there are no 
indications of tremor or dysmetria, then score these items 2 and score speed 
0.  
 If active ROM of affected limb is significantly less than the unaffected limb, 
patients should be scored 0 for speed. 
  
a. Tremor  2  = NO Tremor 
1. .................................................................................  = Slight 
Tremor 
            0  = Marked Tremor 
  
1. Dysmetria   2  = NO Dysmetria 
       1  = Slight Dysmetria 
0 = Marked Dysmetria 
  
2. Speed    2  = maximum difference of 1 second between 
sides 
 1  = 2-5 seconds slower than non affected side 
                0  = more than 5 seconds slower than non affected side 
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  
 
LOWER EXTREMITY 
I. HIP / KNEE / ANKLE all test in supine position are applied first to allow the patient 
to rest 
 
1.1. Reflex activity: test non-affected side first 
  ........................................................................... 0  = No reflex activity  
 2  = reflex activity present 
 
1.2. Volitional movement  
              0  = cannot be performed  
2 = detail performed partially 
 2  = detail performed faultlessly 
 
1.2.1. Within synergies subject in supine position 
Flexor synergy: Starting position: leg fully extended  
Instruction: bring your knee to the chest 
 Extensor synergy: Starting position: Hand from flexor synergy to the hip 
extension/adduction, knee extension and ankle plantar flexion. Slight 
resistance is applied to ensure active movement, evaluate both movement 
and strength. 
 Instruction: Push your foot down  
 
II. COORDINATION and SPEED supine, after one trial with both leg, blind-folded, 
heel to knee cap of the opposite leg, 5 times as fast as possible. Each test is 
timed. 
  
1. Tremor ............................................................ 2  = NO Tremor 
1  = Slight Tremor 
0 = Marked Tremor 
  
2. Dysmetria...................................................  2  = NO Dysmetria 
1  = Slight Dysmetria 
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        ......................................................................................................... 
 .........................................................................  0 = Marked Dysmetria 
  
3. Speed .....................................................................................   2  = 
maximum difference of 1 second between sides 
 1  = 2-5 seconds slower than non affected side 
   0  = more than 5 seconds slower than non affected side 
  
1.2.2. ............................................................................... Mixing 
synergies Starting position: sitting knee 10cm from the edge of the 
chair/bed. 
 Knee flexion beyond 90°: from active or passive extension.  
  Instruction: Pull your knee back under the chair 
 No active motion .................................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 0 
 No flexion beyond 90°, palpate tendon of hamstring .......................... 1 
 Knee flexion beyond 90°, palpate tendon of hamstring ...................... 2 
 Ankle dorsiflexion:  
 Instruction:  Keep your heel on the floor and lift your front foot 
 No active motion .................................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 0 
 Limited dorsiflexion .............................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 1 
 Complete dorsiflexion  ......................................................................... 
 .............................................................................................................. 2 
 
1.2.3. ............................................................................... Without 
synergies Starting position: standing, hip 0°, balance support is allowed 
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 Knee flexion to 90° Instruction:  Keeping your hip still, kick your bottom with 
your heel 
 No active motion or immediate hip flexion ......................................... 0 
 Less than 90° knee flexion or hip flexion during movement ................    1 
 At least 90° knee flexion without hip flexion ....................................... 2 
 Ankle dorsiflexion: Knee extended 
    Instruction:  Keeping your knee extended and your heel on the floor, lift your 
foot 
 No active motion .................................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 0 
 Limited dorsiflexion .............................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 1 
 Complete dorsiflexion  ......................................................................... 
 .............................................................................................................. 
 .............................................................................................................. 
 .............................................................................................................. 2 
1.3. Normal reflex activity: tested only if full score (4 points) achieved on part 1.2.3. 
 Test as in section 1.1 
 Knee flexors, Achilles patellar 
  0  = No full point section 1.2.3. or 2 of 3 reflexes markedly hyperactive 
  1  = 1 reflex markedly hyperactive or at least 2 reflexes lively 
     2  = maximum of 1 reflex lively, none hyperactive 
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Appendix U FMA evaluation sheet 
FMA Evaluation sheet 
SHOULDER / ELBOW / FOREARM: subject in sitting position aim for 90° hip and 90° knee. 
 
Reflex activity:                        Non-affected arm        Affected arm 
 Flexors: biceps and finger flexors   
  
Extensors: triceps     
  
Subtotal (max 4): 
Volitional movement  
Within synergies                                                          Non-affected arm      Affected arm 
Flexor synergy:       
     
Shoulder retraction (scapula) 
Shoulder elevation 
Shoulder abduction 
Shoulder external rotation 
Elbow flexion 
Forearm supination 
  
  
  
  
  
  
 
Extensor synergy:                                                 
 Shoulder adduction/ internal rotation   
 Elbow extension      
 Forearm pronation    
  
 
Subtotal (max 18): 
 
Mixing synergies  
Hand to lumbar spine:   
Shoulder flexion 0-90°:   
 Pronation-supination elbow at 90°:  
 
Subtotal (max 6): 
 
Without synergies 
Shoulder abduction 0 - 90°:   
Shoulder flexion 90 - 180°:  
Pronation/supination elbow at 0°: 
  
Subtotal (max 6): 
 
Normal reflex activity               
 Biceps, triceps, finger flexors 
 
Subtotal (max 2): 
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 WRIST              Non-affected arm        Affected arm 
 
 Stability at 15° dorsiflexion: elbow at 90°  
Repeated dorsifexion / volar flexion: elbow at 90° 
Stability at 15° dorsiflexion: elbow at 0° 
Repeated dorsifexion / volar flexion: elbow at 0 
Circumduction:  
  
Subtotal (max 10):  
 
HAND  
 Mass flexion 
Mass extension 
Distal finger Grasp 
Thumb adduction Grasp    
Thumb to index finger Grasp 
Cylinder Grasp 
Spherical Grasp: 
Mass flexion  
 
Subtotal (max 14):  
 
COORDINATION and SPEED after one trial with non-paretic arm, blind-folded, tip of the 
index finger from knee to nose, 5 times as fast as possible. Each test is timed. 
 
Time Non affected side:  T1      
 
 
Time Affected side:  T1   T2   T3 
 
     T4   T5 
 
       Non-affected arm         Affected 
arm 
 Tremor   
Dysmetria 
Speed 
 
 
Subtotal (max 6):  
 
 
 
 
 
 
LOWER EXTREMITY 
HIP / KNEE / ANKLE 
 
Reflex activity:                       Non-affected arm        Affected arm 
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Flexors: knee flexors     
Extensors: patellar, Achilles    
   
 
Subtotal (max 4): 
Volitional movement  
Within synergies                                                         
Flexor synergy:                                                           Non-affected arm      Affected arm 
 
Hip flexion     
Knee flexion 
 Ankle dorsiflexion  
 
Extensor synergy:  
 Hip extension     
  
 Hip adduction     
   
 Knee extension    
   Ankle plantar flexion      
 
 
Subtotal (max 14): 
 
COORDINATION and SPEED supine, after one trial with both leg, blind-folded, heel to 
knee cap of the opposite leg, 5 times as fast as possible. Each test is timed. 
 
Time Non affected side: T1 
      
 
Time Affected side:  T1   T2   T3  
 
    T4   T5  
Tremor 
Dysmetria 
Speed 
 
Subtotal (max 6): 
 
Mixing synergies  
Knee flexion beyond 90°:   
 Ankle dorsiflexion:  
         
Subtotal (max 4): 
 
Without synergies   Non-affected arm      Affected arm 
 Knee flexion to 90°:   
 Ankle dorsiflexion:  
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Subtotal (max 4): 
 
Normal reflex activity:  
Knee flexors, Achilles patellar  
 
 
Subtotal (max 2): 
 
 
TOTAL SCORE 
Upper limb score: 
 
Lower limb score:  
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Appendix V FMA subjects’ trend over time 
Trends over time of FMA-UL score for each participant randomized to receive FST-UL  
 
Note: x-bar=weeks; y-bar= FMA-UL score; participants’ trial identification number (ID) is reported above 
each graph. 
Trends over time of FMA-LL score for each participant randomized to receive FST-LL  
 
Note: x-bar=weeks; y-bar= FMA-LL score; participants’ trial identification number (ID) is reported above 
each graph. 
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Appendix W Sample size 
The data coming from this feasibility study are used to make a power calculation for the 
upper and lower limb groups assuming that the FMA is used as a primary outcome 
measure69. 
Retrospectively, I used the data gathered at week six for the upper limb group. To have 
80% power at 5% significance to detect a change of 5.25 points on the FMA upper limb 
score and a standard deviation of 11.3 and a loss of patients at follow-up of 30%, it is 
estimated that 118 participants per group are needed. A total of 236 participants are 
then required.  
Retrospectively, I used the data at week five, for the lower limb, as the week which 
seemed related to the higher outcome. To have 80% power at 5% significance to detect 
a change of 10% on the FMA lower limb score and a standard deviation of 4.8 and a loss 
of patients at follow-up of 30%, it is estimated that 82 participants are needed per group. 
A total of 164 participants are then required. 
 
                                                     
69 The sample size calculation is generally made on the study primary outcome. 
